Immnochemical Studies on Glycated Human Serum Albumin: Role of Aminoguanidine and Thymoquinone in the Reduction of Glycation Products in Diabetes Mellitus by Arif, Binish
IMMnHOCHBMICAL STUDIES ON GLYCATED HUMAN 
SERUM ALBUMIN: ROLE OF AMINOGUANIDINE AND 
THYMOQUINONE IN THE REDUCTION OF GLYCATION 
PRODUCTS IN DIABETES MELLITUS 
ABSTRACT 
SUBMITTED FOR THE AWARD OF THE DEGREE OF 
Bottor of J^ftttniopltv 
BINISH ARIF 
Date: 
Approved : 
Prof. Khursheed Alam (Supervisor) 
^ ^ - * 
DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDICINE 
JAWAHARLAL^EHRU MEDICAL COLLEGE 
ALIGARH BIUSLIM UNIVERSITY 
ALIGARH-202 002, INDIA 
2 0 1 2 
Proteins modifications in diabetes may lead to early glycation products (EGPs 
or Amadori product) as well as advanced glycation end products (AGEs). Early 
glycation involves non-enzymatic covalent attachment of glucose with N-terminal and 
lysyl side chain e-amino groups to form unstable Schiff base adduct that rapidly 
progresses to a stable ketoamine derivative, the Amadori product. After Amadori, the 
reactions become more varied and complicated leading to the formation of AGEs. 
Modifications of structural as well as circulating proteins by glycation have drawn 
much attention because of their potential role in the etiopathogenesis of diabetes. 
Although Amadori product is the principal form of glycation mediated modification 
on proteins, most studies so far have demonstrated the formation and role of AGEs in 
various diseases including diabetes, whereas the possible effects of EGPs are poorly 
defined. However, recent investigations by several scientists have shown that elevated 
concentrations of Amadori products (such as glycated albximin) have a substantive 
role in diabetes related complications. 
Glycation of plasma proteins occur during hyperglycemic stages such as those 
preceding diabetes. Protein functions can be impaired by glycation and in conditions 
such as diabetes, the extent of glycation and the degree of damage increases in 
parallel. Early glycation products can have a damaging effect on nonstructural 
proteins such as enzymes. Large-scale clinical studies have established that 
hyperglycemia, the defining metabolic abnormality in diabetes, increases the risk for 
diabetic complications via accelerated formation of Amadori product. Increased 
oxidative stress is a widely accepted participant in the development and progression 
of diabetes related complications. Furthermore, Amadori-albumin generates free 
radicals and augments oxidative stress in diabetes. Moreover, deciphering the 
mechanism of protein damage caused by glycation is fundamental in understanding 
the biochemical basis of diabetes related complications. This may help in the 
development of new therapeutic strategies to minimize the hazards of diabetes. 
Compounds that can block the attachment of sugars with proteins may prove 
beneficial in preventing, delaying or ameliorating the complications of diabetes. 
In the present study, commercially available human serum albumin (HSA) 
was incubated with varying concentration of glucose for one week to generate 
Amadori-rich HSA. The Amadori adduct was assayed by NBT and authenticated by 
boronate affinity chromatography. The structural perturbations in the Amadori-
albumin was analyzed by UV, fluorescence, CD, thermal denaturation studies, FT-IR, 
HPLC, LC-MS and ESI-MS techniques. The studies revealed remarkable changes in 
HSA upon glycation. Furthermore, antibodies were induced in rabbits against native 
and Amadori-albumin. The induced antibodies were characterized by direct binding 
and inhibition ELISA. Antigen-antibody interactions were further confirmed by band 
shift assay. In order to assess the possible role of Amadori-albumin in the etiology of 
diabetic complications, sera from type 1 diabetes patients with and without secondary 
complications were analyzed for their binding to native and Amadori-albumin. 
Furthermore, albumin was also purified from the plasma of diabetic patients and 
changes in the isolated HSA were analyzed with experimentally produced antibodies 
against glycated-HSA. 
UV, fluorescence, CD, thermal denaturation and FT-IR resuhs suggest 
structural changes in HSA modified by glucose. NBT assay showed Amadori product 
formation which was authenticated by retention on boronate affinity matrix. 
Furthermore, generation of furosine (acid hydrolysed product of Amadori adduct; 
fVuctosyl lysine) was detected by HPLC and LC-MS. Formation of the Amadori 
product was further confirmed by ESl-MS. Antiglycation studies using 
aminoguanidine (AG) and thymoquinone (TQ) showed an inhibition in glucose 
mediated HSA glycation. Fructosamine yield in glycated-HSA significantly decreased 
in presence of AG and TQ. Free radical generation during glycation was confirmed by 
quantitation of superoxide radicals in presence and absence of AG, TQ and 
superoxide dismutase (SOD). The results indicate that early glycation generates free 
radicals. Anti-glycation and anti-oxidant role of AG and TQ was also studied in 
diabetic rabbits. Experimental diabetes in rabbits was induced by alloxan and glucose, 
insulin, glycated hemoglobin (HbAic) and fructosamine were measured in control, 
diabetic and AG and TQ treated diabetic rabbits. Effect of chronic hyperglycemia on 
oxidative stress parameters like superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (Gpx), glutathione (GSH), nitric oxide, lipid peroxidation and 
protein carbonyl level was studied. Compared to control rabbits, diabetic animals 
showed decreased level of SOD, CAT, Gpx and GSH. Nitric oxide (NO) level was 
significantly higher in diabetic animals. AG and TQ treatment significantly restored 
the level of the above biochemicals. 
Immunogenicity of native and glycated-HSA was probed in experimental 
animals. Glycated-HSA was found to be a highly immunogenic and induced high titre 
antibodies compared to native HSA. The result suggest generation of glucose 
mediated neo-epitopes on HSA (Amadori product) rendering it highly immunogenic. 
In inhibition ELISA, the anti-glycated-HSA antibodies showed preferential binding 
with glycated-HSA. In band shift assay retardation in antigen-antibody complex was 
observed. The anti-glycated-HSA antibodies also showed binding with glycated 
proteins rich in lysine residues. This suggests common epitopes on glycated-HSA and 
other glycated proteins. 
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Fifty sera of type 1 diabetes patients (with and without secondary 
complications) were tested for the autoantibodies reactive with native, glycated and 
NaBH4 reduced glycated-HSA. Seventy three percent (16 of 22) of type 1 diabetes 
sera with secondary complications showed enhanced binding with glycated-HSA as 
compared to native and NaBHj reduced glycated-HSA. Whereas, only sixty four 
percent (18 of 28) of type 1 sera without secondary complications showed enhanced 
binding with glycated-HSA. Normal human sera did not show appreciable binding 
with coated antigens. The higher recoginition of glycated-HSA by autoantibodies of 
diabetic patients with secondary complications, compared to those without secondary 
complication, point towards the possible involvement of Amadori-HSA (and its 
autoantibodies) in diabetes related complications. Inhibition ELISA reiterated the true 
interaction of autoantibodies with glycated-HSA. Affinity purified IgG of diabetic 
patients showed appreciably high binding with glycated-HSA. The resuUs suggest that 
autoantibodies seen in the sera of type 1 diabetic patients with secondary 
complications might be the consequence of accelerated immunological activity of 
neo-epitopes that have appeared on HSA by glucose modification. 
Albumin purified from the plasma of type 1 diabetic subjects with and without 
complications were subjected to inhibition ELISA with experimentally generated 
antibodies against glycated-HSA. The results demonstrated that albumin purified from 
patients' plasma were glycated because they inhibited anti-glycated-HSA antibody 
binding. However, the degree of albumin glycation varied in the patients as the 
inhibition results were different. Albumin purified from normal healthy individuals 
did not show appreciable binding with the anti-glycated HSA antibodies. Moreover, 
higher inhibition in antibody binding was observed with the HSA isolated from 
diabetic patients with secondary complications. This is in conformity with earlier 
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studies that diabetic state promotes Amadori-modification of many circulating 
proteins. 
Results of this study conclusively point out that the Amadori-albumin is 
highly immunogenic and the major contribution is by the immunogenic epitopes of 
glycated lysine residues. The prevalence of autoantibodies against Amadori-albumin 
in type 1 diabetic patients may be attributed to the powerful immunogenicity of 
endogenously formed Amadori-albumin. Antiglycation properties exhibited by AG 
and TQ has prompted us to think and work in the direction of preventing the 
formation of Amadori proteins in diabetic state. This may prove effective in reducing 
or ameliorating the diabetes related vascular complications. 
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Proteins modifications in diabetes may lead to early glycation products (EGPs 
or Amadori product) as well as advanced glycation end products (AGEs). Early 
glycation involves non-enzymatic covalent attachment of glucose with N-terminal and 
lysyl side chain 8-amino groups to form unstable Schiff base adduct that rapidly 
progresses to a stable ketoamine derivative, the Amadori product. After Amadori, the 
reactions become more varied and complicated leading to the formation of AGEs. 
Modifications of structural as well as circulating proteins by glycation have drawn 
much attention because of their potential role in the etiopathogenesis of diabetes. 
Although Amadori product is the principal form of glycation mediated modification 
on proteins, most studies so far have demonstrated the formation and role of AGEs in 
various diseases including diabetes, whereas the possible effects of EGPs are poorly 
defined. However, recent investigations by several scientists have shown that elevated 
concentrations of Amadori products (such as glycated albumin) have a substantive 
role in diabetes related complications. 
Glycation of plasma proteins occur during hyperglycemic stages such as those 
preceding diabetes. Protein functions can be impaired by glycation and in conditions 
such as diabetes, the extent of glycation and the degree of damage increases in 
parallel. Early glycation products can have a damaging effect on nonstructural 
proteins such as enzymes. Large-scale clinical studies have established that 
hyperglycemia, the defining metabolic abnormality in diabetes, increases the risk for 
diabetic complications via accelerated formation of Amadori product. Increased 
oxidative stress is a v^dely accepted participant in the development and progression 
of diabetes related complications. Furthermore, Amadori-albumin generates free 
radicals and augments oxidative stress in diabetes. Moreover, deciphering the 
mechanism of protein damage caused by glycation is fiindamental in understanding 
the biochemical basis of diabetes related complications. This may help in the 
development of new therapeutic strategies to minimize the hazards of diabetes. 
Compounds that can block the attachment of sugars with proteins may prove 
beneficial in preventing, delaying or ameliorating the complications of diabetes. 
In the present study, commercially available human serum albumin (HSA) 
was incubated with varying concentration of glucose for one week to generate 
Amadori-rich HSA. The Amadori adduct was assayed by NBT and authenticated by 
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boronate affinity chromatography. The structural perturbations in the Amadori-
albumin was analyzed by UV, fluorescence, CD, thermal denaturation studies, FT-IR, 
HPLC, LC-MS and ESI-MS techniques. The studies revealed remarkable changes in 
HSA upon glycation. Furthermore, antibodies were induced in rabbits against native 
and Amadori-albumin. The induced antibodies were characterized by direct binding 
and inhibition ELISA. Antigen-antibody interactions were further confirmed by band 
shift assay. In order to assess the possible role of Amadori-albumin in the etiology of 
diabetic complications, sera from type 1 diabetes patients with and without secondary 
complications were analyzed for their binding to native and Amadori-albumin. 
Furthermore, albumin was also purified from the plasma of diabetic patients and 
changes in the isolated HSA were analyzed with experimentally produced antibodies 
against glycated-HSA. 
UV, fluorescence, CD, thermal denaturation and FT-IR results suggest 
structural changes in HSA modified by glucose. NBT assay showed Amadori product 
formation which was authenticated by retention on boronate affinity matrix. 
Furthermore, generation of furosine (acid hydrolysed product of Amadori adduct; 
fructosyl lysine) was detected by HPLC and LC-MS. Formation of the Amadori 
product was further confirmed by ESI-MS. Antiglycation studies using 
aminoguanidine (AG) and thymoquinone (TQ) showed an inhibition in glucose 
mediated HSA glycation. Fructosamine yield in glycated-HSA significantly decreased 
in presence of AG and TQ. Free radical generation during glycation was confirmed by 
quantitation of superoxide radicals in presence and absence of AG, TQ and 
superoxide dismutase (SOD). The results indicate that early glycation generates free 
radicals. Anti-glycation and anti-oxidant role of AG and TQ was also studied in 
diabetic rabbits. Experimental diabetes in rabbits was induced by alloxan and glucose, 
insulin, glycated hemoglobin (HbAjc) and fructosamine were measured in control, 
diabetic and AG and TQ treated diabetic rabbits. Effect of chronic hyperglycemia on 
oxidative stress parameters like superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (Gpx), glutathione (GSH), nitric oxide, lipid peroxidation and 
protein carbonyl level was studied. Compared to control rabbits, diabetic animals 
showed decreased level of SOD, CAT, Gpx and GSH. Nitric oxide (NO) level was 
significantly higher in diabetic animals. AG and TQ treatment significantly restored 
the level of the above biochemicals. 
Immunogenicity of native and glycated-HSA was probed in experimental 
animals. Glycated-HSA was found to be a highly immunogenic and induced high titre 
antibodies compared to native HSA. The result suggest generation of glucose 
mediated neo-epitopes on HSA (Amadori product) rendering it highly immunogenic. 
In inhibition ELISA, the anti-glycated-HSA antibodies showed preferential binding 
with glycated-HSA. In band shift assay retardation in antigen-antibody complex was 
observed. The anti-glycated-HSA antibodies also showed binding with glycated 
proteins rich in lysine residues. This suggests common epitopes on glycated-HSA and 
other glycated proteins. 
Fifty sera of type 1 diabetes patients (with and without secondary 
complications) were tested for the autoantibodies reactive with native, glycated and 
NaBH, reduced glycated-HSA. Seventy three percent (16 of 22) of type 1 diabetes 
sera with secondary complications showed enhanced binding with glycated-HSA as 
compared to native and NaBH^ reduced glycated-HSA. Whereas, only sixty four 
percent (18 of 28) of type 1 sera without secondary complications showed enhanced 
binding with glycated-HSA. Normal human sera did not show appreciable binding 
with coated antigens. The higher recoginition of glycated-HSA by autoantibodies of 
diabetic patients with secondary complications, compared to those without secondary 
complication, point towards the possible involvement of Amadori-HSA (and its 
autoantibodies) in diabetes related complications. Inhibition ELISA reiterated the true 
interaction of autoantibodies with glycated-HSA. Affinity purified IgG of diabetic 
patients showed appreciably high binding with glycated-HSA. The resuhs suggest that 
autoantibodies seen in the sera of type 1 diabetic patients with secondary 
complications might be the consequence of accelerated immunological activity of 
neo-epitopes that have appeared on HSA by glucose modification. 
Albumin purified from the plasma of type 1 diabetic subjects with and without 
complications were subjected to inhibition ELISA with experimentally generated 
antibodies against glycated-HSA. The resuhs demonstrated that albumin purified from 
patients' plasma were glycated because they inhibited anti-glycated-HSA antibody 
binding. However, the degree of albumin glycation varied in the patients as the 
inhibition resuhs were different. Albumin purified from normal healthy individuals 
did not show appreciable binding with the anti-glycated HSA antibodies. Moreover, 
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higher inhibition in antibody binding was observed with the HSA isolated from 
diabetic patients with secondary complications. This is in conformity with earlier 
studies that diabetic state promotes Amadori-modification of many circulating 
proteins. 
Resuhs of this study conclusively point out that the Amadori-albumin is 
highly immunogenic and the major contribution is by the immunogenic epitopes of 
glycated lysine residues. The prevalence of autoantibodies against Amadori-albumin 
in type 1 diabetic patients may be attributed to the powerful immunogenicity of 
endogenously formed Amadori-albumin. Antiglycation properties exhibited by AG 
and TQ has prompted us to think and work in the direction of preventing the 
formation of Amadori proteins in diabetic state. This may prove effective in reducing 
or ameliorating the diabetes related vascular complications. 
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The term "PROTEIN" was derived from Greek word (prota) which means of 
primary importance. Proteins were first described by the Dutch chemist Gerardus 
Johannes Mulder and named by the Swedish chemist Jons Jacob Berzelius in 1838, 
Early nutritional scientists such as the German Carl von Voit believed that protein 
was the most important nutrient for maintaining the structure of the body, because it 
was generally believed that "flesh makes flesh". Most proteins consist of 
linear polymers built from series of up to 20 different L-a-amino acids. 
All proteinogenic amino acids possess common structural features, including an a-
carbon to which an amino group, a carboxyl group, a hydrogen and a variable side 
chain are bonded. The sequence of amino acids, or primary structure of the protein, is 
dictated by the nucleotide sequence of the gene coding for that particular protein. Like 
other biological macromolecules such as polysaccharides and nucleic acids, proteins 
are essential parts of organisms and participate in virtually every process within cells. 
Many proteins catalyze biochemical reactions which are vital to metabolism. Proteins 
also have structural or mechanical functions, such as actin and myosin in muscle and 
the proteins in the cytoskeleton, which form a system of scaffolding that maintains 
cell shape. Other proteins are important in cell signaling, immune responses, cell 
adhesion and the cell cycle. 
Protein antigenicity 
Oxidative damage to proteins in vivo may affect the function of receptors, 
enzymes, transport proteins, etc. and perhaps generate new antigens that provoke 
immune responses. Antigens are non-self substances, that are recognized by receptors 
on lymphocytes, thereby eliciting the immune response. The receptor molecules 
located on the membrane of lymphocytes interact with small portions of those foreign 
cells or proteins, designated as antigenic determinants or epitopes. The antigenicity of 
a protein refers to its capacity to bind specifically to the binding sites or paratopes of 
certain immunoglobulin molecules. Immunological properties of proteins have been 
widely used to study their structure. Experimental studies on a number of proteins, 
like sperm whale myoglobin (Atassi, 1975), hemoglobin (Kazim and Atassi, 1980, 
1982) and lysozyme (Atassi, 1978) have also pointed out that antigenic sites on 
proteins may be formed either by sequential continuous regions or by bringing 
together several antigenic determinants to form antigenic sites. Thus, the antigenic 
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epitopes of proteins are composed of continuous or discontinuous portions of the 
polypeptide chain. The discontinuous epitopes are formed by two or more non-
contiguous segments brought into proximity by the folding of the protein. 
Human serum albumin 
Albumin is the most abundant protein in human plasma, comprising 60% of 
the total proteins in blood (Shaklai et al, 1984). It is a 66 kDa, single-chain protein 
with 585 amino acid residues, three homologous domains (I-III), and a helical heart-
shaped globule structure (He and Carter, 1992). Each domain is composed of two 
subdomains that are stabilized by internal disulfide bridges. The three domains, I, II 
and ni , are subdivided into two subdomains A and B (Peters, 1996). It possess 28 a-
helical segments which acounts for 67% of the protein secondary structure. The 
remaining secondary structure consists of 10% p-tums and 23% extended peptide 
chain. The sole tryptophan in HSA, Trp-214, is located in domain II (Fig.l). 
After being synthesized in the liver, HSA circulates in the body for 2-3 weeks 
before being degraded and replaced (Brownlee, 1995). It is known as a muhipurpose 
transport protein, as it has a set of quite diverse functions including oncotic pressure 
regulation, binding and transport capacities (Peters, 1996) and antioxidant properties 
(Coussons et al., 1997). HSA also plays an importzmt role in normal physiology by 
transporting a remarkably broad spectrum of molecules throughout the body. These 
include inorganic cationic metals such as Cu^^ and Zn^ ,^ organic anions, amino acids, 
metabolites, many drug compounds, and most importantly hydrophobic molecules 
like bilirubin, hemin, free fatty acids and a spectrum of therapeutic compounds. 
Antigenicity of human serum albumin 
Analysis of the antigenic structure of human serum albumin, after partial 
enzymatic hydrolysis, has demonstrated that the albumin molecule possesses several 
antigenic sites with distinct specificities. Fragments carrying different antigenic sites 
have been obtained by both enzymatic digestion and cyanogen bromide (CNBr) 
degradation (Lapresle and Doyen, 1975; Doyen and Lapresle, 1979). 
(B) 
Lys-212 
Fig. 1 (A) Structure of human serum albumin with domains and subdomain. 
(B) Structure of human serum albumin around Trp-214 with three closest 
lysine residues. 
Source: Mendez, D.L. et al, (2005) Arch. Biochem. Biophys. 444, 
92-99. 
Albumin is a potent antigen. With the advent of monoclonal antibodies and 
monovalent Fab fragments, it became possible to identify particular sites by inhibiting 
or blocking techniques that eliminate the steric problems of aggregation with 
precipitation. Nineteen monoclonal antibodies have recognised thirteen epitopes on 
HSA (Doyen et al, 1985). This is consistent with the no. of sites produced by 
precipitation and suggest that the surface of an albumin is antigenic. 
Glycation 
The first effect of high glucose concentration in biological fluids and tissues is 
an important multi-step process involving chemical modification of reactive amino 
groups in biological macromolecules (proteins, lipids and DNA) by reactive carbonyls 
(Bucala, 1985; Suarez, 1989; Sengupta and Swenson, 2005). The free carbonyl groups 
(-C=0) of the sugars and related moieties react with the free amino groups (-NHj) of 
the macromolecules in a series of chemical processes. This reaction was first 
described by the French biochemist Louis Maillard at the beginning of the 20th 
century, and is known as Maillard reaction. The intermediate products formed are 
known, variously, as Amadori, Schiff Base and Maillard products, named after the 
researchers who first described them (Dalle-Donne et al., 2005). Maillard first 
described the non-enzymatic reaction of glycine with glucose in 1912. In principle, all 
reducing sugars whether aldoses or ketoses (Yaylayan and Huyghues, 1994) and even 
molecules related to sugars, such as ascorbic acid, can initiate the reaction in vivo. 
However, most studies to date have been focused on glycation, the nonenzymatic 
reaction with glucose, because glucose is the most abundant sugar in blood and is 
elevated in diabetes. 
Glycation is initiated by a nucleophilic attack of the aldehyde group of the 
reducing carbohydrate on the free amine to form a SchifT base (Cohen, 2003). The 
reversible N-glucosylamine (Schiff base) reaches an equilibrium over a period of 
several hours. Through acid-base catalysis, the N-glucosylamine undergoes a 
characteristic intramolecular re-arrangement reaction to form chemically stabilised 1-
amino-l-deoxy-2-ketose (ketoamine) (Horvat and Jakas, 2004; LapoUa et al, 2005), 
which is named as Amadori product after the Italian scientist Mario Amadori 
(Amadori, 1925). The Amadori product subsequently cyclizes, and forms a pyranose 
or furanose carbohydrate adduct (Cohen, 2003). Cychzation of the ketoamine to the 
hemiketal structure probably contributes to the stability of the glucosyl-protein adduct 
under physiological conditions (Armbuster, 1987) (Fig. 2a) This product undergoes 
cycles of condensations with additional amines, dehydrations, and oxidative 
fragmentations to yield a class of heterogeneous chemical compounds collectively 
referred to as advanced glycation end products (AGEs) (Fig. 2b). 
The Schiff base and Amadori adduct also undergo facile oxidation, especially 
in the presence of transition metal ions, and fragment to yield shorter chain sugars and 
reactive intermediates, such as glyoxal (GO), methylglyoxal (MGO) and 3-
deoxyglucosone. These reactive carbonyl intermediates, which are much more 
reactive than the sugars from which they are derived, again react with the amino 
groups of proteins and act as propagators of non-enzymatic glycation reactions. Such 
intermediary products (methylglyoxal) are also generated during glycolysis, lipid 
peroxidation (Thomalley et al., 2003) or along the polyolic pathway (Turk, 2001) and 
can also be formed by auto-oxidation of carbohydrates (glyoxal) (Thomalley et al., 
1999; Cervantes-Laurean et al., 2005). These reactions have gained significant 
attention in recent days because of their association with free radicals, which have 
been implicated in the development of cancer, diabetes, heart disease, cataract, 
atherosclerosis, neurodegenerative disorders (e.g., Parkinson's disease, Alzheimers 
disease) etc. 
Adducts of glycation and their pathological fates 
Excessive formation of both early and advanced glycation products appears to 
be the common biochemical link between chronic hyperglycemia and a number of 
pathophysiologic processes potentially involved in the development of long-term 
diabetic complications. The major biological effects of excessive nonenzymatic 
glycosylation include: inactivation of enzymes; inhibition of regulatory molecule 
binding; crosslinking of glycosylated proteins and trapping of soluble proteins 
by glycosylated extracellular matrix; decreased susceptibility to proteolysis; 
abnormalities of nucleic acid function; altered macromolecular recognition and 
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endocytosis; and increased immunogenicity. 
• Early gfycation products 
Early glycation products are direct chemical precursors of a group of more 
slowly forming advanced glycation end products. SchifFs base and fructosamines 
(Amadori product) are called as early glycation adducts (Thomalley et al., 1999). 
They are formed both inside and outside the cells, as glucose rapidly attaches to the 
amino groups of the proteins through the non enzymatic process of nucleophilic 
addition, to form schiff base adducts. Within hours, these adducts reach equilibrium 
levels that are proportional to the blood glucose concentration and subsequently 
undergoes rearrangement to form more stable early glycation products (Amadori 
product), which reach equilibrium over a period of several weeks (Kumar and Kumar, 
2012). During the lifetime of most cellular and plasma proteins, Amadori-products are 
in equilibrium with glucose and, therefore, the levels of Amadori-products tend to rise 
and fall depending on the glucose concentration. High level of Amadori products are 
formed through glucose mediated glycation of collagen, HSA and glutathione (Fu et 
al., 1994; Nagai et al., 1997; Linetsky et al., 2005). Among the substances involved in 
tissue damage, Amadori adducts have been shown to play a significant role (Angulo 
etal., 1996; Amore etal., 1997, 2004; Mandl-Weber e/a/., 2001; Hattori etai, 2002; 
Rodriguez-Manas et al., 2003). Excessive formation of early glycation products may 
adversely affect several functions relevant to diabetic complications. In blood vessels, 
uptake of LDL may be enhanced resulting in atherogenesis (Witzum et al., 1982). 
Free radical mediated damage is also increased (Cillery et al., 1988). These reversible 
biochemical abnormalities probably play a role in the pathogenesis of the early 
ftinctional changes in the diabetic microvasculature. 
• Advanced glycation end products 
Irreversible chemical reactions in Amadori products generate AGEs which may 
be fluorescent with cross-linking properties (such as pentosidine and crosslines) or 
non-fluorescent and non-crosslinking (such as Ne- (carboxymethyl) lysine (CML) or 
non-fluorescent crosslinked product such as pyrrline (Ahmed, 2005). AGEs may be 
generated rapidly or over long times stimulated by a range of distinct triggering 
mechanisms, thereby accounting for their roles in muhiple settings and disease states. 
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AGEs contribute to pro-inflammatory and pro-oxidative processes in diabetes. Several 
mechanisms have been proposed by which AGEs lead to diabetic complications. For 
example :-
> accumulation of AGEs in the extracellular matrix causing aberrant 
crosslinking, resulting in a decreased elasticity of vessels. 
> binding of AGEs to AGE-receptors on different cell types and activation of 
key cell signalling pathways such as NF-KB activation with subsequent 
modulation of gene expression in vascular cells such as endothelial cells, 
smooth muscle cells and macrophages (Stem et al., 2002; Miyazaki et ai, 
2002). 
> intracellular AGE formation leading to quenching of nitric oxide and impaired 
function of growth factors (Shinohara et al., 1998). 
> in endothelial cells, basic fibroblast growth factor is one of the main cellular 
AGE-modified proteins accompanied by markedly decreased mitogenic 
activity (Giardino et al., 1994). 
Some of the biological effects of AGEs are modulated through their 
interaction with the receptor for advanced glycation end-products (RAGE) (Schmidt 
et al., 1996). AGEs bind to specific receptors on cells such as macrophages and 
induces receptor-mediated ROS production, thereby causing intracellular oxidative 
stress as well as the synthesis of growth factors and cytokines (Yan et al., 1994) 
resulting in damage to the affected tissues (Westwood and Thomalley, 1996). AGE 
produce cellular injury by a cascade of receptor-dependent (e.g., RAGE) and 
independent events that include intracellular generation of ROS which activates 
signaling pathways involving activation of protein kinase C (Mene, 1999) tyrosine 
phosphorylation of Janus kinase (JAK)/signal transducers and activators of 
transcription (STAT) (Huang, 2001), transcriptional activation (Lander, 1997) and 
induction of oxidative stress cascades involving NF KB and AP-1 which lead to 
proinflammatory (e.g., NF KB, monocyte chemoattractant protein-1, TNF-a) and 
profibrotic effects (e.g., TGF- a, connective tissue growth factor, PDGF) (Bierhaus et 
al., 2001; Twigg et al., 2002; Zhou et al., 2004). 
Protein glycation 
The process of protein glycation is now understood to be both a marker for the 
progress of diabetes complications and an underlying cause of many of the serious 
complications. Excess glucose binds to proteins throughout the body, changing their 
shape and properties in ways that have been shown to cause damage to both the 
structure and function of body organs. Protein glycation is a complex cascade of 
condensations, rearrangements, fragmentations and oxidative modifications which 
lead to heterogeneous products often with considerable structural alterations at the 
secondary and tertiary levels and consequently functional properties of the proteins 
(Luthra and Balasubramanian, 1993; Liang and Chylack, 1986). Glycation-induced 
damage to proteins associated with complications of diabetes have been investigated 
in the recent years. The damage caused by glycation to long lived structural proteins 
has been studied extensively. However, the proteins that turn over rapidly (like insulin 
and enzymes) are also damaged by glycation (Ganea, 2004; Harding and Elena, 
2006). A number of studies have been carried out the glycation of proteins exposed to 
high glucose concentration, e.g. human serum albumin (Shaklai et al., 1984), lens 
crystalline protein (Stevens et al., 1978), collagen (Fu et al., 1994), IgM and IgG 
(Menini et al., 1993, Newkirk et al., 2003) and haemoglobin (Watkins et al., 1985). 
Glycation primarily occurs at intrachain lysine residues of proteins (Watkins et 
al., 1985). The amino groups of arginine, histidine, tryptophan and cysteine residues 
(Munch et al., 1999) are also prone to glycation. The extent of glycation is 
proportional to glucose concentration in the protein's environment and the duration of 
the exposure. There is growing evidence that under physiological conditions glucose 
reacts nonenzymatically with a wide variety of proteins to form stable adducts (Bunn 
et al., 1978; Schleicher and Wieland, 1981). Accelerated non-enzymatic glycation of 
cellular and extracelluar proteins appears as an interesting mechanism in the 
pathogenesis of diabetic vascular disease (Bucala et al., 1995). 
Impact of glycation on albumin structure 
Albumin is the most abundant protein in human serum, prone to glycation 
(Carter and Ho, 1994). Glycation induced structural alterations has profound impact 
on the functional properties of albumin (Rondeau and Bourdon, 2011). Changes in 
HSA structure and conformation by Amadori product formation strongly affects its 
anti-oxidant properties and foster acquisition of pro-oxidant activity in presence of 
copper (Coussons et al., 1997; Howard, 2005). It has been reported that the drug 
binding property of HSA may be altered at various stages of diabetes as the extent of 
glycation and type of modifications are varied in this protein (Bamaby et al., 2011; 
Lautenslager et al., 2011) 
Non-enzymatic glycation of HSA occurs at muhiple sites (Shaklai et al., 
1984). Evidences suggest that s-amino groups of lysine residues in HSA are preferred 
locus for glycation (Wa et al., 2007; Bamaby et al., 2011). Previous studies have 
indicated that the most significant sites in HSA for early glycation are the N-terminus 
and lysine 199, 281, 439 and 525 (Iberg and Fluckiger, 1986; Robb et al., 1989). In 
several studies, lysine-525 is depicted as the predominant site of the non-enzymatic 
glycosylation of HSA in vivo (Shaklai et al., 1984; Garlick and Mazer, 1983). 
Nonenzymatic adduction of glucose at this residue accounts for 33% of the overall 
glycation (Iberg and Fluckiger, 1986). Decrease in the affinity of in vivo and in vitro 
glycated albumin for different ligands suggests that this principal glycation site may 
play a key role in binding (Rondeau and Bourdon, 2011). Glycation of HSA with 
methylglyoxal has identified certain regions that are prone to advanced glycation end 
product modification (Ahmed et al., 2005b; Wa et al., 2007; Barnaby et al., 2011) 
including arginine 410 as a major region of modification and arginine 114, 186, 218, 
and 428 as regions of minor modification. 
Hemoglobin and albumin as indices of protein glycation 
Glycation of human proteins is currently of much experimental and clinical 
interest, and formation of fructosamine (Amadori adduct) has attracted much attention 
in the context of diabetes. This is because the glycation rate is of first order with 
respect to glucose concentration. Furthermore, fructosamines are thought to 
participate in the pathogenesis of long-term diabetes complications by acting either as 
such (Cohen et al., 1996) or after conversion to advanced glycation end products 
(Baynes, 1991; Brownlee, 2001). 
The chemistry of early glycation products has been well described, with 
HbAic as the best-studied example (Kennedy, 1992). HbAic, the Amadori product of 
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HbA, formed by the non-enzymatic reaction between glucose and the amino groups of 
valine and lysine of p-globin, was the first early glycation product to be detected in 
vivo (Koenig et al., 1976). Most HbAiC reflects the presence of the fructosamine 
residues A'ia-fiiictosylvaline and FL (A^e-fructosyl-lysine) (Zhang et al, 2001). 
Measurement of early glycation products (Amadori product) is routinely used to 
evaluate metabolic control in diabetic patients. HbAiC has been firmly established as 
an index of long term glucose concentrations and as a measure of the risk for the 
development of complications in patients with diabetes mellitus. The degree of 
glycation of hemoglobin provides information about the glucose level (quality of 
diabetes control) over previous 6-8 weeks (Gugliucci, 2000, Cohen et al, 2002). 
Glycated HSA is another important short time (2-3 weeks) indicator of 
glycemic control and diabetes that is more sensitive to changes in blood glucose level 
than HbAic (Ulrich and Cerami, 2001; Kim and Lee, 2012). In fact, the initial 
compounds generated during albumin glycation, the Amadori adducts, are abundant in 
plasma and urine of hyperglycemic subjects (Guthrow et al, 1979). The glycated 
albumin level also provides useful information on short term glycemic control when 
monitoring the efficacy of therapy (Kisugi et al, 2007). The level of glycated albumin 
might also be of value as an indicator of the degree of hyperglycemia in diabetics 
(Nakajou et al, 2003). This process also occurs in individuals having normal blood 
glucose level, but HSA is three times more glycated in conditions of hyperglycemia 
(Guthrow, 1979; Bourdon et al, 1999; Nakajou et al, 2003). 
Importance of early glycation products 
Elevated levels of glycated proteins may lead to long-term tissue damage 
associated with the pathogenic effects observed in diabetics, including poor 
cu-culation to extremities, retinopathy, nephropathy, neuropathy, and coronary artery 
disease (Brownlee, 1995). Glycated HSA accounts for 80% of the circulating glycated 
protein (Cohen, 2003) and has been implicated in several complications associated 
with diabetes (Cohen et al, 1997, 2005). Amadori albumin has been reported in 
glomeruli of patients with diabetic nephropathy (Sakai et al, 1996). Early glycation 
reactions lead to the formation of Amadori products, fructosyl-lysine (FL) and related 
fructosamine residues, which degrade slowly to form AGEs. The FL residues have 
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been detected in protein extracts of rat tissues and plasma proteins. The FL residue 
concentration has been found to be markedly increased in renal glomeruli (6-fold), 
retina (3-fold), sciatic nerve (7-fold) and plasma protein (3-fold) of diabetic rats 
compared to normal controls (Karachalias et al., 2003). A specific and sensitive 
method for the quantification of early glycation products (fructose-lysine) can be 
achieved by determination of furosine (Scheilder and Wieland, 1981). Furosine is 
formed during acid hydrolysis of the fhictosyl-lysine (l-deoxy-fructosyl-lysine) and is 
a widely used marker for evaluation of early stages of glycation in a wide variety of 
foods (Resmini etal, 1990) and biological samples (Forster etal., 2005). 
Diabetes mellitus 
Diabetes mellitus (DM) is not a single disease entity. It is a group of metabolic 
disorders sharing the common underlying feature of hyperglycemia. Advances in 
clinical science during the second half of the 20^ century have led to improvements in 
understanding the causes and complications of diabetes, together with alleviation of 
suffering to an extraordinary degree. DM is characterised by chronic hyperglycemia 
resulting either from a deficiency of insulin, or decreased ability to transduce the 
insulin signal (insulin insensitivity), or both, eventually affecting all systems in the 
body and ultimately leading to a cluster of disorders. It is a systemic metabolic 
disease characterised by aherations in the metabolism of carbohydrates, proteins and 
lipids (Gleisner et al., 2006). Decreased insulin secretion affects glucose metabolism 
causing significant disturbance of water and electrolyte homeostasis. Low level of 
insulin results in hyperglycemia. While exogenous insulin and other medications can 
control many aspects of diabetes, numerous complications affecting the vascular 
system, kidney, retina, lens, peripheral nerves and skin are common and are extremely 
costly in terms of longevity and quality of life. Increased oxidative stress is a widely 
accepted participant in the development and progression of diabetes and its 
complications (Ceriello, 2000; Rains and Jain, 2011). Diabetes is usually 
accompanied by increased free radical production (Baynes and Thorpe, 1999, 2000) 
or impaired antioxidant defences (Halliwell and Gutteridge, 1990; McLennan et al., 
1991; Saxena et al., 1993). The metabolic dysregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ systems that impose a 
tremendous burden on the individual with diabetes. Many other metabolic 
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abnormalities occur, notably an increase in ketone bodies in the blood when there is a 
severe lack of insulin. The classic symptoms of diabetes include polyuria (frequent 
urination), polydipsia (increased thirst), polyphagia ((increased hunger) and 
unexplained weight loss. When the glucose concentration in the blood is raised 
beyond its renal threshold (about 10 mmol/L), reabsorption of glucose in the proximal 
renal tubuli is incomplete and part of the glucose remains in the urine (glycosuria). 
This increases the osmotic pressure of the urine and inhibits reabsorption of water by 
the kidney, resulting in increased urine production (polyuria) and increased fluid loss. 
Lost blood volume is replaced osmotically from water held in body cells and other 
body compartments, causing dehydration and increased thirst. 
Classification of diabetes mellitus 
Although all forms of diabetes mellitus share hyperglycemia as a common 
feature, the pathogenic processes involved in the development of hyperglycemia vary 
widely. Thus DM is classified on the basis of the pathogenic processes that leads to 
hyperglycemia (American Diabetes Association, 2012). The two broad categories are 
designated as type 1 and type 2. 
• Type 1 diabetes 
This form of diabetes results from a severe lack of insulin caused by immune 
mediated destruction of B cells. Type 1 diabetes most commonly occurs in childhood, 
becomes manifested in puberty and progresses with age. It is thought to be caused by 
a combination of environmental factors and viral infection, superimposed on a genetic 
susceptibility. The main cause of the beta cell loss is a T-cell mediated immune attack 
(Rother, 2007). Hyperglycemia accompanied by the classical symptoms of diabetes 
occurs only when 70-90% of P-cells have been destroyed. The rate of P cell 
destruction is quite variable, being rapid in some individuals (mainly infants and 
children) and slow in others (mainly adults). Sensitivity and responsiveness to insulin 
are usually normal, especially in the early stages. 
Type 1 diabetes can be further sub classified into type 1A if autoimmune 
markers can be identified (Diabetes care, 1997) and type IB-an absolute insulin 
deficiency in which no autoimmune markers can be identified. Type IB may be more 
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common in people of Asian heritage (Abim et al, 2002). A number of autoantibodies 
have been detected as the markers of autoimmune diabetes (Winter and Schatz, 2011). 
These include islet cell autoantibodies, autoantibodies to insulin (Atkinson et al., 
1992), autoantibodies to glutamic acid decarboxylase (GAD 65) (Jun etal., 2002) and 
autoantibodies to the tyrosine phosphatases IA-2 and IA-2 p (Lan et al, 1996; Lu et 
al, 1996). Type 1 diabetes is partly inherited and there is a strong association of type 
1 diabetes with individuals who possess particular haplotypes. HLA DR4-DQ8 and 
DR3-DQ2 are present in more than 90% of children with type lA diabetes (Powers, 
2008). Moreover, 30-50% of patients with type lA diabetes are heterozygotes for 
HLA DR4-DQ8 and DR3-DQ2, whereas this combination of alleles is only present in 
2.4% of the general population (Devendra and Eisenbarth, 2003). Type 1 diabetes is 
also triggered by certain infections with some evidence pointing at Coxsackie B4 
virus, enteroviruses and rubella but have not been definitely shown to induce type 1 
diabetes (Lammi et al, 2005). There is a genetic element in individual susceptibility 
to some of these triggers which has been traced to particular HLA genotypes. 
• Type 2 diabetes 
Type 2 diabetes mellitus, or aduh-onset diabetes, is characterized by insulin 
resistance which may be combined with relatively reduced insulin secretion. The 
defective responsiveness of body tissues to insulin is believed to involve the insulin 
receptor. The risk of developing type 2 diabetes increases with age, obesity and lack 
of physical activity. Overweight and obesity (especially central obesity or central 
adiposity) has been related to insulin resistance, hyperinsulinemia, glucose 
intolerance, and with subsequent development of type 2 DM (Wannamethee and 
Shaper, 1999). Furthermore, weight loss is strongly associated in prospective studies 
with decreased progression from impaired glucose tolerance (IGT) to type 2 diabetes 
(Knowler et al, 2002). A metabolic consequence of obesity, especially central 
adiposity, is the development of insulin resistance, which induces an increase in the 
secretion of insulin from the pancreas. Increased insulin production leads to 
compensatory hyperinsulinemia. In addition, many genetic polymorphisms may play 
a part in insulin resistance, possibly through post-insulin receptor signal transduction 
mechanisms (Powers, 2008). 
14 
There are probably many different causes of type 2 diabetes. Insulin resistance 
alone does not cause diabetes. Many obese people do not develop type 2 diabetes 
despite increased insulin resitance (Polansky, 2000). The development of insulin 
resistance is one of the earliest negative effects of obesity and is associated with the 
early altered glucose metabolism, chronic inflammation and oxidative stress. In the 
early stage of type 2 diabetes, the predominant abnormality is reduced insulin 
sensitivity. At this stage hyperglycemia can be reversed by a variety of measures 
and medications that improve insulin sensitivity or reduce glucose production by 
the liver. This form of diabetes frequently goes undiagnosed for many years because 
hyperglycemia develops gradually and at earlier stages is often not severe enough for 
the patient to notice any of the classic symptoms of diabetes. 
It has been proposed that there is measurable beta cell hypertrophy in obsese 
subjects who do not have diabetes. For unclear reasons, P cell secretory capacity 
gradually declines in some individuals leading to the development of type 2 diabetes. 
Several studies have shown that 40% of P-cell mass may be lost in individuals who 
have glucose tolerance and 60% may be lost when clinical type 2 diabetes develops 
(Butler et al., 2003). The cause of P-cell failure in type 2 diabetes is not known. The 
pathogenesis of insulin resistance is currently focussed on PI-3 kinase signalling 
defect which reduces translocation of GLUT 4 to the plasma membrane. Another 
emerging theory proposes that increased level of free fatty acids, a common feature of 
obesity, may contribute to pathogenesis. Free fatty acids can impair glucose 
utilization in skeletal muscles, promote glucose production by the liver and impairs P-
cell function (Powers, 2008). 
Asian Indians are more prone to type 2 diabetes and premature coronary 
disease due to Asian Indian Phenotye. The phenotype refers to certain unique clinical 
and biochemical abnormalities in Indians which include increased insulin resistance, 
greater abdominal adiposity (i.e higher waist circumference despite lower body mass 
index), lower adiponectin and higher C-reactive protein levels (Mohan et al., 2007). It 
also occurs more frequently in women with prior GDM and in individuals with 
hypertension or dyslipidemia, and its frequency varies in different racial ethnic 
subgroups. It is often associated with a strong genetic predisposition, than the 
autoimmune form of type 1 diabetes. However, the genetics of this form of diabetes 
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are complex and not clearly defined. The autoantibodies of type 1 diabetes mellitus 
especially GAD may also occur in up to 10% of adults initially classified as type 2 
diabetes in a condition known as Latent Autoimmune Diabetes in Adults (LADA) or 
type L5 diabetes. The disease process in LAD A patients is similar to that in type 1 
diabetes as they share some HLA genetic susceptibility and some type 1 associated 
autoantibodies (Agardh et al, 2005). 
Epidemiology and prevalence of DM 
Diabetes meJJitus has reached epidemic proportions worldwide. The 
prevalence of diabetes in the United States of America is estimated to be 23.6 million, 
or 8% of the population, with type 2 diabetes accounting for 90% to 95% of all cases 
of diagnosed diabetes (American Diabetes Association, 2009). Type 1 diabetes 
patients are estimated to be 5-10% of all diabetes cases (Daneman, 2006). The 
incidence of type 1 diabetes has been increasing by about 3% per year (Aanstoot et 
al., 2007). In 2006 it affected 440 thousand children under 14 years of age and was 
the primary cause of diabetes in those who were less than 10 years of age (Asnstoot et 
al., 2007). Over the past two decades the worldwide prevalence of diabetes mellitus 
has risen dramatically, from an estimated 30 million cases in 1985 to 177 million in 
2000 (Wild et al, 2004). The incidence of diabetes mellitus is rapidly increasing and 
based on the current trends it is estimated that by the year 2030 more than 360 million 
individuals will be diabetic (Wild et al, 2004). Estimates which have been produced 
by the International Diabetes Federation (IDF) is that there will be 333 million 
diabetics by the year 2025 (International Diabetes Federation, Diabetes Atlas, 2006). 
Evidence has also accumulated that diabetes is also a risk factor for other age-related 
diseases such as Alzheimer's disease and a variety of cancers (Coughlin et al, 2004). 
Recently, it has been estimated that diabetes is the fifth leading cause of death 
worldwride and is responsible for almost 3 million deaths annually, which is a 1.7-
5.2% of deaths worldwide. For developing countries, adult diabetes numbers are 
likely to increase by 69% from 2010 to 2030, compared to 20% for developed 
countries, whereas total adult populations are expected to increase by 36% and 2% 
respectively (Shaw et al, 2010). 
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India now being termed the "diabetes capital of the world" as it leads the 
world with largest number of diabetic subjects. WHO report shows that 32 million 
people in India had diabetes in the year 2000 and is expected to increase to about 80 
million people by 2030. IDF estimated around 36 million diabetics in India in 2003, 
and this is further set to rise to 73.4 million by the year 2025. A recent report, 
estimated that from 50.8 million by the end of year 2010 the number of diabetics will 
shoot up to 87.0 million by the end of year 2030 (Shaw et al., 2010). 
Diagnosis of DM 
Diabetes mellitus is characterized by recurrent or persistent hyperglycemia 
and is diagnosed by demonstrating any one of the following:-
> Fasting plasma glucose level at or above 7.0 mmol/L (126 mg/dL). 
> Plasma glucose at or above 11.1 mmol/L (200 mg/dL) two hours after a 75 g 
oral glucose load as in a glucose tolerance test 
> Symptoms of hyperglycemia and casual plasma glucose at or above 
11.1 mmol/L (200 mg/dL). 
> Glycated hemoglobin (HbAic) at or above 6.5 (This criterion was 
recommended by the American Diabetes Association in 2010, akhough it is 
yet to be adopted by the WHO). 
Pathophysiologic features of various diabetic complications 
Diabetic nephropathy 
During hyperglycemia, glycation of structural and circulating serum proteins 
is a critical event associated with the glomerular dysfiinction accompanying diabetic 
nephropathy (Cohen and Ziyadeh, 1996). It encompasses discrete structural 
alterations, including renal hypertrophy, thickening of basement membranes, 
proteinuria progressing to renal insufficiency and progressive expansion of 
extracellular matrix components, key events in the genesis of diabetic renal damage. 
The earliest detectable change in the course of diabetic nephropathy is 
thickening in the glomerular basement membrane. Various mechanisms that are 
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operative in diabetic milieu (i.e., high glucose concentration, nonenzymatic glycation 
products, and glomerular hypertension) can stimulate the synthesis and release of a 
number of growth factors, cytokines, chemokines and vasoactive agents. These 
factors are thought to stimulate either proliferation or hypertrophy of various renal 
cells, as well as increased extracellular matrix production. Formation of early 
Amadori-glucose adduct and albumin AGEs have been shown to stimulate renal 
expression of various growth factors, including transforming growth factor (TFG-P) 
which are important mediators of diabetic nephropathy (Pugliese et al., 1997). The 
Amadori-glucose adduct, increases TGF-P type II receptor mRNA and protein 
expression in mesangial cell cultures thereby contributing towards the thickening of 
basement membrane, altered function and ultimately loss of glomelular fiinction 
(Ziyadeh et al., 1998). The concentration of the initial Amadori products of glycation 
on collagen (measured as fructosyllysine) are increased about threefold in type 1 
diabetic patients (McCane et al., 1993) and were independently associated with early 
nephropathy. In addition, in patients with long-standing type 1 diabetes with 
nephropathy, Amadori-glycated albumin levels were increased as compared with type 
1 diabetic patients without nephropathy (Schalkwijk et al., 1999). 
Diabetic retinopathy 
Retinopathy is the most common microvascular complication of diabetes, and 
it remains a major cause of visual impairment worldwide (Marshall and Flyvbjerg, 
2006). Microvascular lesions such as microaneurysms, blood barrier dysfunction, 
haemorrhages and infraction affecting retina of the eye accompanied by thickening of 
basement membrane and capillary dropout are key features of diabetic retinopathy 
(Klein et al., 1992). Early and the advanced glycation products differently affect 
retinal microvascular cell growth (Amin et al., 1997). Increased amounts of AGEs as 
well as early glycation products have been detected in the vitreous humor of diabetic 
patients with proliferative diabetic retinopathy (Sebag et al., 1992). In retinal pigment 
epithelial cells, Amadori-modified glycated albumin increases the production of the 
inflammatory cytokines interleukin (IL-8) and monocyte chemotactic protein (MCP-
1) and activates the mitogen activated protein kinase (MAPK) pathway, protein 
kinases, JAK, and the transcription factor nuclear factor (NF)-KB (Bian et al., 1998; 
Ibrahim et al., 2011). Fructoselysine, an initial Amadori adduct in collagen in type 1 
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diabetic patients has been shown to be independently associated with retinopathy 
(McCane et al, 1993). AGEs contribute towards vascular occlusion and increased 
permeability of retinal endothelial cells causing vascular leakage (Chibber et al, 
1997). 
Diabetic atherosclerosis 
Both diabetes and atherosclerosis, the diseases that are intimately linked to one 
another, may be described as diseases resuhing from chronically elevated levels of 
plasma glucose and/or lipids. It is characterized by the deposition of atherosclerotic 
plaques in arterial walls and myocardial infraction. Nonenzymatic glycation of 
Apolipoprotein B (Apo B) in low density lipoproteins (LDL) is considered to be a 
proatherogenic modification contributory to the increased susceptibility of patients 
with diabetes to atherosclerotic disease. Plasma concentrations of glycated LDL 
measured by several different methods are increased in diabetic patients (Jack et al., 
1998; Tames et al, 1992; Cohen et al, 1993; Akanji et al, 2002) and show positive 
associations with other markers of cardiovascular disease such as serum cholesterol 
and triglyceride levels (Cohen et al, 2004). Amount of Amadori-modified LDL 
correlates positively with microalbuminuria (Cohen et al, 2004), a marker of 
inflammation and an independent risk factor for cardiovascular mortality (Agewall et 
al, 1997) that has been found to be associated with increased cardiovascular mortality 
in type 1 and type 2 diabetes (Borch-Johnsen et al, 1985; Jarrett et al, 1984; Nelson 
et al, 1988; Schmitz and Vaeth, 1988). Approximately 2-5% of apo B in the plasma 
of diabetic patients are glycated, compared to about 1% in the plasma of non-diabetic 
control subjects (Turk, 2001). Evidence for the participation of glycated LDL in 
atherogenesis in vivo can be found in results from animal experiments and from 
studies of human atherosclerotic plaques. Syrian hamsters made diabetic with 
streptozotocin developed atheromatous lesions in the aortic arch and exhibited an 
elevated concentration of glycated LDL that is more susceptible to oxidation, and 
glycoxidative products are immunochemically detectable in the foam cells of fatty 
streaks (Yamanouchi et al, 2000). 
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Role of Amadori-modified albumin in the pathophysiology of 
diabetic complications 
Evidence suggest that early glycated albumin is not just an index of glycemia 
or the precursor of AGEs. By itself, it may have important direct impacts on cellular 
functions and thus may play a pathophysiological role in microvascular complications 
of diabetes. It has been observed that Amadori-modified albumin is an independent 
and potent trigger of molecular mediators contributory to complications of diabetes 
(Cohen et al, 1994, 2005). The pathophysiological role of early glycated albumin is 
further evidenced by the finding of existence of specific receptors for early glycated 
albumin (Krantz et al, 1993; Salazar et al, 1995; Verbeke et al, 1996). These 
receptors differentially bind Amadori-modified glycated albumin, but not AGEs, 
suggesting that the functional role of early glycated albumin may differ fi-om that of 
AGEs. Specific receptors for early glycated albumin have also been described on 
murine aortic endothelial cells (Wu and Cohen, 1994). Binding of glycated albumin 
to these receptors inhibits aortic endothelial cell replication and basement membrane 
collagen production (Cohen et al, 1995). It has been demonstrated that the infusion of 
Amadori products in the circulation of normal rats induces glomerular vasodilatation 
and hyperfiltration, similar to those found in streptozotocin-induced diabetic animals 
(Sabbataniefa/., 1992). 
Endothelial dysfunction is closely associated with both micro- and macro-
vascular complications of diabetes (Raptis and Viberti, 2001). Endothelial cells 
preferentially take up circulating glycated proteins which may lead to endothelial 
dysfunction and contribute to diabetic microangiopathy (Williams et al, 1981; 
Schalkwijk et al, 2002). In vitro studies indicate that physiologically relevant 
concentrations of Amadori-modified albumin possesses multiple proatherogenic 
effects that include adhesion of macrophages (foam cells precursor), promoting 
oxidative stress, production of inflammatory mediators, endothelial damage and 
vessel wall hypertrophy, phosphorylation of extracellular signal regulated kinase 
(ERK), increase Transforming Growth Factor (TGF)-pl production and nuclear 
translocation of the transcription factors (NF-KB) (Fig. 3). Interaction of the Amadori-
glucose epitope with specific cell-associated binding proteins is believed to trigger the 
above and other effects (Salazar et al, 2000, 2001). That glycated albumin augments 
oxidative stress and fi-ee radical impairment that contribute to atherogenesis in 
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diabetes is supported by the finding that conformational shifts in the albumin 
molecule attendant to the formation of Amadori adducts, without the extensive 
damage to the folded structure that is typically induced by AGE, can affect anti-
oxidant properties of the protein and foster acquisition of pro-oxidant activity 
(Coussons et al, 1997; Howard and Smales, 2005). Data from experiments with 
glomerular mesangial and endothelial cells have established that an increased level of 
Amadori-modified albumin is accompanied by alterations in key cellular mediators 
that modulate cell signaling pathways which are important in regulating extracellular 
matrix production (ECM) and are known to participate in the development of diabetic 
nephropathy. Glycated albumin-receptor binding elicits a signal transduction pathway 
leading to the generation of oxygen free radicals. These reactive oxygen species 
activate the redox-sensitive transcription factor NF-KB (Hattori et al., 2002), a 
pleiotropic regulator of many genes. Amadori albumin has been shown to elicit the 
microglial activation in retina and secretion of TNF-a (Ibrahim et al., 2011) (Fig.4), 
activate PKC-pl and stimulate the expression of TGF-pi, a 1 (IV) collagen and 
fibronectin, prominent constituents of the expanded ECM that is seen in diabetic 
glomeruli (Howard, 2005; Cohen et al, 1997), (Chen et al., 2001) (Fig. 5). 
Pharmacological approaches to mitigate the deleterious effects of Amadori-albumin 
may be therapeutic approaches to adverse cardiovascular consequences of diabetes. 
Autoimmunity 
It is a physiological inherent feature of the immune system defined by the 
presence of auto-reactive lymphoc5^es and antibodies (Wardemann and Yurasov, 
2003). An autoantigen is usually a normal protein or complex of proteins (and 
sometimes DNA or RNA) that is recognized by the immune system as non-self 
leading to autoimmune reactions which causes serious damage to cells and organs. 
Sometimes the damage to self-cells or organs is caused by antibodies; in other cases, 
T cells are the culprit. Many autoimmune diseases such as type 1 diabetes are 
characterised by tissue destruction mediated directly by T-cells. Additionally, diseases 
such as rheumatoid arthritis and multiple sclerosis are primarily due to the 
action of self 
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Fig. 3 Glycated albumin promotes oxidative stress, produces inflammatory 
mediators and may cause endothelial damage and vessel wall hypertrophy. 
Source: Adapted from Epinex diagnostics, 2008 "Glycated albumin and 
diabetes monitoring." 
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albumin in a rat model of diabetes. 
Source: Ibrahim et al, (2011) Diabetes 60, 1122-1133. 
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cytokines like TGF beta leading to glomerular dysfunction. 
Source: Adapted from Epinex diagnostics, 2008 "Glycated albumin and 
diabetes monitoring." 
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reactive T-cells. 
In order to elicit an immune response, a molecule must be recognised as non-
self by the biological system. Studies with experimental auto-immune animal models 
have revealed a central role for CD4 TH cells in the development of autoimmunity. 
Numerous mechanisms have been proposed for induction of autoimmunity including:-
> Releaseof sequestered antigens 
> Molecular mimicry 
> Inappropriate class IIMHC expression on cells 
> Polyclonal B-cell activation 
It has been suggested that self proteins are rendered immunogenic if chemically or 
post-translationally modified under physiologic or pathologic conditions (Doyle and 
Mamula, 2001; Utz and Anderson, 1998). Protein modifications may lead to the 
generation or unmasking of new epitopes that will serve to activate B-cells and/ or T-
cells, thereby impassing immunological tolerance (Ohmori and Kanayama, 2005). 
Amadori products of HSA are immunogenic and type 1 diabetic patients with 
retinopathy and nephropathy have higher Amadori albumin levels than those without 
it (Cohen and Ziyadeh, 1994; Schalkwijk et al., 1999). AGE modified proteins are 
highly immunogenic and CML is one of the major epitopes recognised by anti-AGE 
antibodies (Reddy et al, 1995; Ikeda et al., 1996). 
Sources of ROS in diabetes 
At high concentrations, ROS may be deleterious to cell structures, nucleic 
acids, lipids and proteins (Valko et al., 2006). Diabetes is one of the pathological 
processes known to be related to an unbalanced production of ROS, such as hydroxyl 
radicals (OH), superoxide anions (O2 ) and H2O2. Under normal conditions, the key 
sites of superoxide formation in the mitochondrial membrane are complex I and the 
ubiquinone-complex III interface (Kwong and Sohal, 1998). However, diabetes alters 
the primary sites of superoxide generation so that complex II becomes the primary 
source of electrons that contribute to superoxide formation under diabetic conditions 
(Nishikawa et al, 2000). Another source of ROS in diabetes is NAD(P)H. Several 
lines of evidence support that NAD(P)H oxidases are a major source of glucose 
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induced ROS in the vasculature and kidney cells, confirming thus NAD(P)H as a 
mediator of diabetic complications (Li and Shah, 2003). Involvement of other cells 
has not been satisfactorily confirmed. Since hypertension is a common complication 
of diabetes, it is possible that expression of NAD(P)H oxidase is regulated similarly in 
both disease states. This arises from increased angiotensin II labelling in cardiac 
myocytes and endothelial cells from human diabetic patients (Li and Shah, 2003). 
High glucose-induced formation of ROS and p47phox [cytosolic component of 
activated NAD(P)H)] can be blocked with Ang II type 1 receptor antagonists, 
confirming thus a link between the two pathways of NAD(P)H oxidase activation. 
The NAD(P)H oxidase-mediated production of ROS in diabetes can be suppressed by 
a variety of PKC inhibitors, implicating this family of kinases in the regulation of 
hyperglycemia-induced NAD(P)H oxidase activity 
ROS and beta cell damage 
More than three decades ago, it was demonstrated that pancreatic islets contain 
relatively small amounts of the antioxidant enzymes CuZn-SOD, Mn-SOD, catalase, 
and glutathione peroxidase (GPx) (Grankvist et al, 1981). Further work demonstrated 
that p cells in rats were sensitive to peroxide and that the activity of GPx was low 
(Gorus et al., 1982). These and many other observations have reinforced the notion 
that the intrinsically low levels of antioxidant activity of islets render them 
particularly at risk for ROS-induced damage. Due to the low level of antioxidant 
enzyme expression and activity, the beta cells are at greater risk of oxidative damage 
than tissues with higher levels of antioxidant protection. For protection from the 
highly toxic hydroxyl radical and other ROS, the beta cells must metabolize hydrogen 
peroxide via catalase and GPx. However, a potentially major problem for the beta 
cells is their unusually low complement of SOD, catalase and GPx. This unusual 
situation sets up the beta cell as an easy target for ROS, whether generated by 
interactions with cytokines or elevated level of glucose. 
Recent studies suggest that oxidative and nitrosative stress play major role in 
the onset of diabetic complications. Nitric oxide synthase oxidizes arginine to 
citruUine in the presence of biopterin, NADPH, and oxygen. Generally, nitric oxide at 
physiological levels produces many benefits to the vascular system. However, 
26 
increased oxidative stress and subsequent activation of the transcription factor NF-KB 
have been linked to the development of late diabetic complications. The NF- KB 
enhances nitric oxide production which is believed to be a mediator of islet beta-cell 
damage. 
Mechanism of action of alloxan 
Alloxan (2,4,5,6-tetraoxypyrimidine; 5,6-dioxyuracil) was first described by 
Brugnatelli in 1818. The diabetogenic properties of this drug were reported in the year 
1943 by Dunn and McLetchie, who studied its effect in rabbits and reported specific 
necrosis of pancreatic islets. Since then, alloxan diabetes has been commonly utilized 
as an animal model of insulin dependent diabetes mellitus (IDDM). Alloxan is a toxic 
glucose analogue, which selectively destroys insulin-producing beta cells in the 
pancreas when administered to rodents and many other animal species. This causes an 
insulin-dependent diabetes mellitus (called "Alloxan Diabetes") in these animals with 
characteristics similar to type 1 diabetes in humans. Alloxan is selectively toxic to 
insulin-producing pancreatic beta cells because it preferentially accumulates in beta 
cells through uptake via the GLUT2 transporter. Alloxan, in the presence of 
intracellular thiols, generates ROS in a cyclic reaction with its reduction product, 
dialuric acid. It is then re-oxidized back to alloxan establishing a redox cycle 
generating superoxide radicals (Munday, 1988). Moreover, superoxide radicals 
undergo dismutation to hydrogen peroxide. In presence of Fe^^ and hydrogen 
peroxide, highly reactive hydroxyl radicals are then formed by Fenton reaction. The 
action of hydroxyl radicals following alloxan treatment has been reported in vitro 
(Grankvist etal, 1981; Munday, 1988) and in vivo (Kurahashi etai, 1993). Alloxan 
mediated toxicity of beta cells is initiated by free radicals formed in this redox 
reaction. 
Alloxan has two distinct pathological effects; it selectively inhibits glucose-
induced insulin secretion through specific inhibition of glucokinase, the glucose 
sensor of the beta cell, and it causes a state of insulin-dependent diabetes through its 
ability to induce ROS formation, resulting in the selective necrosis of beta cells. 
These two effects can be assigned to the specific chemical properties of alloxan, the 
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common denominator being selective cellular uptake and accumulation of alloxan by 
the beta cells. 
Beta cell selectivity of alloxan 
The alloxan molecule is structurally so similar to glucose that the GLUT2 
glucose transporter in the beta cell plasma membrane accepts this glucomimetic and 
transports it into the cytosol (Gorus et al, 1982). Alloxan does not inhibit the function 
of the transporter (Eisner et al, 2002), and can therefore selectively enter beta cells in 
an unrestricted manner. Alloxan has a central 5-carbonyl group that reacts very avidly 
with thiol groups. Glucokinase (hexokinase IV) is the most sensitive thiol enzyme in 
the beta cell (Tiedge et al, 2000). Alloxan reacts with two -SH groups in the sugar 
binding site of glucokinase resulting in the formation of the disulfide bond and 
inactivation of the enzyme. Inhibition of glucokinase reduces glucose oxidation and 
ATP generation (Gunnarsson and Hellerstrom, 1973) thereby suppressing the ATP 
signal that triggers insulin secretion (Lenzen and Panten, 1988). 
Beta cell toxicity and diabetogenicity of alloxan 
Alloxan exerts its diabetogenic action when administered intravenously, 
intraperitoneally or subcutaneously. It exhibits a high affinity to the SH-containing 
cellular compounds, reduced glutathione (GSH), cysteine and protein-bound 
sulfhydryl groups (including SH containing enzymes) (Lenzen and Munday, 1991). 
The reduction of alloxan to dialuric acid in the cell requires a suitable thiol, typically 
the tripeptide glutathione (GSH) to generate the redox cycling partner, dialuric acid, 
and oxidised glutathione (Bromme et al, 2000) The triketone structure of alloxan is 
vitally important for this two-step reaction with glutathione (Eisner et al, 2008) 
which generates the alloxan radical as an intermediate product. Thiols such as 
cysteine (which are present at lower concentrations in the cell), dithiols and ascorbic 
acid are also suitable reducing agents and may therefore contribute to alloxan 
reduction (Eisner et al, 2006). Alloxan can also generate ROS by reaction with thiol 
groups on enzymes (Lenzen and Mirzaie-Petri, 1992) and albumin (Sakurai and 
Miura, 1989). During each typical redox cycle a small amount of'Compound 305', an 
alloxan-GSH adduct, is formed (Bromme et al, 2002).The intracellular concentration 
of compound 305 increases in a time-dependent manner which gradually decreases 
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the amount of reduced GSH available in the cell for redox cycling, thus producing a 
lower pro-oxidative ratio between alloxan and GSH, rather than a higher antioxidative 
ratio. 
Hyperglycemia and free radical link 
Pathogenesis of diabetic complications continues to be a central issue in 
current diabetes research. Hyperglycemia, a key clinical manifestation of diabetes 
mellitus causes enhanced non-enzymatic glycosylation of proteins that leads to 
secondary complications in diabetes (Brownlee et al, 1984; Kirschenbaum, 1984). In 
diabetes, sugar concentration, extent of glycation and the degree of damage increases 
in parallel. Free radicals are formed disproportionately by glucose auto-oxidation, 
non-enzymatic glycation and due to subsequent degradation of glycated proteins. 
Excessively high levels of free radicals cause damage to cellular proteins, membrane 
lipids and nucleic acids, and eventually cell death. Various mechanisms have been 
suggested for the formation of reactive oxygen free radicals. Glucose oxidation is 
believed to be the main source of free radicals (Robertson et al., 2003). In its enediol 
form, glucose is oxidized in a transition-metal dependent reaction to an enediol 
radical. This radical reduces molecular oxygen to generate superoxide radical and 
becomes oxidized itself to a dicarbonyl ketoaldehyde that is converted into reactive 
ketoaldehydes that reacts with protein amino groups forming a ketoamine. 
Ketoamines are similar to, although more reactive, than Amadori products and 
participate in AGE formation (Ahmed, 2005). The superoxide radicals undergo 
dismutation to hydrogen peroxide, which if not degraded by catalase or glutathione 
peroxidase, and in the presence of transition metals, can lead to production of 
extremely reactive hydroxyl radicals (Wolff and Dean, 1987; Jiang et al, 1990; 
Robertson et al., 2003). Superoxide radicals can also react with nitric oxide to form 
reactive peroxynitrite radicals (Zou et al, 2002). Hyperglycemia is also found to 
promote lipid peroxidation of low density lipoproteins (LDL) by a superoxide-
dependent pathway resulting in the generation of free radicals (Kawamura et al, 
1994). Another important source of free radicals in diabetes is the interaction of 
glucose with proteins leading to the formation of an Amadori product and then AGEs 
(MuUarkey et al, 1990; Thomas et al, 2005). 
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Superoxide radical 
Superoxide anion is an oxygen-centered radical with selective reactivity. This 
species is produced by a number of enzyme systems, by autooxidation reactions, and 
by nonenzymatic electron transfers that univalently reduce molecular oxygen. In 
aqueous solution, O j ' can oxidize ascorbic acid. It can also reduce certain iron 
complexes such as cytochrome c and ferric ethylenediaminetetraacetic acid 
(Fe^ -^EDTA). Superoxide dismutase (SOD) accelerates the dismutation of 62", 
converting it to H2O2 and O2. During glycation, Amadori products generate 02~ 
which is converted to H2O2 by non-enzymatic dismutation reaction (Nagai et ai, 
1997). 
Hydroxy I radical 
It is a highly reactive oxygen-centered radical with an estimated in vivo half-
life only 10~^ s. One feature of OH is that it begets another radical i.e. when it reacts 
with a molecule, the result is the formation of another radical species. The resulting 
species usually has lower reactivity than OH. Hydroxyl radical attacks proteins, 
DNA, PUFA in membranes and almost any biological molecule it touches. During 
glycation, hydroxyl radical generated by Fenton reaction between Fe^ ^ and Amadori 
derived endogeneous H2O2 plays an important role in oxidative cleavage of Amadori 
compounds into CML (Nagai et al., 1997). 
Protein damage by free radicals 
Protein damage by free radicals is critical in many biological processes 
(Cabiscol et al., 2000). It causes cross-linking, backbone fragmentation, as well as 
amino acid modification leading to functional inactivation of proteins (Dean et al., 
1997). Amino acids can undergo oxidative damage if they interact with oxygen free 
radicals. As free radicals are capable of initiating chain reactions, cross-linking of 
soluble and membrane/or membrane bound proteins yield larger aggregates. The 
direct consequence is a change in higher order structure of the protein, resulting in 
loss of biological function (Dhalla et al., 2000; Schoonover, 2001). Usually the 
inactivated proteins are degraded, so that proteolysis forms a secondary defence after 
anti-oxidants. However, when the target proteins are critical for rapid homeostatic 
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mechanisms (e.g., transport proteins) or when the proteolytic defence and or/other 
anti-oxidant defences are over whelmed, toxic events may ensue. The physiologically 
damaged proteins are degraded and replaced by the cells (Thomalley et al, 2003). 
Cellular proteolysis liberates the glycated and oxidized amino acids as free adducts. 
The plasma concentration and urinary secretion of the free adducts are increased 
excessively in type 1 diabetes (Ahmed et al, 2005a). 
Protection against glycation 
Having understood the damaging effects of glycation, scientist are exploring 
the methods of protection against glycation. The underlying inhibitory mechanisms of 
anti-glycating agents is mainly through the blocking of sugar attachment to proteins, 
attenuating glycoxidation and oxidative stress through trapping or scavenging some 
intermediates including reactive dicarbonyls, free radicals and nitrogen species 
produced in the process of glycation. Recent studies on AGE inhibition by synthetic 
compounds and natural products have led to the development of various AGE 
inhibitors and AGE-cross-link breakers 
Anti-glycating agents 
Synthetic inhibitors 
Synthetic AGE inhibitors are generally strong nucleophiles capable of reacting 
with reducing monosaccharides and other carbonyl metabolites and hence prevent 
modifications of protein amino groups (Khatami et al., 1988; Lewis and Harding, 
1990). A few of them exert their effect at the early stage of glycation (Type a and b 
inhibitor) by interfering with the initial attachment between reducing sugars and 
amino groups, thus inhibiting the further formation of Schiff base and AGEs (Harding 
and Ganea, 2006). Several potential drug candidates have been examined in vitro or in 
diabetic animal models (Blakytny and Harding, 1992; Shyadehi and Harding, 2002). 
A competitive mechanism of action of these drug candidates is mainly ascribed to 
their scavenging abilities on both reactive carbonyls (Type c inhibitor) and radicals 
(Type c inhibitor) formed during glycation, or blocking the formation of intermediate 
Amadori products (Type e inhibitor) (Harding and Elena, 2006 ). 
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Among the pharmacological agents tested, aminoguanidine (AG) has been 
reported to be one of the most effective inhibitors of AGE formation in lens proteins 
(Lewis and Harding, 1990; Matsumoto et al., 1997). Other guanidine derivatives like 
arginine (Menzel et al, 1991) and metformin (Beisswenger et al., 1999) have shown 
similar effects on protein glycation. It has been found that free amino acids (lysine, 
glycine, glutamic acid and aspartic acid) reduce the incorporation of radioactive 
labeled glucose (Ramakrishnan et al., 1996) and galactose (Ramakrishnan et al, 
1997) into lens proteins. Potential beneficial effects on the prevention of protein 
glycation have been reported for vitamin Bl and vitamin B6 (Booth et al, 1996), 
camosine (Hipkiss, 2005; Argirova and Argirov, 2003) and taurine (Devamanoharan 
etal, 1997), 
Natural inhibitors 
Natural products as anti-glycating agents are relatively safe for human 
consumption as compared to synthetic compounds. The anti-glycation activities of 
both plant materials and naturally occurring phenolic compounds with antioxidant 
properties have been investigated (Salem, 2005; Ismail et al, 2010; Liu et al, 2011). 
As oxidative stress accompanies and accelerates the formation of AGEs, antioxidant 
compounds appear to be promising agents for the prevention of AGE formation. 
Anti-glycating agents as scavengers of free radical in hyperglycemia 
Several groups have reported that Schiff base or Amadori product generate 
reactive oxygen species (MuUarkey et al, 1990). Therefore, scavenging of free 
radicals by preventing radical formation and intercepting radical fi^om further activity 
are done by antioxidants (Cotgreave and Gerdes, 1998). Any compound (natural or 
synthetic) with antioxidant and antiglycating activity might totally or partially 
alleviate this damage. Amoung the synthetic compounds, aminoguanidine is quiet 
interesting as it has both antioxidant and antiglycating properties. Aminoguanidine, a 
nucleophilic hydrazine has been proposed to react with the Amadori product and 
block fiirther reactions (Januel et al, 2003; Bucala et al, 1994). Hydrazine 
compounds are capable of interaction with carbonyl groups of different biological 
constituents, including glucose. The hydrazine moiety of aminoguanidine can mop up 
with the carbonyl group of glucose and thus can prevent the attachment of the sugar 
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residue with the amino groups of the proteins. It also prevents the loss of antioxidant 
enzyme activities as well as cellular damage (Kedziora-Komatowska et ai, 1998). 
Another compound thymoquinone (TQ) [2-Isopropyl-5-methyl-l, 4-benzoquinone] is 
one of the most active ingredients of Nigella Sativa seeds. Thymoquinone is a 
powerful antioxidant (Nagi et al., 1999; Ismail et al, 2010) and a potent superoxide 
radical scavenger (Badary., et al, 2003 ; Kruk et al, 2000). Morever, animal studies 
have also shown that thymoquinone has anti-diabetic effect (Kanter et al, 2003; 
2004). 
Antioxidant classification 
Endogenous compounds in cells can be classified as enzymatic antioxidants 
and non-enzymatic antioxidants. The major antioxidant enzymes directly involved in 
the neutralization of reactive oxygen species are: superoxide dismutase (SOD), 
catalase (CAT), glutathione peroxidase (GPx) and glutathione reductase (GRx) 
(Haliiwell, 2007). Superoxide dismutase, the first line of defense against fi-ee radicals, 
catalyzes the dismutation of superoxide anion radical (O2 ) into hydrogen peroxide 
by reduction. The hydrogen peroxide is transformed into water and oxygen by 
catalase or glutathione peroxidase. The selenoprotein Gpx enzyme consumes 
hydrogen peroxide for oxidizing reduced glutathione (GSH) into oxidized glutathione 
(GSSG). Glutathione reductase, a flavoprotein enzyme, regenerates GSH fi-om GSSG, 
with NADPH as a source of reducing power. Besides hydrogen peroxide, Gpx also 
reduces lipid or nonlipid hydroperoxides while oxidizing glutathione (GSH) (Bahorun 
et al, 2006; Genestra, 2007). Non-enzymatic antioxidants include lipoic acid, mixed 
carotenoids, coenzyme QIO, several bioflavonoids, antioxidant minerals (copper, 
zinc, manganese and selenium) and cofactors (folic acid, vitamins Bl, B2, B6, B12). 
Antioxidants defence status in diabetic patients 
Aerobic metabolism is always accompanied by the production of ROS, 
consequently all aerobic organisms possess some sort of anti-oxidant defence system 
with enzymatic and non-enzymatic constituents capable of preventing excess radical 
production, neutralizing fi-ee radical and repairing the damage caused by them (Sies, 
1993). Under diabetic conditions, ROS increases in various tissues and are involved in 
the development of diabetic complications (Dandona et al, 1996; Brownlee, 2001; 
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Mokini, 2010). Antioxidant defence mechanism are overwhelmed in diabetic patients 
and an altered balance between ROS production and antioxidant levels have been 
reported (Ceriello, 2000). The overproduction of ROS lowers antioxidant defence and 
ahers enzymatic pathways in humans with poorly controlled diabetes mellitus 
(Hoghkinson et al., 2003). 
Oxidative stress under hyperglycemic conditions 
Pancreatic P-cells have emerged as a target of oxidative stress-mediated tissue 
damage (Kaneto et al., 1996; Evans ei al., 2003). The P-cells express abundant levels 
of the high-Km glucose transporter GLUT2 and thereby display highly efficient 
glucose uptake when exposed to high glucose concentrations. Accordingly, 
extracellular hyperglycemia causes intracellular hyperglycemia in P-cells leading to 
the induction of ROS in pancreatic islets of diabetics. Sources of ROS production in 
cells are (1) the non-enzymatic glycosylation reaction (Matsouka et al., 1997), (2) the 
electron transport chain in mitochondria (Nishikawa et al., 2000) and (3) the 
hexosamine pathway (Kaneto et al., 2001). Glycation suppresses the insulin gene 
transcription in P-cells by provoking oxidative stress (Matsouka et al., 1997) Chronic 
hyperglycemia suppresses insulin biosynthesis and secretion by provoking oxidative 
stress through various pathways which play a role in maintaining normal P-cell 
function by regulating many important P-cell genes including insulin, GLUT2 and 
glucokinase (Petersen et al., 1994). Also, the electron transport chain in mitochondria 
is likely to be an important pathway triggering the production of ROS. Indeed, it has 
been suggested that mitochondrial overwork, which causes the emergence of ROS, is 
a potential mechanism causing impaired first-phase glucose-stimulated insulin 
secretion found in the early stage of diabetes (Sakai et al., 2003) as well as diabetic 
complications. 
Role of antioxidants in ameliorating oxidative stress 
Human body is equipped with several mechanisms to counteract oxidative 
stress. Both endogenous antioxidants and exogeneous antioxidants are involved in 
handling oxidants. The roles of antioxidants are to neutralize the excess of free 
radicals, to protect cells against their toxic effects and to contribute to disease 
prevention. An antioxidant functions in one of the two ways: 
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• chain-breaking 
• or prevention 
When a radical releases or steals an electron, a second radical is formed. The last one 
exerts the same action on another molecule and continues until either the free radical 
formed is stabilized by a chain-breaking antioxidant (vitamin C, E, carotenoids, etc), 
or it simply disintegrates into an inoffensive product. The classic example of such a 
chain reaction is lipid peroxidation. Antioxidant enzymes like superoxide dismutase, 
catalase and glutathione peroxidase can prevent oxidation by reducing the rate of 
chain initiation (e.g. either by scavenging initiating free radicals or by stabilizing 
transition metal radicals such as copper and iron) (Young and Woodside, 2001). 
Beneficial effects of antioxidant therapy 
Beta cells are particularly sensitive to ROS because they are low in free-
radical quenching enzymes such as catalase, glutathione peroxidase and superoxide 
dismutase. Oxidative stress is implicated in apoptosis of pancreatic beta cells and 
impaired insulin signalling in diabetes (Newsholme et al., 2007). Antioxidant 
treatment may exert beneficial effects in diabetes. Antioxidant treatment can suppress 
apoptosis in cells without changing the rate of cell proliferation, supporting the 
hypothesis that in chronic hyperglycemia apoptosis induced by oxidative stress causes 
reduction of cell mass. In a previous study, antioxidant treatment preserved the 
amounts of insulin content and insulin mRNA (Kaneto etal, 1999). 
Objectives of the present study 
Recent studies have clearly pointed out that nonenzymatic glycation products 
(early and advanced) are involved in hyperglycemia-induced diabetic complications. 
Efforts are continuing to develop physiologically active substances which can delay 
or prevent protein modifications by glycation. Accumulated Amadori products may 
lead not only to AGE deposition in tissues but also to other pathophysiological 
consequences, such as activation of oxidative stress by excessive free radical 
generation. These products and free radicals are known to cause severe protein 
damage resuhing in major structural alterations which is implicated either through 
their ftmctional disability or these being highly immunogenic. It has been found that 
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in diabetic state, serum proteins containing Amadori glucose adducts acquire biologic 
properties that are strongly linked to the pathogenesis of vascular complications of 
diabetes. The in vitro exposure of protein to glucose results in the non-enzymatic 
covalent attachment of glucose to lysine side chains in a manner that is observed in 
vivo. As lysine residues are potential target for early glycation, lysine rich proteins 
like HSA can be used as marker for early glycation induced changes and antibody 
detection against it might emerge as an important parameter for early diagnosis of 
diabetes related complications. Moreover, deciphering the mechanism of protein 
damage caused by glucose is fundamental in understanding the biochemical basis of 
diabetic complications and in the development of new therapeutic strategies 
The major objectives of the study were; i) to study biophysical and 
immunological changes in HSA after modification with glucose, ii) antiglycation 
effect of aminoguanidine and thymoquinone both in vitro and in vivo and iii) 
evaluation of autoantibodies against glycated-HSA in sera of type 1 diabetes patients. 
To achieve the objectives, the work was carried out according to the following plan:-
Commercially available human serum albumin was modified by D-glucose to obtain 
high yield of Amadori products (an early glycation product). The Amadori product 
was assayed by NBT assay and authenticated by boronate affinity chromatography. 
Structural changes were studied by uhraviolet, fluorescence, circular dichroic and FT-
ER. spectroscopy, heat induced thermal denaturation, HPLC, LC-MS and ESI-MS. The 
inhibition of glycation and free radical production by aminoguanidine and 
thymoquinone have also been studied. Antigenicity of native and glycated-HSA was 
probed by inducing antibodies in rabbits and assessed by direct binding ELISA. 
Specificity of the induced antibodies was evaluated by competition ELISA and gel 
retardation assay. Binding profile of autoantibodies against glycated-HSA in sera of 
type 1 diabetic patients have been studied to assess the correlation between 
progressive rise in autoantibodies and secondary complications in diabetes. The 
polyclonal anti-glycated-HSA antibodies were used as immunochemical probe to 
detect glycation induced changes in albumin isolated from diabetic patients. 
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MATERIALS 
Chemicals 
Human serum albumin, alloxan monohydrate, aminoguanidine hydrochloride, 
thymoquinone, diethylene triaminepenta-acetic acid (DTPA), catalase, superoxide 
dismutase (SOD), bovine serum albumin, protein A-agarose (2.5ml pre-packed 
column), agarose, sodium azide, cytochrome c, Tween-20, dialysis tubing, anti-human 
and anti-rabbit IgG alkaline phosphatase conjugate, para-nitrophenyl phosphate, 
Tween 20, NADPH, Freund's complete and incomplete adjuvants, 
m-aminophenylboronic acid, dextran blue, haematoxylin, eosin and Coomassie 
Brilliant Blue G-250 were purchased from Sigma Chemical Company, USA. Furosine 
was procured from Polypeptide Laboratories, Strastbourg, France. D-glucose, sodium 
borohydride (NaBR*), 2, 4-dinitrophenylhydrazine (DNPH) and ethylacetate were 
purchased from Merck, India. Acrylamide, bisacrylamide, ammonium persulphate and 
N,N,N',N'-tetramethylethylenediamine (TEMED) were from Bio-Rad Laboratories, 
USA. Pyrogallol, 5, 5,dithio-bis 2-nitrobenzoic acid (DTNB), succinic acid, nitroblue 
tetrazolium (NBT), ammonium bicarbonate, 2,4,6-trinitrobenzene sulphonic acid 
(TNBS), sulphosalicyclic acid and sodium dodecyl sulphate (SDS) were from Sisco 
Research Laboratries, India. Polystyrene microtitre flat bottom ELISA plates and 
modules were purchased from NUNC, Denmark. Sephacryl S-200 HR was purchased 
from Amersham Biosciences, Sweden. Ammonium sulphate, dimethyl sulphoxide 
(DMSO), D-mannitol, sodium nitrite, silver nitrate, xylene, sodium carbonate, 
hydrogen peroxide, trichloroacetic acid, sodium chloride, isopropanol, fr)rmaldehyde, 
glacial acetic acid, EDTA and oxalic acid were obtained from Qualigens Fine 
Chemicals, India. All other chemicals and reagents were of the highest analytical 
grade available. 
Equipments 
Spectrophotometer (model, UV-1700; Shimadzu, Japan) attached with a 
temperature-programmer and controller unit, Spectrofluorometer (model, RF-5301; 
Shimadzu, Japan), Spectropolarimeter (model, Jasco J-815; USA), ELISA reader 
(Labsystem Multiskan, Finland), pH meter (model, Ll-120; ELICO, India), 
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Polyacrylamide gel electrophoresis assembly (Genei, India), Avanti 30 table top high 
speed refrigerated centrifuge (Beckman, USA), Glucometer (Accu-check), 
Hemoglobin Aic analyser (Bio-Rad D-IO *^^ ), Gel- doc (Bio-Rad laboratories, USA), 
Agilent 1100 HPLC system (Palo Alto, California) and C-18 column ( Synergi, USA), 
an orthogonal time of flight (TOF) mass spectrometer (Applied Biosystems, Mariner 
atmospheric pressure ionization TOF workstation, Framingham, MA, USA) equipped 
with standard ESI source and LC-MS; Micromass Quattro II triple quadrupole mass 
spectrometer (Beverly, MA, USA) coupled with HPLC and FT-IR spectrometer 
(Perkin Elmer, Germany) were the major equipments used in this study. 
Collection of blood samples 
Fasting blood samples were collected from diabetic patients (type 1) attending 
OPD clinics at Rajiv Gandhi Center for Diabetes and Endocrinology, Jawaharlal 
Nehru Medical College Hospital, Aligarh Muslim University, India after obtaining 
their verbal consent. It was ensured that none of the diabetic patients were suffering 
from other auto-immune diseases. Normal human blood was obtained from age- and 
sex- matched apparently healthy individuals. All blood samples were collected in 
plain glass test tubes and left for clot formation. Sera were separated and heated at 
56°C for 30 min to inactivate complement proteins and stored in small aliquots at -
20°C with 0.1% sodium azide as preservative. 
Experimental animals 
Twenty four male rabbits (1-1.5 kg) were obtained from the Central Animal 
facility of the Jawaharlal Nehru Medical College, Aligarh Muslim University, India. 
Animals were housed in cages (with wide square mesh at the bottom to avoid 
coprophagy) and placed in a well ventilated animal room with 12 h light/ 12 h dark 
cycle, 50% humidity and 28 ± 2°C temperature. The animals were acclimatized to 
laboratory conditions for about a week. All animals received a standard diet and water 
ad libitum. The protocol and procedure for the experiments was duly approved by the 
Animal Ethics Committee of the institution. 
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METHODS 
Determination of protein concentration 
Protein was estimated in samples by the method of Lowry et al., (\951) and 
Bradford (1976). 
Lowry method for protein estimation 
'7-*-
Protein estimation by this method utilizes alkali (to keep the pH high), Cu 
ions (to chelate proteins) and tartarate (to keep the Cu^ ^ ions in solution at high pH). 
(a) Folin- Ciocalteau reagent 
Commercially available Folin-Ciocalteau reagent was diluted 1:4 with distilled 
water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as under; 
(i) Two percent sodium carbonate in lOOmM sodium hydroxide. 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium-potassium tartarate. 
The working reagent was prepared fresh by mixing components (i) and (ii) in 50:1 
ratio. 
(c) Procedure 
Varying amounts of protein (BSA) in 1.0 ml volume was mixed with 5.0 ml of 
freshly prepared alkaline copper reagent and incubated at room temperature for 10 
min. One ml working Folin-Ciocalteau reagent was added followed by 30 min 
incubation at room temperature. The absorbance was monitored at 660 nm. Protein 
content of unknown sample was determined from the standard plot of bovine serum 
albumin. 
Bradford method 
This assay is based on the change in absorption maximum of an acidic 
solution of Coomassie Brilliant Blue G-250 from 465 nm to 595 nm when protein 
39 
binds to the dye. Both hydrophobic and ionic interactions stabilize the anionic form of 
the dye, causing a visible color change. 
Dye preparation 
One hundred mg Coomassie Brilliant Blue G-250 dye was dissolved in 50 ml 
of 95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid added. The resulting 
solution was diluted to 1 litre and fihered through whatman filter paper (No. 1) to 
remove undissolved particles. 
Protein assay 
To one ml of solutions containing 10-100 mg protein, 5.0 ml of dye solution 
was added and the contents were mixed by vortexing. The absorbance was read at 595 
nm after 5 min against the blank reagent. 
Modification of human serum albumin by glucose 
Human serum albumin (HSA) was modified by glucose according to the 
protocol described by Cohen and Hud (1989). Briefly, HSA (10 \iM) was incubated 
with glucose (50 mM) in 20 mM phosphate buffered saline (PBS, pH 7.4) in presence 
of 0.01 mM diethylene-triaminepenta-acetic acid (DTPA) at 37 °C in sterile and 
capped vials for one week incubation, samples were extensively dialyzed against 
PBS to remove excess/ unbound glucose. As a control, HSA (10 i^M) in PBS 
incubated under identical conditions served as control. 
Ultraviolet analysis of native and glycated-HSA 
The UV absorption profile of native HSA and glycated samples were recorded 
in the wavelength range of 190-400 nm on spectrophometer using quartz cuvette of 
1cm path length. The increase in absorbance (hyperchromicity) was calculated as 
follows; 
Percent hyperchromicity = ^ modified HSA "ativeHSAJ ^ JQO 
-^modified HSA 
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Estimation of Amadori product (Fructosamine) by NBT 
The Amadori content (fructosamine), in native HSA and glucose modified-
HSA was determined by NBT assay (Johnson et a/., 1982). Native and modified-HSA 
samples (100 \il each) were added in duplicate to 96-well microtiter plates followed 
by 100 ^l NBT reagent (250 \imoV\ in 0.1 mol/1 carbonate buffer, pH 10.35) in each 
well. The microtitre plates were then incubated at 37 °C for 2 hr. The color was read 
at 525 nm on a microplate reader. Amadori products were quantitated using an 
extinction coefficient of 12640 cm'^ mol"^ for monoformazan (Mironova et al., 2005). 
Detection of 5-hydroxymethylfurfural (HMF) 
Formation of 5-hydroxymethylfurfural from the Amadori product of glycated 
HSA was detected by thiobarbituric acid (TBA) reaction according to the method 
described by Ney et al., (1981). Briefly, 1 ml each of native HSA and modified-HSA 
samples were mixed with 1 ml of oxalic acid (1 M) and incubated at 100°C for 2 hr. 
Then, the protein from the assay mixture was removed by precipitation with 40% 
trichloroacetic acid. 0 25 ml of TBA (0.05 M) was added to 0.75 ml of protein free 
filtrate and incubated at 40°C for 40 min. The color was read at 443 nm and amount 
of HMF was calculated using molar extinction coefficient of 4x lO^'crn'mol' 
Sodium borohydride (NaBH4) reduction of glycated-HSA 
Glycated HSA was reduced with NaBHi as described earlier (Njoroge et al., 
1988). Briefly, 1 ml of glycated-HSA was reduced by adding NaBH4 (IM NaBH4 in 
0.1 N NaOH) followed by 1 hr incubation at room temperature. Excess borohydride in 
the reaction mixture was destroyed by slow addition of IN HCl. 
SDS-polyacrylamide gel electrophoresis 
SDS-PAGE of native and glycated-HSA samples was performed as described 
earlier (Laemmli, 1970). The following stock solutions were prepared:-
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Acrylamide-hisacrylatmde (30:0.8) 
A stock solution was pepared by dissolving 30 gm acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. The solution was filtered 
and stored at 4°C in an amber color bottle. 
Resolving gel buffer 
A stock solution was prepared by dissolving 9.08 gm Tris base in 40 ml 
distilled water. The pH was adjusted to 8.8 by 6 N HCl and the final volume brought 
to 50 ml with distilled water. 
Electrode buffer 
3 gm Tris base, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and final volume was made to one litre. 
Procedure for PAGE 
Thoroughly cleaned glass plates separated by 1.5 mm thick spacer were sealed 
with 1% agarose fi-om sides and bottom. The resolving gel mixture (10%) was 
prepared by mixing the components and poured between the glass plates and allowed 
to polymerize at room temperature. Protein samples mixed with one fourth of sample 
dye (10% SDS, 50% glycerol, IM Tris, pH 6.8 and 1% bromophenol blue [w/v] as a 
tracking dye) were loaded into the wells, and electrophoresis was carried out at 80 
vohs for 3-4 hr in Tris-glycine buffer. 
Recipe for 10% resolving gel 
Component Volume 
Acrylamide-biacrylamide (30:0.8) 3.3 ml 
Resolving gel buffer 2.5 ml 
Distilled water 4.0 ml 
10% SDS 0.1ml 
1.5% ammonium persulphate 0.1 ml 
TEMED 4.0 |il 
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Silver staining 
After completion of the electrophoresis, the bands were visualized by silver 
staining. The procedure involved fixing of protein bands for 10 min in a mixture of 
40% methanol and 13.5% formaldehyde followed by two washings with distilled 
water, at an interval of 5 min. Then the gel was immersed in 0.02% sodium 
thiosulphate solution for 1 min followed by two washings with distilled water at an 
interval of 20 sec. The gel was immersed in 0.1% silver nitrate solution for 10 min 
and finally washed with distilled water. 
The gel was then immersed in the developer solution (3% sodium carbonate, 
.02% sodium thiosulphate and 0.05% formaldehyde) to facilitate staining and on 
appearance of bands, the reaction was stopped by a stopper solution (25% 
isopropanol, 10% glacial acetic acid). 
Boronate affinity chromatography 
The formation of Amadori adducts in the glycated-HSA samples was further 
evaluated by boronate affinity chromatography following the method of Chesne et al., 
(2006). Briefly, 10 ml of the separating gel (11 mmol m-aminophenylboronic acid) 
was equilibrated with binding buffer (0.2 M ammonium acetate, pH 8.8). Native and 
glycated-HSA samples were diluted with binding buffer and 1 ml of the solution was 
applied per ml of the separating gel. Three ml fractions were collected and absorbance 
of each fraction was recorded at 280 nm. After collecting non-bound albumin, 
boronate bound albumin (corresponding to Amadori product) was eluted using the 
elution buffer (NaCl 0.15 M, MgCb 10 mM, sorbitol 0.2 M, pH 3.4). 
Fluorescence studies 
Native and glycated-HSA samples were subjected to fluorescence studies on 
spectrofluorophotometer. Samples were excited at 295 nm and the emission 
intensities were recorded between 300-500 nm. Loss of fluorescence intensity was 
computed as follows: 
Percent loss of FI = ^ ^^-"""'"^ ~ ^ "^-"dfedHSA) ^ ^^^ 
FI 
' ^native HSA 
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Circular dichroism (CD) measurments 
Glycation induced conformational/structural changes were studied with the 
help of spectropolarimeter. Far-UV CD profiles were recorded at 25°C by placing 
samples in temperature controlled cell holder attached to Neslab's RTE 110 water 
bath (temperature accuracy of ± 0.1 °C). The protein concentration was fixed at 3.0 
pM. The MRE (mean residue ellipticity) was calculated according to the formula 
given below and the resuh was expressed in deg cm mol 
MRE CD 
(lOxnxlxCp) 
where, CD is in milli-degree, n is the number of amino acid residues in human 
albumin (585), 1 is the path length of the cell in cm, and Cp is the mole fraction. The 
percentage of a helix, p sheet and random coil was calculated by K2D software. 
Thermal denaturation studies 
Native and glycated-HSA samples were subjected to controlled heating to 
study stability of HSA upon glucose modification. Mid point mehing temperature 
(Tm) of the samples was evaluated (Ahmad et al., 2011). The samples were melted 
from 30°C to 90 °C at a rate of 1.0 °C/min. The change in absorbance at 280 nm was 
recorded with increasing temperature. 
Percent denaturation was calculated using the following equation:-
A - A Percent denaturation = — ^^ x 100 
where. 
AT = Absrorbance at temperature T°C 
Amax= Final absorbance on the comphion of denaturation (95°C) 
A30 = Initial absorbance at 30°C 
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Fourier transformed-infra red (FT-IR) spectroscopy 
FT-IR profiles of native and glycated-HSA were recorded on FT-IR 
spectrophotometer in the wavelength range of 400-4000 nm. Samples were first 
lyophilized and prepared as KBr pellets and then analysed. 
Detection of furosine by HPLC and LC-MS 
Furosine (a product formed by acid hydrolysis of fructosyl lysine) was 
detected in glycated-HSA by capillary HPLC system (Aligent 1100 series) attached 
with a synergi Cig analytical column. Prior to loading, the native and glycated-HSA 
samples were hydrolysed in 6 N HCl at 95 "C for 18 h (Schleicher and Wieland, 
1981). The hydrolysates were filtered through a medium grade filter paper. The 
general chromatographic set up was as follows; C-ig reverse phase column (4 mm x 
250 mm with 5 p,m particle size); The eluents used were; 0.4% acetic acid (Solvent 
A), 0.2% acetonitrile (Solvent B) each containing 2% formic acid. Gradient elution 
protocol was as follows: 0% to 2% solvent B in the first 5 min, from 2% to 6% 
solvent B over 19 min, 6% to 80% solvent B in 11 min, and then raised to 80% to 
wash the residual material off the column at a constant flow rate of 0.5 ml/min. Mass 
spectrometric analysis was then carried out on Micromass Quattro Ultima Triple 
Quadrupole Mass spectrometer interfaced to an Agilent 1100 capillary HPLC system. 
The mass spectrometer was operated in a positive ion mode and full scan mass spectra 
were recorded in 0-400 m/z range. 
Electrospray ionization mass spectrometry (ESI-MS) of glycated-
HSA 
ESI-MS is a powerfial technique for producing intact ions in vacuo fi"om large 
and complex species in solution. For this experiment we used an orthogonal time of 
flight (TOF) mass spectrometer (Applied Biosystems Mariner Atmospheric Pressure 
Ionization TOF Workstation, Framingham, MA, USA) attached with the standard ESI 
source. Nitrogen was used as the nebuliser gas. The instrument was outfitted with an 
integrated syringe pump with a dual syringe rack for direct infiision of the sample 
onto the mass spectrometer. The sciex heater was set to 350° C and the spray tip 
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potential was set at 4,000V. The mass spectrometer was operated in a positive ion 
mode and the mass spectra were recorded over the mass range of 100-800 m/z. 
Studies on aminoguanidine and thymoquinone as anti-glycating 
agent 
Aminoguanidine (a carbonyl trapping agent as well as an antioxidant) and 
thymoquinone (an antioxidant) was separately added to glass tubes containing HSA 
(10 pM) and glucose (50 mM) in 10 mM sodium phosphate buffer, pH 7.4 for desired 
time period. HSA-glucose served as control. Quenching in HSA modification by 
glucose in presence of aminoguanidine and thymoquinone was calculated from 
absorbance measurments at 280 nm. 
Effect of AG and TQ onfructosatnine level 
In order to determine the effect of aminoguanidine and thymoquinone on 
fructosamine level. The Amadori content of glycated-HSA glycated in absence and 
presence of AG and TQ was quantitated by NBT assay as described elsewhere. 
Quantitation ofs-amino groups by TNBS 
Free 8-amino groups were estimated in native, glycated and other samples 
with the help of 2, 4, 6-trinitrobenzene sulphonic acid (TNBS) reagent. It specifically 
reacts under mild conditions with e-amino groups to form trinitrophenyl derivatives 
(Bubnis and Ofner, 1992). Briefly, 100 ^1 of 0.5% (w/v) TNBS was added to 0.5 ml 
of samples and incubated for 1 hr at 37°C. At the end of the incubation the samples 
were solubilised in 0.25 ml of 10% SDS followed by the addition of 0.1 ml of HCl 
(IN). Absorbance was recorded at 420 nm and 8-amino groups were calculated using 
molar extinction coefficient of 19,200 cm"^  mof' (Fields, 1971). Furthermore, the 
extent of glycation in HSA was evaluated using the following formula:-
Percent glycation of e-amino groups = 
(Amount of s amino group in native HSA) - (Amount of e amino group in HSA after glycation) 
(Amount of e amino group in native HSA) 
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Detection of superoxide anion radicals in glycated-HSA in presence and absence of 
aminoguanidine and thymoquinone 
The effect of aminoguanidine and thymoquinone on the generation of 
superoxide radicals during glycation of HSA was determined by cytochrome c 
reduction assay (Beauchamp and Fridovich, 1971). The reaction tube contained HSA 
(10 \M), glucose (50 mM), DTPA (0.01 mM), AG (10 mM)/TQ (2.5 mM) and 
cytochrome C (200 |iM ) in 10 mM phosphate buffer (pH 7.4). The reduction rate was 
monitored at 550 nm. 
In-vivo studies 
Rabbits were divided into four groups and each group contained six animals. 
Group I: normal (non-diabetic), group H: diabetic (treated with alloxan only), group 
III: diabetic but treated with aminoguanidine (100 mg/kg body weight) and group IV: 
diabetic but treated with thymoquinone (50 mg/kg body weight). Animals of each 
group were maintained for eight weeks and given standard food and water ad libitum. 
Induction of diabetes in rabbits 
Rabbits were fasted for 12 hr and given a single intravenous injection of 
alloxan (90 mg/kg b.w.) dissolved in sterile saline 0.9% (w/v) in marginal ear vein. 
Blood glucose level was measured weekly with the help of a glucometer (Accu-
check). Induction of diabetes was confirmed by sustained hyperglycaemia and 
hypoinsulinemia. 
Animal Treatment 
> Group I (non-diabetic control): Animals in this group were given 0.9% saline. 
> Group II (diabetic): Animals in this group received alloxan only 
> Group ni: Animals in this group received one i.p injection of aminoguanidine 
(100 mg/kg) prior to alloxan administration. From the next day of alloxan 
injection, the animals received same amount of aminoguanidine daily for eight 
weeks 
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> Group IV: Animals in this group received one i.p injection of thymoquinone (50 
mg/kg) prior to alloxan administration. From the next day of alloxan injection, the 
animals received same amount of thymoquinone daily for eight weeks. 
Blood sampling 
Blood samples were withdrawn from the marginal ear vein of rabbits on 
weekly basis for eight weeks and transferred in plain glass vials. Sera were separated 
and stored at -20° C. Serum samples of animals of group I-IV were processed and 
following parameters were studied :-
(i) Insulin level 
Quantity of insulin was measured by radioimmunoassay using commercially 
available kit (Insulin IRMA Kit, Inc., Immunotech). 
(ii) Glycated haemoglobin (HbAic) 
Concentration of HbAlc in the samples was determined by HPLC method 
(Bio-RadD-10, USA). 
(iii) Fructosamine 
Fructosamine level was measured according to the method of Johnson et al., 
1982). Briefly, samples (200 1^) were added to 96-well microtiter plates in duplicate 
followed by 100 ^1 of NBT reagent (250 ^mol/1 in O.lmol/1 carbonate buffer, pH 
10.35 was added to each well and incubated at 37 °C for 2 hours. The color was read 
at 525 nm on a microplate reader. The purple colored monoformazan was quantitated 
using an extinction coefficient of 12640 cm" Vo l ' (Mironova et al, 2005). 
(iv) Superoxide dismutase 
SOD activity was determined by the method of Marklund and Marklund 1974. 
Briefly, sera (50 1^) were mixed with 0.1 ml of 8 mM pyrogalllol dissolved in 50 mM 
Tris succinate buffer, pH 8.2. The blank contained distilled water instead of serum. 
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The change in absorbance at 420 nm was recorded every 30 sec for 3 min. SOD 
activity was expressed as U/mg protein. 
(v) Catalase activity 
Catalase activity was measured as described earlier (Aebi, 1974). A typical 
assay tube contained 50 \i\ serum, 1.0 ml of 30 mM H2O2 and 1.95 ml of 50 mM 
phosphate buffer, pH 7.0. The contents were mixed and change in absorbance at 240 
nm was recorded every 30 sec for 2 min. Catalase activity was expressed as U/mg of 
protein. 
(vi) Glutathione peroxidase (GPx) activity 
GPx activity was measured according to the method of (Flohe and Gunzler, 
1984). Briefly, 100 ^l serum was mixed with 1 mM EDTA, 2.4 U/mL glutathione 
reductase and 10 mM glutathione and the volume was made to 3.0 ml with 20 mM 
potassium phosphate buffer pH 7.4. The reaction mixture was incubated for 10 mins 
at 37°C followed by addition of 0.19 mM NADPH and 12 mM t-butyl hydroperoxide. 
The decrease in absorbance was recorded at 340 nm was measured for 3 mins. Gpx 
activity was expressed as U/mg protein. 
(vii) Reduced glutathione 
Reduced glutathione level was measured by DTNB method (EUman, 1959) 
with slight modifications. One ml of serum was precipitated with 1 ml sulphosalicylic 
acid (4%) and left for 1 hr at 4°C. The samples were then centrifuged at 1,200 g for 
15 min at 4°C. To 400 [d of the supernatant, 2.2 ml of phosphate buffer (0.1 mM, pH 
8.1) and 400 pi of 3 mM 5,5- dithio-bis (2-nitrobenzoic acid) (DTNB) (3 mM) was 
added. The yellow color was measured at 412 nm and the amount of reduced 
glutathione was calculated using the molar extinction coefficient value of 1.36 x lO"* 
cm'molV 
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(viii) Malondialdehyde 
Malondialdehyde in sera was measured as thiobarbituric acid reactive 
substances (TEARS) using thiobarbituric acid reagent (Gallo etal, 1993). Briefly, 10 
i^l of 1 mM EDTA was added to 0.5 ml of serum sample followed by 1 ml of 15% 
(w/v) trichloroacetic acid. The contents were mixed and centrifuged at 3000 g for 10 
min to facilitate protein precipitation. The supernatant was then treated with 200 nl of 
1 % (w/v) thiobarbituric acid and immersed in a boiling water bath for 60 min. After 
cooling, the resulting chromogen (600 \i\) was mixed with 600 ^1 of n-butanol and 
extracted. This was followed by centrifugation at 900 g for 10 min. Finally, 250 nl 
was micropipetted from the butanolic phase and absorbance was read at 535 nm in 
microplate reader. The concentration of TEARS was calculated using the molar 
extinction coefficient value of 1.56 x lO^ cm'^mol'* (Stocks and Dormondy, 1971). 
(ix) Protein carbonyl 
Protein carbonyls were assayed by the method of Levine et al., (1990). 
Briefly, 100 |xl of serum samples were precipitated with 10% (w/v) ice-cold TCA and 
incubated for 10 min at 4°C. The samples were centrifuged at 11000 g for 3 min. The 
pellet thus obtained was re-suspended in 500 ^1 of 10 mM 2, 4-
dinitrophenylhydrazine (DNPH) prepared in 2 M HCl. The samples were then 
vortexed at room temperature for 1 hr and precipitated with 0.5 ml of 20% (w/v) TCA 
followed by 3 min centrifugation at 11,000 g. After centrifugation, the pellet was 
washed thrice with 1.0 ml of ethanol/ethyl acetate (1:1) to remove extra DNPH 
reagent. The protein pellet was finally suspended in 1 ml of 6 M guanidinium 
hydrochloride dissolved in 20 mM potassium phosphate buffer (adjusted to pH 2.3, 
with trifluoroacetic acid). Absorbance was recorded at 360 nm and the concentration 
of protein carbonyls was calculated using molar absorption coefficient of 22,000 cm' 
mof . Carbonyl content was expressesd as nmol/mg of protein. 
(x) Nitrite 
Serum nitrite was quantitated with Griess reagent (1 g/1 sulfanilamide, 25 g/1 
phosphoric acid, and 0.1 g/1 A'-l-naphthylethylenediamine dihydrochloride) according 
to the method Green et al., (1982). Briefly, 200 |il of sera were deproteinized with 
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40% (w/v) ZnS04. The samples were vortexed and incubated at room temperature for 
15 min. After incubation, the samples were centriftjged at 3000 g for 5 min and 100 |il 
of the supernatant was added to 96-well microtiter plates in duplicate. Hundred 
microlitre of Griess reagent was added to each well and incubated at 37°C for 10 min. 
The purple color developed was read at 540 nm on microplate reader. The 
concentration of nitrite levels in the serum was determined using sodium nitrite as the 
standard. 
Immunization schedule 
Rabbits (1-1.5 kg) were immunized with native and glycated-HSA 
respectively. Native and glycated-HSA (100 ^g) was emulsified with an equal volume 
of Freund's complete adjuvant and was injected into animals intramuscularly at 
muhiple sites. Subsequent injections of same dose of the immunogens were given in 
Freund's incomplete adjuvant at weekly intervals for six weeks. One week after the 
last injection marginal ear vein of animals was punctured and blood was carefiilly 
collected to prevent hemolysis. Serum was separated and complement proteins were 
inactivated by heating at 56 °C for 30 min. Pre-immune blood was collected fi^om 
each animal prior to immunization. The sera were stored in small aliquots at -20 ''C 
with 0.1% sodium azide as preservative. 
Isolation of IgG on protein A-agarose column 
Serum IgG was isolated by affinity chromatography on protein A-agarose 
affinity column. Serum (0.5 ml) diluted equal volume of PBS, pH 7.4 was applied to 
column (12 mm x 45 mm) previously equilibrated with the same buffer. The wash 
through was recycled 2-3 times and unbound proteins were removed by extensive 
washing with PBS, pH 7.4. The bound IgG was eluted with 0.58% acetic acid in 
0.85% sodium chloride (Goding, 1978) and neutralized with 1 ml of IM Tris-HCL, 
pH 8.5. Three ml fractions were collected. IgG concentration was determined 
considering 1.40 OD28o=l 0 mg mammalian IgG/ml. The isolated IgG was dialyzed 
against PBS, pH 7.4 and stored at -20 ''C with 0.1% sodium azide. 
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Immunological detection of antibodies 
Pre-immune and immune sera were tested for antibodies by enzyme linked 
immunosorbent assay and gel retardation assay. 
Enzyme linked immunosorbent assay: Following reagents were prepared and used in 
ELISA. 
• Antigen coating buffer: 15 mM sodium carbonate, 35 mM sodium bicarbonate, 
pH9.6 
• Tris buffered saline (TBS) 10 mM Tris, 150 mM NaCl, pH 7.4 
• Tris buffered saline containing Tween 20 (TBS-T): 20 mM Tris, 144 mM 
NaCl, 2.68 mM KCl, pH 7.4 containing 500 ^L Tween 20 per litre 
• Carbonate-bicarbonate buffer: 15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6 ontaining 2 mM magnesium chloride. 
• Substrate: 500 ^g p-nitrophenyl phosphate (PNPP) per ml of carbonate-
bicarbonate buffer, pH 9.6. 
Procedure 
ELISA was carried out on flat bottom polysorp plates as described earlier (Ali 
and Alam, 2002). Briefly, microtitre wells were coated with one hundred microlitre of 
10 ng/ml of native or glycated-HSA (dissolved in antigen coating buffer) and 
incubated for 2 hr at 37 °C and over night at 4 °C. Each sample was coated in 
duplicate and half of the plate, devoid of antigen, served as control. The test-wells 
were emptied and washed thrice with TBS-T to remove the unbound antigen. 
Unoccupied sites were blocked with 150 \i\ of 2 % non-fat dry milk (in TBS, pH 7.4) 
for 4-5 hr followed by single wash with TBS-T. In direct binding ELISA, test serum 
(serially diluted in TBS-T)/ purified IgG were directly added into antigen-coated 
wells and incubated for 2 hr at 37 "C and overnight at 4 '^ C. The wells were emptied 
and thoroughly washed with TBS-T. Anti-immunoglobulin G alkaline phosphatase 
conjugate was added to each well and incubated at 37 "C for 2 hr and then the plates 
were washed thrice with TBS-T followed by a single wash with distilled water. Para-
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nitrophenyl phosphate was added and the developed color was read at 410 nm on a 
microplate reader. The resuhs were expressed as mean of difference of absorbance 
values in test and control wells (Atest - Acontroi) 
Competition ELISA 
The antigenic specificity of the antibodies was determined by competition 
ELISA (Alam et al., 2007). Varying amounts of inhibitors (0-20 ng/ml) were mixed 
with constant amount of antiserum or IgG. The mixture was incubated at room 
temperature for 2 hr and overnight at 4 ° C. Immune complexes was coated in the 
wells instead of the antiserum. The remaining steps were the same as in direct binding 
ELISA. Percent inhibition was calculated using the formula: 
Percent inhibition = 1- f^ "^ "^ '"^  xlOO 
uninhibitod 
Gel retardation assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assays were performed (Alam et al., 2007). Immune 
complexes were prepared by incubating constant amount of native and glycated-HSA 
(10 i^g/ml) with varying amounts of affmity purified IgG and incubated for 2 hr at 
37 ^C and overnight at 4"C. At the end of incubation, one-fourth volume of sample 
buffer was added to antigen-antibody complex and electrophoresed on 10% SDS-
PAGE for 4 hr at 80 V. The gels were stained with silver nitrate and photographed. 
Isolation of albumin from normal and type 1 diabetes plasma 
Albumin was isolated from the plasma of normal and type 1 diabetic subjects. 
Briefly, required quantity of 4 M ammonium sulphate solution (pH 7.0) was added to 
plasma to achieve ammonium sulphate strength of 2.26 M. The mixture was kept at 
room temperature for 12 hr and then carefully diluted with water, with frequent 
additions of 0.5 N H2SO4, until the final concentration of ammonium sulphate was 
reduced to 1.9 M and pH to 4.2. After incubation for 12 hr at room temperature, the 
precipitate was collected by centrifugation at 3000 g for 30 min. The supernatant was 
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discarded and the pellet was washed three times with 2.2 M ammonium sulphate (pH 
4.2) and dissolved in 0.06 M sodium phosphate buffer (pH 7.4) containing 0.08 M 
NaCl. The material was extensively dialyzed against 6 litres of 0.06 M sodium 
phosphate buffer (pH 7.4) and stored at 4 "C. A column of Sephacryl S-200 HR (60 x 
1.5 cm) was carefully packed according to a published procedure (Tayyab and Qasim, 
1990). The column was equilibrated with 0.06 M sodium phosphate buffer (pH 7.0) 
and the void volume of the column was determined by passing solution of blue 
dextran (5 mg/ml). The dialyzed material was loaded on top of the column and eluted 
with 0.06 M sodium phosphate buffer, pH 7.0. The column was operated at a flow 
rate of 15-20 ml/hr and 3 ml fractions were collected. Protein in each fraction was 
determined by the method of Lowry et al, (1951) and the protein was subjected to 
purity test on SDS-PAGE along with standard protein markers. 
Statistical analysis 
Data are presented as mean ± SD. Statistical significance of the data was 
determined by Student's t-test (Statgraphics, Origin 6.1). Xp value of < 0.05 was 
considered statistically significant. 
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Pilot experiments were carried out to work out the optimum incubatiori time 
and glucose concentration for preparation of Amadori-HSA. Human serum albumin 
(10 |iM) incubated with varying concentration (12.5, 25 and 50 mM) of glucose for 
one week at 37 °C was subjected to UV analysis. Native HSA gave a characteristic 
peak at 280 nm (Fig. 6). Upon glycation, modified-HSA samples showed marked 
hyperchromicity of 14.3%, 38.4% and 58.2% respectively. The results are 
summarized in Table 1. 
Quantitation of Amadori product in glycated-HSA 
Fructosamine (an index of early glycation products also known as Amadori 
product), was confirmed in glycated-HSA samples by NBT assay. In alkaline 
medium, the dye got reduced upon reaction with Amadori product. The yield of 
Amadori product in HSA modified with 12.5 mM, 25 mM and 50 mM of glucose was 
found to be 27.4±2.2, 51.3±1.4 and 94.4±3.2 nmol/mg, respectively (Fig. 7a). Under 
identical conditions fructosamine concentration in native HSA was only 2.3±0.96 
nmol/mg. Furthermore, after reduction with NaBHi the level of fructosamine in 
glycated-HSA samples decreased to 12.2±1.5, 21.3±1.80 and 46.1± 2.9 nmol/mg, 
respectively (Fig. 7b). 
Thiobarbituric acid assay for hydroxy methyl furfural (HMF) 
Treatment of Amadori product with weak acid (oxalic acid or acetic acid) 
yields HMF (Gottachalk, 1952), which reacts with TBA and forms a derivative 
having Xmax at 443 nm (Keeney and Basette, 1959). The TBA assay measures the 
amount of ketoamine bound to protein. It is based on the release, by hydrolysis, of the 
adducted glucose as 5-hydroxymethylfurfural (5-HMF). The amount of HMF formed 
in HSA modified with 12.5 mM, 25 mM and 50 mM was 2.8±0.12, 4.7±0.38 and 
8.9±0.53 nmol/mg, respectively (Fig. 8). Native HSA incubated under identical 
conditions without glucose served as control, had almost negligible content of HMF. 
Moreover, NaBHt reduction caused significant decrease in HMF content and was 
calculated to be 1.4±0.15, 2.2±0.33 and 3.1±0.22 nmol/mg, respectively (Fig. 8). 
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240 290 340 
Wavelength (nm) 
390 
Fig. 6 Ultraviolet absoqjtion spectra of native HSA ( ) modified with 
12.5 mM ( ), 25 mM (- - -) and 50 mM ( ) glucose. 
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TABLE 1 
UV characteristics of native and glucose modified-HSA 
Sample 
Native HSA 
HSA+12.5mMglu 
HSA+25 mM glu 
HSA+50 mM glu 
Absorbance at 280 nm 
0.305 
0.356 
0.495 
0.732 
Percent hyperchromicity 
-
14.3 
38.4 
58.2 
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120 
120 
a 100 
E BO 
c 60 
E 
s 
Native <i'i2.5mM+25mM -t-SOmM 
HSA glu glu glu 
(b) 
Native •i>12.5miVi -i-25mlM +50mlW 
liSA glu glu glu 
Fig, 7 Content of Amadori product in HSA modified with 
12.5 mM, 25 mM and 50 mM glucose before (a) and after 
(b) NaBH4 reduction. 
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Native +12.5 mM +25 mM +50 mM 
HSA giu glu glu 
Fig. 8 Quantitative estimation of hydroxymethylflirfUral in HSA 
modified with 12.5 mM, 25 mM and 50 mM glucose before (§) 
and after (i) NaBH* reduction. 
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SDS-polyacrylamide gel electrophoresis of native and glycated-HSA 
Fig. 9 shows the migration pattern of native and glycated-HSA. As compared 
to native HSA, glycated samples showed appreciable change in electrophoretic 
mobility with concomitant increase in band intensity. Moreover, HSA incubated with 
50 mM glucose showed maximum change in electrophoretic mobility accompanied by 
an increase in band intensity. 
Boronate affinity chromatography for Amadori product 
Native and glycated-HSA samples were passed through boronate column to 
evaluate Amadori formation. Native HSA passed through boronate matrix did not 
show any binding and all of the loaded HSA appeared in wash through (W) fraction 
(Fig. 10a). By contrast, glycated-HSA samples showed gradual decrease in unbound 
fraction and systemic increase in boronate retained fraction (Fig. lOb-d). SDS-PAGE 
of wash through and eluted fraction (E) clearly indicate Amadori formation. The 
percentage of Amadori retained by the matrix in HSA glycated with 12.5 mM, 25 mM 
and 50 mM was found to be 20.5%, 49.4% and 74% respectively (Fig. 11). 
Fluorescence analysis of native and glycated-HSA 
Tryptophan specific fluorescence of native and glycated-HSA samples were 
measured by spectrofluorometer. Both native and glycated-HSA samples were excited 
at 295 nm. Native HSA showed a strong emission peak at 340 nm because of its 
single tryptophan residue (Trp 214), Glycation induced structural changes in glycated 
samples were evident from 19.3%, 26.8% and 43.2% loss in fluorescence intensity 
(Fig. 12). The resuHs are compiled in Table 2. Furthermore, the glycated-HSA 
samples did not show AGE specific fluorescence at 370 nm and 450 nm (data not 
shown). Thus, on the basis of higher level of Amadori content (as detected by NBT), 
boronate binding, increased hyperchromicity, significant change in electrophoretic 
migration pattern and loss of fluorescence intensity in HSA modified with 50 mM 
glucose, we chose it for frirther studies. 
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200kD 
ll6kD 
97kD 
66kD 
45kD 
29kD 
Fig. 9 Electrophoretic pattern of native HSA (lane 2 and 6) and HSA incubated for 
one week with 12.5 mM, 25 mM and 50 mM glucose (lane 3, 4 and 5 
respectively). Lane 1 contains a standard protein marker. Samples were 
electropheresed on 10% SDS-PAGE for 4 h at 80V. 
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Fig. 10 Boronate affinity chromatography of (a) native HSA (b) HSA+ 12.5 mM giu 
(c) HSA+ 25 mM glu, and (d) HSA+ 50 mM glu. Inset: SDS-PAGE of 
non-glycated (W) and glycated (E) HSA. Binding buffer of pH 8.8 was used 
to collect wash through fractions; Elution buffer of pH 3.4 was used to 
collect bound fractions. 
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Fig. 11 Boronate affinity chromatography of native HSA and HSA 
incubated with different concentrations of glucose for 7 days. 
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Fig. 12 Fluorescence emission profile of native HSA ( ) and 
HSA modified with 12.5 mM ( ), 25 mM ( ) and 
50 mM glucose ( ). The samples were excited at 295 
nm. 
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Table 2 
Fluorescence characteristics of native and glycated-HSA 
Sample 
Native HSA 
HSA+12.5mMglu 
HSA+25 mM glu 
HSA+50 mM glu 
F.I. at 295 nm 
823.0 
664.0 
602.0 
467.1 
Percent loss in F.I. 
-
19.3 
26.8 
43.2 
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Circular dichroism (CD) analysis of native and glycated-HSA 
CD is useful for rapid assessment of secondary structures of proteins. The 
amide chromophores of the proteins' peptide bonds show ellipticity in the far-UV 
range (200-250 nm). Proteins rich in alpha-helix give negative bands near 222 nm and 
208 nm. Whereas, proteins containing pure beta-sheets display negative bands near 
216 nm and 175 nm. Fig. 13a show^ s the far-UV CD profile of native HSA and its 50 
mM glucose modified counterpart. Far UV CD profile of native and glycated-HSA 
sample are nearly similar. However, both native and glycated-HSA samples exhibited 
two minima, one at 208 nm and another at 222 nm, indicative of a- helical content. 
Native HSA showed ~ 58% a- helix whereas, glycated-HSA showed -65%. The post-
glycation increase in alpha-helical content of HSA indicates conformational change. 
The MRE and other parameters are summarised in Table 3. 
Near-UV CD characteristics of native and glycated-HSA 
To study glucose-induced structural changes in more detail, CD measurements 
were carried out in near-UV region. It may be recalled that peptide backbone 
orientations contribute to the far-UV CD characteristics, whereas, side chains of 
aromatic amino acids (phenylalanine, tyrosine and tryptophan) contribute to CD 
characteristics observed in the near-UV CD region (250-300 nm) (Kelly and price, 
1997; Woody, 1995) thus elucidating the tertiary structure of the proteins. Fig. 13b 
depicts the near-UV CD profile of native and glycated-HSA. Native HSA exhibited 
two minima, one at 262 nm and another at 268 nm. The minima at 292 nm is 
characteristic of disulphide and aromatic chromophores (Lee and Hirose, 1992). In 
case of glycated-HSA, the loss of signal at 292 nm and the disappearance 262 nm and 
268 nm minima indicate a substantial loss of tertiary structure. 
Thermal denaturation of native and glycated-HSA 
Effect of glycation on the thermal stability of HSA was studied by recording 
heat induced changes in absorbance at 280 nm. The mid-point melting temperature 
(Tm) of native and glycated-HSA was found to be 63 °C and 70° C, respectively. An 
increase of 7° C in the Tm value indicates that glucose modification has stabilized 
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Table 3 
CD characteristics of native and glycated-HSA 
Parameter 
*MREat 222 nm 
262 nm 
268 nm 
Alpha helix 
P sheet 
Random coil 
Native HSA 
16848.4 
2042.17 
1803.3 
58% 
8% 
34% 
Glycated-HSA 
19050.9 
1167.37 
826.68 
65% 
5% 
30% 
MRE measured in deg cm mol' 
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the structure of HSA. The thermal denaturation profile of native and glycated-HSA is 
depicted in Fig. 14. 
FT-IR analysis of native and glycated-HSA 
FT-IR spectra recorded for both native (Fig. 15a) and glycated-HSA (Fig. 15b) 
were analysed on the basis of shape and frequency of the amide I and II bands and 
other characteristic group present in their respective structures. Amide I band (arising 
from C=0 stretching) in native HSA showed a peak at about 1660 cm' which was 
consistent with absorption peak of a-helix. This band at 1660 cm"' shifted to 1651cm'' 
in glycated-HSA. The amide II band (originating from N-H bending vibrations of 
peptide groups) at 1543 cm"' in native HSA shifted to 1532 cm"' in glycated-HSA. A 
new peak at 1711.2 cm"' corresponding to keto (C=0) group of Amadori product was 
observed in the spectra of glycated-HSA. Moreover, in native HSA the band at 3209.1 
cm"' related to the stretching vibration of the OH group shifted to 3309.1cm"' in 
glycated-HSA. Low intensity absorbtion peak observed at 1082.7cm"' in glycated-
HSA may be due to C-C/C-0 stretching. 
HPLC analysis of native and glycated-HSA 
The HPLC profile of standard fijrosine (Fig. 16a) shows a well defined peak 
with a retention time of-28.1 min. Glycated-HSA also showed a peak with retention 
time of -28.3 min (Fig. 16c) which matches with the retention time of fiirosine. 
Native HSA, included as control, was devoid of fiirosine. It may be concluded that 
reaction of glucose with HSA has resulted in the formation of fructosyl lysine 
(Amadori adduct) detected as fiirosine. Therefore, fiirosine is the hallmark of early 
glycation. NaBHt reduced glycated-HSA did not show fiirosine peak (Fig. 16d). This 
shows that NaBH* has completely reduced the Amadori product and subsequent 
formation of fiirosine has not taken place. 
Detection of furosine in native and glycated-HSA by LC-MS 
Furosine, a known gold standard of Amadori adduct, was evaluated in the acid 
hydrolzate of glycated-HSA. Fig. 17a-c shows mass spectroscopic profile of standard 
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Fig. 14 Thermal denaturation profile of native (-n-) and 50 niM glucose 
modified-HSA (-•-). 
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Fig. 15 FTIR Spectra of (a) native HSA, and (b) HSA glycated with 50 mM glucose. 
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Fig. 17 Mass spectroscopic profile of (a) standard furosine, (b) acid hydrolyzed 
native HSA, and (c) acid hydrolyzed glycated-HSA. 
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fUrosine, acid hydrolyzed native HSA and acid hydrolyzed glycated-HSA. As shown 
in Fig 17c, the acid hydrolyzate of glycated-HSA showed a m/z value of 255, 
matching with the m/z value of standard fiirosine. No such species was observed 
in the hydrolyzate of native HSA. Peak identity was assigned by retention time, 
chromatographic pattern and spike of authentic standard. 
Electrospray ionization mass spectrometry (ESI-MS) of native and 
glycated-HSA 
Hydrolysates of native and glycated-HSA samples were further subjected to 
ESI-MS analysis to confirm the formation of Amadori product. Fig. 18a & b shows 
the profiles of hydrolysed native and glycated-HSA, respectively. The ion at m/z 
value of 309 [M+H]^ is consistent with the Amadori product (fiuctosyl lysine), 
resulting fi-om the condensation of lysine residue (Mr 146.16) v^ nth glucose (Mr 180) 
with the loss of a water molecule. The ion at m/z value of 291 is speculated to result 
from the loss of a water molecule fi"om the Amadori product. A further loss of water 
molecule generated the product ion at m/z of 273. Subsequent elimination of a water 
molecule accompanied by the loss of CHO group fi-om the glucose moiety produced 
the fragment ion at m/z 225. 
Studies on Aminoguanidine (AG) and thymoquinone (TQ) as in vitro 
inhibitors of glycation 
Both aminoguanidine (10 mM) and thymoquinone (2,5 mM) showed 
antiglycating action when percent modification of the samples was calculated from 
respective absorbance values at 280 nm (Fig. 19). In presence of aminoguanidine, 
HSA was inhibited by 76%, while with thymoquinone the inhibition was found to be 
48% (Fig. 19). 
Effect of AG and TQ on generation of fructosamine 
After one week of incubation, the fructosamine content in glycated-HSA was 
found to be 94.2±3.3 nmol/mg (Fig. 20a). In presence of AG and TQ the fiiictosamine 
content dropped to 43.1 ±2.21 nmol/mg and 78.4±2.8 nmol/mg, respectively. 
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Fig. 19 Effect of aminoguanidine (AG) and thymoquinone (TQ) in assay 
mixture containing HSA and glucose. The samples were 
incubated for 7 days at 37" C. 
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Fig. 20 (a) Effect of AG and TQ on fructosamine yield. 
HSA (10 yM) was incubated with glucose (50 mM) in 
presence of AG (10 mM) and TQ (2.5 mM). (b) Percent 
Amadori blocking by AG and TQ. 
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Fructosamine data was exploited to calculate percentage of Amadori group 
blocking by AG and TQ using the expression 100-P, were P is the percentage of 
fructosamine in glycated-HSA with respect to samples glycated in absence of AG and 
TQ. The percent Amadori group blocking by AG and TQ was found to be 55.2% and 
18.7% respectively (Fig. 20b). 
Quantitation of £-amino groups in native, glycated-HSA and TQ and 
AG containing glycated-HSA 
Figure 21 shows the amount of free e-amino groups in native HSA, glycated-
HSA and AG and TQ containing glycated-HSA. Under our experimental conditions 
the amount of free s-amino groups in native HSA was found to be 21.7±0.89 
nmol/mg. After glycation the amount of free £-amino groups dropped to 6.2±0.38 
nmol/mg. However, the amount of free e-amino groups in glycated-HSA containing 
AG and TQ was 14.6±0.67 nmol/mg and 11.3±0.49 nmol/mg, respectively. The 
results suggest that AG and TQ can prevent the attachment of glucose with e-amino 
groups of HSA; e-amino group blocking with AG and TQ was 32.7% and 47.9% 
respectively (Fig. 22). 
AG and TQ ameliorates glycation through its dismutation action 
Effect of AG and TQ on in vitro generation of superoxide radical during 
glycation was analyzed by cytochrome c reduction method (Fig. 23a). SOD was used 
as the standard quencher of superoxide radical (Fig. 23b). In reaction mixture 
containing HSA and glucose, the amount of superoxide radical was found to be 19.04 
nmol/ml. In presence of AG and TQ the superoxide concentration was decreased to 
10.2 and 9.7 nmol/ml, respectively. 
In vivo effect of AG and TQ on biochemical parameters in alloxan 
induced diabetic animals 
Effect of AG and TQ on blood glucose and serum insulin level 
Animals injected with alloxan showed double to triple increase in blood 
glucose level compared to control group. Furthermore, the experimental 
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hyperglycemia persisted during the whole study period. However, alloxan 
administration in animals pre-treated with AG and TQ resulted in initial increase in 
glucose level but declined significantly (p < 0.05) during eight weeks treatment with 
AG and TQ (Fig. 24). Animals challenged with alloxan showed significant ((p <0.05) 
decrease in serum insulin (Fig. 25) compared to control animals. Treatment with AG 
and TQ appears to have reduced the toxicity of alloxan and decrease in insulin level 
was significantly ((p <0.05) less compared to diabetic group. TQ appears to have 
offered better proteaion against alloxan induced-toxicity. 
Effect of AG and TQ on glycated haemoglobin (HbAic) and 
fructosamine 
The changes observed in HbAic level in different groups of animals are 
presented in Fig. 26. The persistent hyperglycemia had significantly (p <0.05) 
increased the %HbAic in diabetic animals. Continous treatment with AG effectively 
reduced the %HbAiC, TQ was less effective in controlling glycosylation of 
haemoglobin. 
Fructosamine concentration in diabetic animals (652.3±14nmol/mg) was 
found to be significantly higher as compared to control (164.2 ±12 |imol/mg) (Fig. 
27). Results suggest that AG was effective in controlling fiiictosamine increase. TQ 
exhibited lesser effect on fructosamine. 
Effect of AG and TQ on oxidative stress parameters 
Results shown in Fig. 28-31 suggest that the diabetogenic action of alloxan 
involves free radical mechanism and hence alloxan treated animals showed sharp 
decrease in SOD, catalase, glutathione peroxidise and glutathione as compared to 
control animals. AG and TQ administration in diabetic rabbits appears to have offered 
protection against free radical formed during alloxan metabolism. AG offered more 
quenching action than TQ. Fig. 32-34 indicate that carbonyl, TBARS and nitric oxide 
were elevated after alloxan exposure and reduction in the level of these parameters in 
presence of AG and TQ suggest their protective role. These results corroborate with 
the resuhs of our in vitro studies. 
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Fig. 25 Effect of AG and TQ treatment on insulin level in diabetic animals. 
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Fig. 26 Effect of AG (-A-) and TQ (-A-) on HbAic in alloxan-induced 
diabetic (-•-) and control (-a-) rabbits. Each data point represent 
the mean of six independent observations. 
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Fig. 27 Effect of AG (-A-) and TQ (-A-) on fiiictosamine in alloxan-induced 
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Fig. 28 Effect of AG (-A-) and TQ (-A-) treatment on SOD activity in 
diabetic animals (-•-). SOD activity in control animals is represented 
by (-a-). Each point represents the mean of six independent 
measurements. 
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Fig. 29 Effect of AG (-A-) and TQ (-A-) treatment on catalase in 
diabetic animals (-•-). Catalase activity in control animals are 
represented by (-n-). Each point represents the mean of six 
independent measurements. 
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Fig. 30 Effect of AG (-A-) and TQ (-A-) treatment on Gpx in diabetic animals 
(-•-). Gpx activity in control animals are represented by (-n-). Each 
point represents the mean of six independent measurements. 
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Fig. 31 Effect of AG (-A-) and TQ (-A-) treatment on glutathione in 
diabetic animals (-•-). Glutathione level in control animals is 
represented by (-n-). Each point represents the mean of six 
independent measurements. 
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Fig. 32 Carbonyl content in the serum of control (-n-), diabetic (-•-), AG 
treated (A) and TQ treated (A) diabetic rabbits. Each point 
represents the mean of six independent measurements. 
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Fig. 33 Effect of AG (-A-) and TQ (-A-) on TBARS in diabetic (-•-) 
aninials. TBARS in control animals has been depicted by (-D-). Each 
point represents the mean of six independent measurements. 
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Fig. 34 Nitric oxide concentration in different groups of animals 
measured as nitrite. Each bar represents the mean of six 
independent measurements. 
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Immunogenicity of native and glycated-HSA 
Antibody inducing property of native and glycated-HSA was evaluated in 
rabbits. Antisera were subjected to direct binding ELISA on polysorp microtitre 
modules coated with respective immunogens. Antigen binding specificity 
of the induced antibodies was ascertained by inhibition ELISA. Antigen-antibody 
interation was visualized by retardation assay in polyacrylamide gel. 
Antibodies against native HSA 
Native HSA injected into rabbits induced moderate antibody response with a 
titre of <1.6400 as revealed by direct binding ELISA (Fig. 35a). Preimmune serum, 
included as control, showed negligible binding with the immunogen. A maximum of 
57.4% inhibition was observed at 20 ^g/ml of the immunogen (Fig. 35b). 
Antibodies against glycated-HSA 
Glycated-HSA was found to be a potent immunogen and induced high titre 
antibodies (>1:12,800) (Fig. 36a). Under identical experimental conditions 
preimmune serum included as control showed negligible binding the immunogen. A 
maximum of 76.1% inhibition in antibody binding was observed at 20 ng/ml of the 
immunogen (Fig. 36b). 
Purification and characterization of serum IgG 
Immunoglobin G (IgG) was isolated from sera by affinity chromatography on 
Protein-A agarose column (Fig 37). The purity of IgG was ascertained from single 
band movement in SDS-polyacrylamide gel (Fig. 37 inset). Direct binding ELISA of 
the IgG purified from the antisera of native and glycated-HSA showed strong binding 
towards their respective immunogens. The amount of anti-HSA IgG required for 
coated antigen (native HSA) saturation was found to be (60 ^g/ml) (Fig. 38a). 
Inhbition ELISA with anti-HSA IgG showed a maximum of 69.8% inhibition in 
antibody binding. Fifty percent inhibition was achieved at 6.5 ^g/ml of the 
immunogen (Fig. 38b). The amount of anti-glycated-HSA IgG required for antigen 
(glycated-HSA) saturation was 40 ng/ml (Fig. 39a). Antigenic specificity of the 
isolated anti-glycated-HSA IgG was evaluated by inhibition ELISA, wherein 88.9% 
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Fig. 35a Level of induced antibodies against native HSA. 
Direct binding ELISA with pre-immune (-a-) and 
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Fig. 36a Level of induced antibodies against glycated-HSA. Direct 
binding ELISA with pre-immune (-a-) and immune sera 
(-•-). The microtitre wells were coated with glycated-HSA 
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Fig. 37 Elution profile of anti-glycated HSA IgG on protein-A agarose affinity 
column. Inset: SDS-gel photograph of purified IgG on 10% 
polyacrylamide gel. 
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Fig. 38a Binding of anti-HSA IgG and preimmune IgG with 
native HSA. Microtitre wells were coated with native 
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Fig. 38b Inhibition ELISAofaffinity purified anti-HSA IgG (-•-) 
and pre-immune IgG (-n-) binding with native HSA. 
Native HSA was used as a coating antigen as well as 
inhibitor. 
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Fig. 39a Binding of anti-glycated-HS A IgG and preimmune IgG with 
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Inhibition ELISA of affinity purified anti-glycated-HSA 
IgG (-•-) and preimmune IgG (-D-) binding with 
glycated-HSA. Glycated-HSA was used as a coating 
antigen as well as inhibitor. 
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inhibition in the antibody binding was achieved by glycated-HSA, only 3.5 ng/ml of 
the immunogen was required for 50% inhibition (Fig. 39b). However, NaBIlt reduced 
glycated-HSA showed considerably reduced inhibition of 69.5% as compared to 
glycated-HSA (Fig. 40). 
Band shift assay 
Visual detection of antigen-antibody interaction was monitored by band shift 
assay. Constant amount of native or glycated-HSA was incubated with varying 
amount of anti-glycated HSA IgG for 2 hr at 37° C and overnight and then 
electrophoresed on 10% polyacrylamide gel containing SDS. Formation of immune 
complex between glycated-HSA and anti-glycated-HSA IgG was ascertained from 
appearance of high molecular weight immune complex accompanied by a retarded 
mobility (Fig. 41a). The unbound antigen showed proportional decrease in intensity. 
However, under identical experimental conditions native HSA incubated with the 
same amount of anti-glycated-HSA IgG did not show high molecular weight immune 
complex but a slight decrease in the intensity of the unbound antigen was observed, 
which indicates that though the induced antibodies against glycated-HSA are specific 
but they are also recognizing the old epitopes on native HSA, a property exhibited by 
polyspecific antibodies (Fig. 41b). 
Cross-reactions of anti-glycated-HSA IgG 
Antigenic specificity of anti-glycated-HSA antibodies was further ascertained 
by inhibition ELISA. The anti-glycated-HSA IgG exhibited binding with glycated 
forms of BSA, IgG, histone and PLL (poly-L-lysine). The antigen binding 
characteristics of anti-glycated-HSA antibodies has been summarized in Table 4. 
Cross-reactions of anti-native HSA IgG 
Competition ELISA of anti-HSA IgG with native HSA showed a maximum 
inhibition of 69.8%. Anti-HSA IgG partially recognized glycated-HSA and showed an 
inhibition of 52.4%. The anti-HSA IgG did not exhibit appreciable binding with 
glycated forms of BSA, IgG, histone and PLL (poly-L-lysine). Binding characteristics 
of the anti-HSA antibodies with various inhibitors have been summarized in Table 5. 
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Fig. 40 Inhibition ELISA of anti-glycated-HSA IgG binding with 
glycated-HSA. The inhibitors were glycated-HSA (-•-) and 
NaBH4 reduced glycated-HSA (-•-). The microtitre wells were 
coated with glycated-HSA (10 ^ g/ml). 
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Fig. 41 Band shift assay of anti-glycated-HSA IgG binding to (a) glycated-HSA and 
(b) native HSA. Electrophoresis was performed on 10% SDS-
polyacrylamide gel for 4 h at 80 V. 
(a) Glycated-HSA (25 i^g, lane 1) was incubated with 10, 20. 30 and 40 i^g 
anti-glycated HSA IgG respectively (lanes 2-5) for 2 hr at 37°C and 
overnight at 4 °C. 
(b) Native HSA was incubated with 10, 20, 30 and 40 fxg anti-glycated HSA 
IgG respectively (lanes 2-5) under identical conditions. Lane 6 in both 
figures contains anti-glycated HSA-IgG alone. 
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Table 4 
Cross-reaction of affinity purified anti-glycated HSA IgG with 
various inhibitors as determined by inhibition ELISA 
Inhibitors 
Glycated HSA 
Native HSA 
NaBH, reduced glycated HSA 
ROS-glycated HSA 
Native BSA 
Glycated BSA 
ROS-glycated BSA 
Native human IgG 
Glycated human IgG 
ROS-glycated human IgG 
Native Histone 
Glycated Histone 
ROS-glycated Histone 
Native poly L-lysine 
Glycated poly L-lysine 
ROS-glycated poly L-lysine 
Native lysine 
Glycated lysine 
ROS-glycated lysine 
Native Arginine 
Glycated Arginine 
ROS-glycated Arginine 
Native Tryptophan 
Glycated Tryptophan 
ROS-glycated Tryptophan 
Native tyrosine 
Glycated tyrosine 
ROS-glycated tyrosine 
Native Phenylalanine 
Glycated Phenylalanine 
ROS-glycated phenylalanine 
Maximum 
% inhibition 
at 20 ^g/ml 
89.3 
48.2 
69.4 
28.5 
35.5 
57.1 
30.3 
26.5 
45.7 
24.5 
25.7 
42.8 
23.6 
17.4 
49.4 
21.6 
38.6 
74.7 
33.2 
23.4 
30.2 
19.3 
20.1 
41.6 
39.2 
22.1 
38.6 
21.7 
22.3 
33.8 
24.5 
Concentration 
for 50% 
inhibition 
(^g/ml) 
3.5 
-
11.1 
-
-
18.2 
-
-
-
-
-
-
-
-
-
-
-
10.8 
-
-
-
-
-
-
-
-
-
-
-
-
-
Percent 
relative 
affinity 
100 
-
31.5 
-
-
19.3 
-
-
-
-
-
-
-
-
-
-
-
32.4 
-
-
-
-
-
-
-
-
-
-
-
-
-
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Table 5 
Cross-reaction of affinity purified anti-native HSA IgG with various 
inhibitors as determined by inhibition ELISA 
Inhibitors 
Native HSA 
Glycated HSA 
ROS-glycated HSA 
Native BSA 
Glycated BSA 
ROS-glycated BSA 
Native human IgG 
Glycated human IgG 
ROS-glycated human IgG 
Native Hi stone 
Glycated Histone 
ROS-glycated Histone 
Native poly L-lysine 
Glycated poly L-lysine 
ROS-glycated poly L-lysine 
Native lysine 
Glycated lysine 
ROS-glycated lysine 
Native Arginine 
Glycated Arginine 
ROS-glycated Arginine 
Native Tryptophan 
Glycated Tryptophan 
ROS-glycated Tryptophan 
Native tyrosine 
Glycated tyrosine 
ROS-glycated tyrosine 
Native Phenylalanine 
Glycated Phenylalanine 
ROS-glycated phenylalanine 
Maximum 
% inhibition at 
20^g/ml 
69.8 
52.4 
30.3 
49.5 
34.8 
27.2 
46.1 
21.7 
20.3 
28.5 
23.1 
14.6 
24.0 
19.5 
18,6 
54.5 
30.3 
24.1 
48.9 
20.0 
22.4 
33.8 
26,5 
21.7 
34.5 
23.6 
20,1 
30.9 
22.0 
17.4 
Concentration 
for 50% 
inhibition 
(\ig/ml) 
6.5 
18.0 
-
-
-
-
-
-
-
-
-
-
-
-
-
16.0 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Percent 
relative 
affinity 
100 
36.1 
-
-
-
-
-
-
-
-
-
-
-
-
-
40.6 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
104 
Direct binding ELISA of autoantibodies in type 1 diabetes sera with 
native, glycated and NaBH4 reduced glycated-HSA 
The demographic profile of the patients is summarized in Table 6. Patients' 
sera were diluted to I.IOO and subjected to direct binding ELISA on solid phase 
coated with equal amounts of native, glycated and NaBH4 reduced glycated HSA. 
Sixteen of twenty two sera (73%) with secondary complications showed 
enhanced binding with glycated-HSA as compared to the native form or NaBJit 
reduced glycated-HSA (Fig. 42-43). Whereas, eighteen of twenty eight sera (64.2%) 
without secondary complication showed enhanced binding with glycated-HSA (Fig. 
44-46). Overall, thirty four of fifty sera (68%) showed significantly higher binding 
with glycated-HSA 
Inhibition ELISA of serum autoantibodies in type 1 diabetes patients 
by native, glycated and NaBRi reduced glycated-HSA 
Sixteen sera with secondary complications were subjected to antigen binding 
specificity by inhibition ELISA. The observed inhibition at 20 ^g/ml native, glycated 
and NaBHj reduced glycated forms of HSA was in the range of 21-33.1%, 54.2-
68.2% and 36.1-49.5%, respectively. The mean percent inhibition with native, 
glycated and NaBHi reduced glycated-HSA was found to be 26.2±3.8%, 63.08±4.9% 
and 43.9±4.3% (Fig. 47-50). The data has been summarized in Table 7. 
Inhibition ELISA of IgG purified from sera of type 1 diabetes with 
secondary complications 
Specific interaction of IgG, purified fi^om the selected sera of patients, with 
native, glycated and reduced glycated-HSA was studied by inhibition ELISA. The 
results given in Fig. 51-53 suggest that glycated-HSA was still the preferred antigen 
for IgG binding. The observed inhibition in IgG binding with glycated-HSA was fi-om 
65.5-77.4%. With native and reduced glycated-HSA the range varied fi-om 27.2-
36.2% and 43.3-53%, respectively. Table 8 summarizes the results of this experiment. 
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Table 6 
Demographic profile and clinical features of normal and diabetic subjects 
Variables 
Type 1 Type 1 diabetics 
Normal diabetics with without 
subjects secondary secondary 
complications complications 
Sample size (ri) 
Age (years) 
Sex (Male:Female) 
HbAic (%) 
BMI 
21 
39 ± 3 
9: 12 
4.2±.04 
21.7±3.9 
22 
54 ± 8 
7:15 
8.1±1.5 
25.5±5.2 
28 
27 ± 6 
16:12 
7.2±1.3 
26.3±4.6 
Blood glucose (mg/dl) 107±6.8 361±32.4 326 ±21.3 
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NHS 1 5 6 
Sera 
8 9 10 11 
Fig. 42 Direct binding ELISA of serum autoantibodies in type 1 diabetes 
patients (having secondary complications) with native HSA (- -), 
glycated-HSA (-•-) and NaBR* reduced glycated-HSA (-•-). Normal 
human sera (NHS) served as control. The plate was coated with the 
respective antigens (10 \ig/ml). 
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NHS 12 13 14 15 16 17 18 19 20 21 22 
Sera 
Fig. 43 Direct binding ELISA of serum autoantibodies in type 1 diabetes 
patients (having secondary complications) with native HSA (- -), 
glycated-HSA (-•-) and NaBH4 reduced glycated-HSA (-•-). Normal 
human sera (NHS) served as control. The plate was coated with the 
respective antigens (10 ng/ml). 
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Fig. 44 Direct binding ELISA of serum autoantibodies in type 1 diabetes 
patients (without secondary complications) with native HSA (-•-), 
glycated-HSA (-«-) and NaBR* reduced glycated-HSA (-•-). Norma! 
human sera (NHS) served as control. The plate was coated with the 
respective antigens (10 ^g/ml). 
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NHS 11 12 13 14 15 16 
Sera 
17 18 19 20 
Fig. 45 Direct binding ELISA of serum autoantibodies from type 1 diabetes 
patients (without secondary complications) with native HSA (- -), 
glycated HSA (-«-) and NaBH4 reduced glycated-HSA (-•-)• Normal 
human sera (NHS) served as control. The plate was coated with the 
respective antigens (10 ng/ml). 
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Fig. 46 Direct binding ELISA of serum autoantibodies from type 1 diabetes 
patients (without secondary complications) with native HSA (-•-), 
glycated-HSA (-«-) and NaBH4 reduced glycated-HSA (-•-). Normal 
human sera (NHS) served as control. The plate was coated with the 
respective antigens (10 |ig/ml). 
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Fig. 47 Inhibition of serum autoantibodies binding by native HSA (-n-), 
glycated-HSA (-•-) and NaBHi reduced glycated-HSA (-o-). Sera 1, 
3, 5 and 6 were analyzed on the microtitre plate coated with glycated-
HSA (10 jig/ml). 
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100 
0.01 0.1 1 10 100 
Inhibitor concentration (|jg/ml) 0.01 0.1 1 10 100 Inhibitor concentration (|jg/nil) 
Fig. 48 Inhibition of serum autoantibodies binding by native HSA (-n-), 
glycated-HSA (-•-) and NaBH4 reduced glycated-HSA (-o-). Sera 7, 8, 
10 and 12 were analyzed on the microtitre plate coated with glycated-
HSA (10 tig/ml). 
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10 100 
0.01 0.1 1 10 100 
Inhibitor concentration (pg/ml) 
0.01 0.1 1 10 100 
inhibitor concentration (pg/ml) 
Fig. 49 Inhibition of serum autoantibodies binding by native HSA (-D-), 
glycated-HSA (-•-) and NaBH4 reduced glycated-HSA (-o-). Sera 13, 
15, 16 and 18 were analyzed on the microtitre plate coated with 
glycated-HSA (10 ng/ml). 
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100 
0.01 0.1 1 10 100 0.01 0.1 1 10 100 
Inhibitor concentration (Mg/ml) Inhibitor concentration (|jg/ml) 
Fig. SO Inhibition of serum autoantibodies binding by native HSA (-n-), 
glycated-HSA (-•-) and NaBH4 reduced glyctaed-HSA (-o-). Sera 19, 
20, 21 and 22 were analyzed on the microtitre plate coated with 
glycated HSA (10 ng/ml). 
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Table 7 
Inhibition of serum autoantibodies in type 1 diabetes patients with 
different secondary complications by native, glycated and NaBHi 
reduced glycated-HSA 
Sample 
01 DN 
03 DN 
05 DN 
06 DN 
07 DN 
08 DN 
10 DR 
12 DR 
13 DR 
15 DR 
16 DR 
18 DR 
19 DA 
20 DA 
21 DA 
22 DA 
Mean ± SD 
Maximum percent inhibition at 20 |ig/ml 
Native HSA 
24.3 
21.0 
33.3 
25.2 
26.1 
24.9 
26.4 
25.7 
32.1 
26.0 
31.5 
22.0 
26.7 
31.0 
22.4 
21.1 
26.2±3.8% 
Glycated-HSA 
62.5 
54.4 
68.2 
66.0 
67.3 
57.0 
67.9 
61.1 
67.0 
60.8 
64.0 
58.6 
67.3 
68.0 
65.0 
54.2 
63.08±4.9% 
Reduced glycated-HSA 
41.7 
36.8 
49.5 
46.3 
48.0 
39.6 
48.3 
40.2 
47.1 
41.0 
44.5 
47.0 
45.0 
49.1 
43.3 
36.1 
43.9±4.3% 
DN = diabetic nephropathy, DR = diabetic retinopathy, DA = diabetic atherosclerosis 
The "sample" mentioned in this Table refer to sera nos. in Fig. 42,43. 
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Fig. 51 Inhibition of IgG binding by native (-•-), glycated (-•-) and NaBH* 
reduced glycated-HSA (-o-). The IgG was purified from sera (1, 5, 6 
and 7) of diabetic patients with secondary complications and microtitre 
plate was coated with glycated-HSA (10 jig/ml). 
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Fig. 52 Inhibition of IgG binding by native (-•-), glycated (-•-) and NaBH4 
reduced glycated-HSA (-o-). The IgG was purified from sera (10, 12, 
13 and 15) of diabetic patients with secondary complications. The 
microtitre plate was coated with glycated-HSA (10 ng/ml). 
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0.01 0.1 1 10 100 
Inhibitor concentration {\iglml) 0.01 0.1 1 10 100 Inhibitor concentration (|ig/ml) 
Fig. 53 Inhibition of IgG binding by native (-D-), glycated (-•-) and NaBRt 
reduced glycated-HSA (-o-). The IgG was purified from sera (16, 19, 
20 and 21) of diabetic patients with secondary complications. The 
microtitre plate was coated with glycated-HSA (10 |ig/ml). 
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Table 8 
Inhibition data of IgG purified from selected sera of patients with 
secondary complications 
Maximum percent inhibition at 20 fig/ml 
Sample 
Native HSA Glycated-HSA Reduced glycated-HSA 
52.0 
49.1 
51.0 
52.0 
45.5 
53.0 
47.8 
50.2 
45.0 
49.1 
43.3 
MeaniSD 31.07±3.2% 71.03±3.8% 49.7±2.6% 
DN = diabetic nephropathy, DR = diabetic retinopathy, DA = diabetic atherosclerosis 
The "sample" mentioned in this Table refer to sera nos. in Fig. 42, 43 
01 DN 
05 DN 
06 DN 
07 DN 
10 DR 
12 DR 
13 DR 
15 DR 
16 DR 
19 DA 
20 DA 
21 DA 
28.1 
35.0 
29.0 
28.5 
27.2 
31.4 
35.7 
30.0 
36.2 
29.7 
34.1 
28.0 
68.9 
73.0 
72.6 
71.2 
69.0 
68.7 
71.0 
65.5 
69.1 
73.4 
73.0 
77.0 
120 
Gel retardation assay 
To confirm the true interaction of native and glycated-HSA with IgG purified 
from the sera of diabetic patients with secondary complication, gel retardation assay 
was performed. Constant amount of native/glycated-HSA was incubated with 
increasing concentration of the purified IgG for 2 hr at 37°C and overnight at 4°C. 
The complex was then electrophoresed on polyacrylamide gel. With increasing 
concentration of the IgG, formation of high molecular weight species was observed 
with glycated-HSA (Fig. 54a) accompanied by concomitant decrease in unbound 
antigen. However, native HSA incubated with the IgG did show interaction but at 
higher antibody concentration. (Fig. 54b). 
Probing the surface of serum albumin purified from diabetic patients 
with secondary complications using experimentally generated anti-
glycated-HSA antibodies 
HSA was isolated from the plasma of twelve patients with secondary 
complications and eight heahhy individuals. The albumin eluted in a single 
symmetrical peak on Sephacryl S-200 HR column (Fig. 55) and showed a single 
homogenous band in SDS-polyacrylamide gel (Fig. 55). Inhibition ELISA of the 
patients' albumin was carried out with experimentally produced anti-glycated-HSA 
antibodies on microtitre plate coated with glycated-HSA. The patients' albumin was 
found to be strongly recognized by anti-glycated-HSA antibodies, but the recognition 
level varied from sample to sample 62.5% to 78.8% (Fig. 56-59). The albumin 
purified from the sera of apparently healthy individuals showed inhibition in the range 
of 20.7-36.5%. The resuhs are compiled in Table 9. 
Probing the surface of serum albumin purified from patients without 
secondary complications using experimentally generated anti-
glycated-HSA antibodies 
Albumin was also isolated from the plasma of six diabetic patients without 
secondary complications and five heahhy individuals. Inhibition ELISA of the 
patients' albumin was carried out with experimentally produced anti-glycated-HSA 
antibodies on microtititre plate coated with glycated-HSA. The patients' albumin was 
recognized by anti-glycated-HSA antibodies, but the recognition level varied from 
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(a) 
(b) 
Fig. 54 Band shift assay of an IgG of secondary complications patient binding to (a) 
glycated-HSA and (b) native HSA. Electrophoresis was performed on 10% 
SDS-polyacrylamide gel for 4 h at 80 V. 
(a) Glycated-HSA (25 |a,g, lane 1) was incubated with 20, 30, 40 and 50 |a.g 
IgG respectively (lanes 2-5) for 2 hr at 37°C and overnight at 4 °C. 
(b) Native HSA was incubated with 20, 30, 40 and 50 i^g diabetic IgG 
respectively (lanes 2-5) under identical conditions. Lane 6 in both figures 
represent IgG alone. 
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Fig. 55 Elution profile of serum albumin of a diabetes patient with secondary 
complications on Sephacryl S-200. Inset: SDS-polyacrylamide gel 
photograph of the purified HSA on 10% polyacrylamide gel. 
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Fig. 56 Inhibition of anti-glycated-HSA IgG binding by aibumin 
isolated from sample 1,5 and 6 of diabetes patients with 
secondary complications. The microtitre plate was coated 
with glycated-HSA (10 [ig/ml). Albumin 1 (-•-), Albumin 5 
(-A-) and Albumin 6 (-•-). The open symbols represent 
albumin from heahhy individuals (a, A,o). 
Fig. 57 
0.01 0.1 1 10 100 
Inhibitor concentration (MQ/ml) 
Inhibition of anti-glycated HSA IgG binding by albumin 
isolated from sample 7, 10 and 12 of diabetes patients with 
secondary complications. The microtitre plate was coated with 
glycated-HSA (10 ^ig/ml). Albumin 7 (-•-), Albumin 10 (-A-) 
and Albumin 12 (-•-). The open symbols represent albumin 
from heahhy individuals. 
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Fig. 58 Inhibition of anti-glycated-HSA IgG binding by albumin 
isolated from sample 13, 15 and 16 of diabetes patients with 
secondary complications. The microtitre plate was coated 
with glycated-HSA (10 ng/ml). Albumin 13 (-•-), Albumin 
15 (-A-) and Albumin 16 (-•-). The open symbols represent 
albumin from healthy individuals. 
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Fig. 59 Inhibition of anti-glycated-HSA IgG binding by albumin 
isolated from sample 19, 20 and 21 of diabetes patients with 
secondary complications. The microtitre plate was coated 
with glycated-HSA (10 ng/ml). Albumin 19 (-•-), Albumin 
20 (-A-) and Albumin 21 (-•-). Theo pen symbols represent 
albumin from healthy individuals. 
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Table 9 
Inhibition data of binding of anti-glycated-HSA antibody by albumin 
purified from diabetic patients with secondary complications 
Sample 
Type 1 diabetic 
patients with 
secondary 
complications 
Normal human 
Sample size 
12 
8 
Maximum percent inhibition at 
20 ^g/ml 
62.5,78.8,71.3,68.7,75.4,67.8,76.2, 
70.3,77.1,72.4,78.4,74.8 
20.7, 26.8, 30.6, 27.7, 33.2, 36.5, 
31.9,28.4 
Mean ± SD 
73.0±4.8 
29.47±4.7 
The microtitre plates were coated with glycated-HSA 
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from sample to sample 64.0-68.5% (Fig. 60-61). The albumin purified from the 
plasma of apparently healthy individuals showed inhibition in the range of 24.2% to 
32.3%. The results are summarized in Table 10. 
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Fig. 60 Inhibition of anti-glycated-HSA IgG binding by albumin 
isolated from sample 2, 5 and 6 of diabetes patients without 
secondary complications. The microtitre plate was coated 
with glycated-HSA (10 |ig/ml). Albumin 2 (-•-), Albumin 5 
(-A-) and Albumin 6 (-•-). Symbol (-o-) and (n) represent 
inhibition by normal albumin 
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Fig. 61 Inhibition of anti-glycated-HSA IgG binding by albumin 
isolated from sample 14, 18 and 22 of diabetes patients without 
secondary complications. The microtitre plate was coated with 
glycated-HSA (10 ng/ml). Albumin 14 (-•-), Albumin 18 
(-A-) and Albumin 22 (-•-). Symbol (-o-), (n) and (A) 
represent inhibition by normal albumin. 
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Table 10 
Inhibition data of binding of anti-glycated-HSA antibody by albumin 
purified from patients without secondary complications 
Sample 
Type 1 diabetic 
patients without 
secondary 
complications 
Normal human 
Sample size 
6 
5 
Maximum percent inhibition at 
20 ^g/ml 
68.5, 64.0, 67.9, 66.1, 67.0, 62.1 
28.1,26.4,32.3,24.2,27.0 
Mean ± SD 
65.9±2.6 
27.6 ±2.67 
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Viscussion 
» - I* 
Hyperglycemia plays a critical role in the pathogenesis of diabetes related 
complications by enhanced protein glycation. Glycation is a major cause of 
spontaneous damage to cellular and extracellular proteins in physiological systems, 
affecting 0.1-0.2% of lysine and arginine residues (Thomalley, 1999; Thomalley et 
al., 2003). Diabetic state promotes the Amadori-modification of many proteins in 
circulation (Jaleel etal., 2005). Such modifications on proteins may lead to generation 
of neo-antigens which could in turn initiate autoimmunity. The predominant form of 
glycated proteins in plasma exist as Amadori products rather than the more labile 
Schiff base form or AGEs (Curtiss and Witzman, 1983). Furthermore, concentration 
of Amadori proteins is at least 2% of serum proteins, whereas the concentrations of 
AGE-equivalents is less than 0,01% (Makita et al., 1992). Numerous studies have 
indicated that serum proteins containing Amadori glucose adducts play a substantive 
role in various diabetic complications (Hansson, 2005; Cohen et al., 2006). 
Physiologically relevant concentrations of Amadori-modified albumin possesses 
multiple proatherogenic effects that include promotion of oxidative stress, production 
of inflammatory mediators, endothelial damage and vessel wall hypertrophy. Free 
radicals are formed disproportionately in diabetes by glucose auto-oxidation, non-
enzymatic glycation and subsequent degradation of glycated proteins (Hunt, 1988). 
Massive increase in ROS generation during acute and chronic hyperglycemia is 
attributed to non-enzymatic glycation, which might alter the structure and function of 
antioxidant enzymes such that they are unable to detoxify free radicals, exacerbating 
oxidative stress. Glycation not only causes an increase in free radical production but it 
also reduces free scavenging defences (Marra et al., 2002), This may lead to cellular 
damage. The effect of increased glycation on ROS generation and cellular damage, 
therefore, can be additive or synergistic. Therefore, preventing the non-enzymatic 
early glycation of relevant proteins or blocking their subsequent effects may be 
helpful in ameliorating the vascular complications of diabetes. 
In the present study, HSA modified with varying concentration of glucose for 
a week resulted in high content of Amadori product as detected by NBT reagent. The 
reagent is specific for Amadori products and not for AGEs (Johnson et al., 1982; 
Lapolla et al., 2005). However, the Amadori yield decreased when glycated samples 
were treated with NaBH4 The treatment causes elimination of keto group of Amadori 
products and consequent decrease in the fructosamine. DTPA added to the mixture of 
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HSA and glucose did not interfere with early glycation (i.e. Amadori formation) but 
prevented AGE formation by inhibiting glycoxidation and cross-linking (Graf et al, 
1987; Fu et al, 1994; Lapolla et al, 2005). The occurence of AGEs in our preparation 
was further ruled out by negligible absorbance of the glycated samples in 300-400 nm 
wavelength range. Additional evidence of HSA glycation was provided by the 
thiobarbituric acid (TBA) assay (Ney et al, 1981) which was originally developed 
for providing evidence of hexose adduction to haemoglobin (Fluckiger and 
Winterhalter, 1976). The method is now widely used for quantification of glycated 
proteins as it detects ketoamine linkage in glycated proteins. Increase in TBA reactive 
HMF in glycated samples was observed. This observation is supported by an earlier 
study (Ney e/a/., 1981). 
SDS-PAGE of glycated-HSA samples showed gradual decrease in 
electrophoretic mobility with concomitant increase in band intensity. The observed 
shift in mobility may be due to the adduction of glucose moieties with the amino 
groups of the protein. The extent of Amadori adduct in glycated-HSA samples was 
evaluated on boronate affinity matrix. The glycated species retained on the boronate 
matrix speaks of Amadori product. The glycated species was retained on the boronate 
whereas, the non-glycated portion was washed away. On the basis of resuhs it may be 
plausible to think that at high glucose concentration adduct formation is facilitated in 
a short period of time. 
Early glycation primarily occurs on the 8-amino groups of lysine residues 
(Bamaby et al, 2011). Glycation of lysine residues might aher the tryptophan micro-
environment. Since HSA contains only one tryptophan residue (Tryp-214), the 
observed loss in the fluorescence intensity in glycated-HSA samples could be 
ascribed to the alteration of tryptophan-214 micro-environment as a resuh of glucose 
adduction. 
Since Amadori products are stable ketoamines they have a definite effect on 
protein structure. The results of far-UV CD studies on glycated-HSA indicated 
increase in alpha helix content as compared to native HSA, This is in agreement with 
an earlier report (Nejad et al, 2002), where incubation of HSA with low 
concentrations of glucose for 7 days destabilized protein's structure but caused 
increase in alpha helix at high glucose concentration. Furthermore, the substantial 
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increase in the Tm of glycated-HSA may be linked to increase in alpha helical content 
as suggested earlier (Nejad et al., 2002). 
FT-IR spectral analysis helped us locate the position and intensity of 
characteristic bands in native and glycated-HSA. It is well known that an IR spectrum 
of protein exhibits a number of amide bands, which represent different vibrations of 
peptide moieties (Rahmelow and Hubner, 1996). Amide I and II constitute two major 
bands of the protein infrared spectrum. Amide T band is mainly associated with the 
C=0 stretching vibration of the peptide linkage and corresponds mainly to a-helix. 
The amide II band, in contrast, derives mainly from N-H in-plane bending and from 
C-N stretching vibrations (Rahmelow and Hubner, 1996). The shifting of amide I and 
II bands and decrease in intensity indicate changes in intramolecular bonding and in 
present case may arise from the impact on overall protein conformation due to early 
glycation. Appearance of a new peak at 1711.2 cm' corresponding to the carbonyl 
group of glycated-HSA ketones suggested Amadori product (Wnorowsky and 
Yaylayan, 2003). The vibrational mode due to OH stretching is observed in the 
region 3100-3600 cm' (Lertsiri et al., 1998). An increase in absorption in the 
stretching vibration region of OH groups observed in glycated-HSA sample could be 
due to the attachment of glucose moieties with HSA. Furthermore, the IR profile of 
glycated-HSA exhibited a low intensity absorbtion peak at 1082.7cm"'. This might be 
due to C-C/C-0 stretching of glucose adducted to HSA, because carbohydrates 
(glucose) have strong absorption bands in this region (Mazdak and Jennifer, 2006). 
Furosine, formed during acid hydrolysis of fructosyl-lysine (Amadori product) 
(Schleicher and Wieland, 1981; Wu et al., 1995; Krause et al., 2003) is currently the 
most specific and important indicator of early Maillard reactions. HPLC analysis of 
standard furosine showed a retention time of 28.3 min. A matching peak with a 
retention time of 28.9 min was observed in glycated-HSA. Native and NaBH4 reduced 
glycated-HSA did not show any peak at the above retention time. Furosine presence 
in the hydrolysate of glycated-HSA was re-confirmed by LC-MS. 
For a typical non-enzymatic glycation reaction to occur, the carbonyl group of 
reducing sugars (like glucose) must first react with the free amino groups of a protein 
to form Schiffs base and the intermediate then undergoes Amadori rearrangement to 
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generate stable ketoamine product. Our ESI-MS data on glycated-HSA is in 
conformity with the above events and the ions at m/z 309, 273 and 225 suggests 
Amadori product, oxonium ion, and fiirylium ion respectively. 
It is known that ROS are produced at many steps of the sequential glycation 
cascade. Both SchifTs base and Amadori product generate free radicals. Superoxide 
radical is generated when the Amadori product takes on an enaminol structure. It has 
been reported that glycated proteins in vitro produce 50 times more superoxide 
radicals and cause a twofold increase in peroxidation of lipid vesicles (Mullarkey et 
al, 1990). Formation of superoxide radicals under our experimental conditions was 
confirmed by using superoxide dismutase (known quencher of superoxide), AG and 
TQ. The results suggest that AG and TQ are potent quenchers of superoxide generated 
during glycation process. Our resuhs are in agreement with previous reports showing 
that Amadori product generate ROS, mainly superoxide anions (Vallejo et al., 2000; 
Yoo et al., 2004; Ortwerth et al., 1988). 
The antiglycating/antioxidant effect of AG and TQ was also studied in 
diabetic rabbits. The alloxan-induced type I diabetes model is well-established in 
rabbits. It is also known that alloxan causes severe necrosis of pancreatic P-cells (Dun 
and McLetchie, 1943; Gumieniczek et al., 2007). Both alloxan and its metabolite, 
dialuric acid, establishes a redox cycle and superoxide radicals are formed. These 
radicals undergo dismutation to hydrogen peroxide. Thereafter highly reactive 
hydroxyl radicals are formed. Thus, the cytotoxic action of alloxan on beta cells is 
mediated by the generation of superoxide and hydroxyl radicals (Munday, 1988; 
Kurahashi et al., 1993). High blood glucose level confirmed the efficacy of alloxan in 
producing experimental diabetes. However, the alloxan effect on pancreas of the 
rabbits was reduced in presence of AG and TQ. The effect may be attributed to the 
potent scavenging action of AG and TQ for superoxide and hydroxyl radicals. 
Previous studies have shown that the concentration of Amadori-product 
exceeds that of AGEs not only in serum, but also in in vitro protein preparations that 
contain AGEs (Makita, 1992; Schalkwijk, 1999). Therefore, it may be argued that the 
effects that have been ascribed to AGEs may be in fact due to Amadori-proteins 
(fructosamines). Diabetics tend to have elevated concentration of sugars, therefore, 
the degree of glycation of Hb has been considered as an index of glycation (Jain etai, 
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1989). Glycation of Hb probably reflects the level of glycation of other proteins as 
well (Valeri et al., 2004). The most encouraging result of our in vivo study was the 
significant decrease in HbAiC and serum fructosamine in diabetic animals treated with 
AG and TQ as compared to diabetic group. Here, it is important to mention that 
although AG is a potent inhibitor of AGEs, but under our experimental conditions AG 
prevented the formation of early glycation products (Amadori product). However, the 
mechanism by which AG prevents the formation of early glycation products remain to 
be fully elucidated. Previous studies suggest that AG inhibits the original glycation by 
limiting the attachment of glucose with the amino groups of the proteins (Lewis and 
Harding, 1990; Hirsch et al., 1995; Khatami et al., 1988). It has been further 
suggested that AG probably interacts with the carbonyl groups of early glycation 
products and forms stable products that do not react fixrther (Edelstein and Brownlee, 
1992; Chen and Cerami, 1993). Against this backdrop, the reduction in the indices of 
early glycation products in our study may be attributed to fast binding of AG 
(compared to glucose) with proteins or due to the interaction of AG with unstable 
earliest glycation products preventing their accumulation. 
It has been widely held that oxidative stress plays vital role in the pathogenesis 
of various complications of diabetes. In healthy subjects both enzymatic and non-
enzymatic antioxidants play important role in scavenging free radicals. During 
hyperglycemia increased glycation promotes fi-ee radical generation. Therefore, 
inactivation of enzymes (especially antioxidant ones) by glycation or free radical 
attack appears to be inevitable during hyperglycemia. SOD is inactivated by glycation 
at specific lysine residues (Arai et al., 1987). Glycation also induces random 
fragmentation of the enzyme (Ookawara et al., 1992; Park and Lee, 1995). The 
decreased serum level of SOD, catalase, GPx and GSH observed in diabetic rabbits 
reiterates that hyperglycemia promotes fi^ee radical generation. Restoration of the 
parameters of oxidative stress in AG and TQ treated group support their role as 
antioxidant/antiglycating agents. Hydroxyl radical attack on unsaturated fatty acids of 
phospholipid components of membranes produce malondialdehyde (MDA), a lipid 
peroxidation product. The serum MDA level in AG and TQ treated diabetic rabbits 
was found to be significantly dropped as compared to diabetic rabbits. This finding is 
consistent with the results of El-Missiry and El-Gindy (2000), where increased lipid 
peroxidation and decrease in antioxidant enzymes level in diabetes mellitus has been 
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reported. Carbonyl content is the most common marker of protein oxidation (Shacter, 
2000) and provides a significant clue to the magnitude of oxidative stress under 
disease conditions, such as diabetes (Beal, 2002). The decrease in carbonyl content in 
AG and TQ treated diabetic rabbits may be attributed to the antioxidant action of both 
AG and TQ. 
Increased nitric oxide (NO) production in early diabetes has been reported 
(Lindsay et al, 2009), which can damage pancreatic beta cell DNA, effect insulin 
secretion and cell viability. NO as a free radical is relatively unstable in oxygenated 
solutions where it rapidly and spontaneously reacts with molecular oxygen to yield a 
variety of nitrogen oxides. The only stable product of NO in oxygenated medium are 
nitrites and nitrates, which are considered to be indicators of NO production (Guevara 
et al., 1998). Nitrite level in AG treated diabetic rabbits sharply decreased in 
comparison to diabetic group. This shows that AG is a potent inhibitor of iNOS 
(Corbett and McDaniel, 1996). Moreover, TQ might have exhibited its protective 
effect by down regulating the immunological inflammatory effects mediated by nitric 
oxide (El-Mahmoudy et al., 2005). 
Proteins modified by glycation and glycoxidation processes are 
immunologically active and can elicit strong antibody response. Native human serum 
albumin per se is immunogenic (Doyen et al., 1985). However, glycation and free 
radical modification of HSA may result in the generation of highly immunogenic new 
epitopes (Rasheed and Ali, 2006; Khan et al., 2010). Lysine residues play an 
important role in the enhanced immnunogenicity of HSA (Arif e/ al, 2012). In vivo, 
direct role of glycated lysine residues in the immunogenicity has been advocated on 
the basis of reports of autoantibodies against glycated proteins in diabetes (Turk 2001; 
Araki et al., 2001; Ansari et al, 2009). The in vivo generation of autoantibodies 
appear to be the result of hyperglycemia mediated modifications in protein structure 
leading to induction of antibodies. 
Antigenicity of native and glycated-HSA was evaluated by inducing antibodies 
in rabbits. Glycated-HSA was found to be a potent immunogen and induced high titre 
antibodies compared to native HSA which induced low titre antibodies. The results 
suggest glycation-induced generation of immunologically active neo-epitopes. 
Specificity studies on affinity purified anti-glycated-HSA IgG reiterated that glycated-
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HSA was preferentially recognized. Notable feature of the anti-glycated HSA IgG 
was that the maximum inhibition in antibody binding was caused by glycated-HSA 
followed by NaBRj-reduced glycated HSA and least with the native HSA. Reduction 
of Amadori product by NaBRj leads to the elimination of keto group which causes 
shift in the existing equilibrium between the linear configuration and the fiiranose or 
pyranose ring structures more towards the linear configuration (Schalkwijk et al., 
1999). Therefore, anti-glycated-HSA antibodies showed decreased binding with 
NaBHt treated glycated-HSA. This is in agreement with the earlier report that the ring 
structure of Amadori-HSA is essential for antibody recognition (Schalkwijk et al., 
1999). Furthermore, anti-glycated-HSA antibodies showed binding with glycated 
BSA, IgG, histone and poly-L-lysine, most likely due to epitope sharing. 
Furthermore, glucose-modified lysine was effectively recognized by anti-glycated-
HSA antibodies. The importance of lysine residues in Amadori generation has been 
demonstrated in HSA and poly-L-lysine (Ansari et al., 2009; Anfet al., 2012). 
Accumulation of Amadori-proteins and protein-AGE play important role in 
the pathogenesis of various diabetes related complications. More recent studies have 
highlighted the role of Amadori-configured proteins in various complications of 
diabetes (Schalkwijk et al., 2000). Amadori products have been found in various 
tissues of diabetic rats as well as in diabetic subjects (Myint et al., 1995; Schalkwijk 
et al., 1999; Jaleel et al., 2005). That Amadori-albumin is an independent and potent 
trigger of complications of diabetes has been demonstrated in experimental animals. 
The results pointed out that neutralizing the biologic effects or inhibiting the 
formation of glycated albumin can ameliorate structural, ftinctional and cell biology 
abnormalities in the kidney and retinal microvasculature of diabetic rodents (Cohen et 
al., 1994, 2005). 
Much of the information regarding the possible role of Amadori-HSA in the 
pathogenesis and natural history of diabetes has been obtained from type 1 diabetic 
subjects with and without secondary complications. The likely involvement of 
glycated-HSA in diabetes related complications was derived from binding of 
autoantibodies in sera of diabetic subjects with and without secondary complications. 
Autoantibodies in type 1 diabetic subjects with secondary complications showed 
higher recognition of glycated-HSA, indicating a causal role of Amadori-glycated 
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proteins in the pathogenesis of diabetes related complications. Amadori-HSA is found 
to be immunogenic and type 1 diabetic subjects with retinopathy and nephropathy 
have higher Amadori albumin (Schalkwijk et al., 1999; Cohen and Ziyadeh, 1994). 
Furthermore, animal studies have shown that elevated concentrations of Amadori 
albumin promote a generalized vasculopathy (Cohen et al., 1996) and have been 
implicated in the development of diabetic nephropathy (Cohen et al., 1994; Cohen 
and Ziyadeh, 1996) and retinopathy (Clements et al., 1998). Likely presence of in 
vivo Amadori-epitopes on HSA purified from diabetic subjects was probed with 
experimentally produced anti-glycated HSA antibodies. The data suggests that a 
significant population of diabetic albumin bears the epitopes typical of Amadori-
HSA 
Based on the above studies following conclusions can be drawn:-
> Good amount of Amadori product can be formed if HSA is kept under high 
glucose concentration for one week. 
> Early glycation of HSA results in hyperchromicity and decreased fluorescence 
intensity. 
> Glycation confers stability on HSA. 
> Under our experimental conditions Amadori product formation was confirmed by 
FT-IR, HPLC, LC-MS and ESI-MS 
> Free radicals are generated during Amadori product formation, and both AG and 
TQ are effective quenchers of free radicals. 
> Amadori formation during hyperglycemia may be ameliorated by AG and TQ. 
> During hyperglycemia immunogenicity of HSA may be augmented due to 
generation of neo-epitopes. 
> The induced antibodies against glycated-HSA were specific for the immunogen 
but exhibited polyspecificity and recognise glycated form BSA, poly-L-lysine, 
IgG and histone. 
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> Decreased recognition of NaBKt reduced glycated-HSA by anti-glycated-HSA 
antibodies indicate immunogenic role of Amadori product. 
> Autoantibodies derived from the sera of diabetic subjects, with and without 
secondary complications, showed higher recognition of glycated-HSA. This 
indicates that the major population of autoantibodies in diabetes patients are 
directed against Amadori component of the glycated-HSA. 
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A B S T R A C T 
Proteins modifications In diabetes may lead to early glycatlon products (EGPs) as well as advanced gly-
cation end products (AGEs). Whereas no extensive studies have been carried out to assess the role of EGPs 
In secondary complications of diabetes, numerous Investigators have demonstrated the role of ACEs. 
Early glycation involves attachment of glucose on E-NHJ of lysine residues of proteins leading to gener-
ation of the Amadori product (an early glycation species). This study repons the structural and Immuno-
logical characterization of EGPs of HSA because we believe that during persistent hyperglycemia the HSA, 
one of the major blood proteins, can undergo fast glycation. Glucose mediated generation of EGPs of HSA 
was quantitated as Amadori products by NBT assay and authenticated by boronate affinity chromatogra-
phy and LC/MS. Compared to native HSA changes in glycated-HSA were characterized by hyperchromlc-
ity, loss in fluorescence intensity and a new peak in the FTIR profile. Immunogenicity of native- and 
glycated-HSA was evaluated by inducing antibodies In rabbits. Results suggest generation of neo-epi-
topes on glycated-HSA rendering It highly immunogenic compared to native HSA. Quantization of EGPs 
of HSA by authentic antibodies against HSA-EGPs can be used as marker for early detection of the initi-
ation/progression of secondary complications of diabetes. 
© 2012 Elsevier Inc. All rights reserved 
Introduction 
Non-enzymatic glycation is a multi-step process, involving 
chemical modification of reactive amino groups In proteins by 
reducing sugars and carbohydrate derived reactive carbonyls. Early 
glycation involves the reaction of glucose with N-terminal and ly-
syl side chain amino groups to form Schiffs base (an aldimine) 
which through acid-base catalysis undergoes rearrangements to 
form more stable early glycation product known as Amadori prod-
u t t |1] . After Amadori. the reactions become more varied and com-
plicated leading to the formation of advanced glycation end 
products (ACEs).' that interact with various AGE receptors, thereby 
playing an important role in the long-term sequelae of diabetes. On 
the other hand, the Amadori-modification Is structurally distinct 
from those asstxriated with ACEs and Amadori-modified proteins 
operate through receptors different fi-om that of ACEs |23J. 
The emphasis of research in recent years has been on AGEs. little 
attention has been paid on the characterization of early glycation 
products. However, it was only recently that the role of Amadori-gly-
* Corresponding author. Fax: +91 571 2720030. 
E-mail addi«s: kalam786@redifiinaU.com (K. Alam). 
' Abbreviations used: ACEs. advanced glycation produas:HSA. human serum 
albumin; NBT. nitroblue tetrazolium: DTPA. diethylene-triaminepentaacetic add; 
IgC. immunoglobulin C. 
cated proteins has come into consideration |4] . Studies have shown 
that both Amadori produrt as well as Amadori-derived AGEs are in-
volved in the secondary complications of diabetes [S). Furthermore. 
Amadori adducts have been shown to be important contributors in 
the development of various diabetic complications such as micro-
angiopathy |6 j . Amadori adduct (fructosyl lysine) in type 1 diabetic 
patients was also found to be independently associated with reti-
nopathy and early nephropathy |7] . In addition to the implicarions 
of Amadori adduct in the pathogenesis of diabetic micro and 
macro-vascular complications, glucose metabolism in skeletal mus-
cles is likely to be affeaed by /Amadori adduct | 8 | . 
The most abundant protein in human serum, prone to glycation 
is albumin |9] . Clycation induced structural alterations has pro-
found impact on the functional properties of albumin 110). Changes 
in HSA structure and conformation by Amadori product formation 
strongly affects its anti-oxidant properties and foster ac<|uisition of 
pro-oxidant activity in presence of copper | n . l 2 ) . It has been re-
ported that the drug binding piwperty of HSA may be altered at 
various stages of diabetes as the extent of glycation and type of 
modifications are varied in this protein 113-15]. Non-enzymatic 
glycation of HSA occurs at multiple sites. Evidence suggests that 
E-amino groups of lysine residue in human serum albumin are 
preferred locus for eariy glycation 113.16]. As glycation primarily 
occurs at intra-chain lysine residues, lysine rich proteins like HSA 
0003-9861/$ - see front matter © 2012 Elsevier Inc. All rights re.served. 
http://dx.doi.Org/10.1016/j.abb.2012.04.005 
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125 mM ( - • -X 25 m M ( - A ) and 50 m M ( - • - ) glucose. 
Fig. 1. Content of Amadori product in HSA modified w i th 12.5 mM. 25 mM and 
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Fig. 2. Boronate affinity chromatography of native HSA and HSA incubated w i th 
different concentrations of glucose for 7 days. 
Fig. S. Fluorescence emission profile o f native HSA (-) and HSA glycated wi th 
50 mM glucose ( — ) . The samples were excited at 295 nm. 
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Ffe. 6. FTIR Spectra of (a) native HSA and (b) HSA glycated with 50 mM glucose 
having 59 lysine residues could be used as a marker for early gly-
cation induced changes. 
In the present study. HSA was incubated with varying concen-
tration of glucose for one week to generate Amadori-rich glycated 
HSA. Structural changes were investigated by UV, fluorescence and 
FT-\R spectroscopy as well as by SDS-PAGE. The Amadori product 
was assayed by NBT and authenticated by boronate affinity chro-
matography and LC/MS using furosine as standard. Antigenicity 
of native and glycated-HSA was probed in rabbits. Binding specific-
ity of the induced antibodies was assessed by inhibition ELISA. 
Presence of autoantibodies against native and glycated-HSA in 
the sera of type 1 diabetic patients was also investigated. 
Materials and methods 
Human serum albumin (HSA). m-aminophenylboronic acid, 
anti-rabbit/anti-human IgC-alkaline phosphatase conjugate, p-ni-
tro-phenyl phosphate. Protein A-agarose CL-4B pre-packed 
column. Tween-20 and Freund's complete & incomplete adjuvants 
were purchased from Sigma Chemical company (St. Louis. USA). 
Furosine was obtained from Polypeptide Laboratories (Stras-
bourg. France). D-glucose and sodium borohydride (NaBH4) were 
obtained from Merck (Darmstadt. Germany). Nitroblue tetrazolium 
(NBT) was purchased from SRL Chemicals (India). Polystyrene flat 
bottom microliter plates and modules were from Nunc (Roskilde. 
Denmark). All other chemicals and reagents used were of highest 
analytical grade available. 
Preparation of Amadori-HSA 
Glycated HSA containing high level of Amadori products was pre-
pared according to the method of Cohen and Hud 117]. Briefly, HSA 
(10 pM) was incubated with different concentrations of glucose 
(12.5, 25 and 50 mM) in 20 mM phosphate buffered saline (PBS, 
pH 7.4) in presence of 0.01 mM diethylene-triaminepentaaceticacid 
(DTPA) at 37 °C under sterile conditions in capped vials for one week. 
At the end of incubation, the samples were extensively dialyzed 
against phosphate buffer (pH 7.4) to remove excess glucose. Equal 
concentration of HSA dissolved in the same buffer and kept under 
identical conditions served as control. 
Reduction of glycated samples with NaBH^ 
Glycated samples were reduced with NaBH4 in PBS. pH 8.0, as 
desCTibed previously 118]. Slow addition of 1 N HCl was used to re-
move excess borohydride. 
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Fig. 7. Mass spectroscopic profile of (a) staridard furosine. (b) acid hydrolyzed native HSA and (c) add hydrolyzed glycated-HSA. 
Characterization of Amadori product (Fruaosamine) by NBT assay 
Content of Amadori product, measured as fructosamine in the dia-
lyzed preparations, was evaluated by NBT assay 119]. Native and gly-
cated samples {100 jil each) were added to 96-well microliter plates 
in duplicate. One hundred microlitre of NBT reagent (250 |imol/l in 
0.1 mol/l carbonate buffer. pH 10.35) was added to each well and 
incubated at 37 °C for 2 h. The color was read on a microplate reader 
at 525 nm. Amadori produrts were determined using an extinction 
coefficient of 12640 cm~'mor ' for monofotmazan |20). 
fioronate affinity chromatography 
Presence of Amadori produa in glycated samples was assessed on 
boronate affinity column following the proceduiie described earlier |21 ]. 
Spectroscopic analysis 
UV absorption characteristics of native and glycated samples 
were recorded in the wavelength range of 190-400 nm on a Shima-
dzu UV-1700 spectrophotometer using quartz cuvette of 1-cm 
path length. Fluorescence analysis of native and glycated samples 
was done on Shimadzu (RF 5301-PC) spearofluorometer. The sam-
ples were excited at 295 nm and the emission intensities were re-
corded in the range of 300-500 nm. Possible presence of the AGEs 
in the glycated samples was verified with AGE-specific fluores-
cence at 440 nm after excitation at 370 nm 122]. FT-IR measure-
ments of native and glycated samples were carried on Shimadzu 
FT-IR spectrophotometer (8201-PC) in the spectral range of 400-
4000 cm"'. Samples to be analyzed on FT-IR spectrophotometer 
were first lyophilized and prepared as KBr pellets. 
Liquid chromatography-mass spectrometry flC/MSj 
HSA glycated with glucose was subjected to LC/MS studies for 
adduct identification. Prior to loading, the samples were hydro-
lyzed as described previously [23]. The hydrolysates were filtered 
through a medium grade filter paper. Reversed-phase separation 
was carried out on an Agilent 1100 series capillary HPLC system 
equipped with a synergi C,g analytical column (2 x 250 mm with 
5 pm particle size). The chromatographic conditions were as fol-
lows; 0.4% acetic acid (Solvent A). 0.2% acetonitrile (Solvent B) each 
containing 2% formic acid. Gradient elution protocol was as fol-
lows: 0% to 2% solvent B in the first 5 min. from 2% to 6% solvent 
B over 19 min. 6% to 80% solvent B in 11 min, and then raised to 
80% to wash the residual material off the column at a constant flow 
rate of 0.5 ml/min. Mass spectrometric analysis was then carried 
out on Micromass Qualtro Ultima Triple Quadropole Mass spec-
trometer interfaced to an Agilent 1100 capillary HPLC system. 
The mass spectrometer was operated in a positive ion mode and 
full scan mass spectra were recorded in 0-400 m/z range. 
E/ertrop/ioresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) of native and glycated samples was (jerformed as de-
B. Arifet al / Archives of Biochemistry and Biophysics 522 (2012) 17-25 
scribed earlier 124]. Electrophoresis was done at 80 V for 4 h at room 
temperature and the bands were visualized after silver staining. 
Immunization schedule 
According to a previously described protocol |25), white New 
Zealand female rabbits were immunized with native and glycated-
HSA. Briefly, rabbits (n - 4 ; two each for native and glycated-HSA) 
were immunized intramuscularly at multiple sites with 100 pg of 
antigen emulsified with an equal volume of Freund's complete adju-
vant. Animals were boosted with the same amount of antigen in 
Freund's incomplete adjuvant at weekly intervals for 6 weeks. To 
evaluate antibody titer, test bleeds were performed after alternate 
booster dose. After an appropriate level of antibody was reached, 
the animals were finally bled and the separated sera were heated 
at 56 °C for 30 min to inactivate complement proteins. 
Enzyme linked immunosorbent assay 
Titre of induced antibodies was monitored by direct binding ELISA 
which was carried out on polystyrene plates as described earlier |26]. 
Antigenicspecificityoftheantibodieswasascertained by competition 
EUSA |27|. Percent inhibition was calculated using the formula: 
Percent inhibition = 1 - (Ai„hibited/Au„inhibit«)) x 100 (1) 
Purification ofIgG 
Immunoglobulin C (IgC) was isolated from preimmune and im-
mune sera on Protein A-agarose pre-packed column 128). The 
homogeneity of isolated IgG was assessed on 10% SDS-PAGE. 
Band shift assay 
For the visual detection of antigen antibody interaction and im-
mune complex formation, gel retardation assay was performed 
[28]. Immune complex was prepared by incubating constant 
amount of glycated-HSA with varying amounts of affinity purified 
IgG in PBS for 2 h at 37 °C and overnight at 4 °C. After incubation, 
the samples were electrophoresed on 10% SDS-PAGE for 4 h at 
80 V. The bands were visualized using silver nitrate staining. 
Blood collection from human subjects and sera separation 
Blood was collected from voluntary donors with a history of 
type 1 diabetes attending Rajiv Gandhi center for diabetes and 
endocrinology, J.N. Medical College, Aligarh Muslim University, 
India. Sera from normal healthy subjects served as control. A de-
tailed history on demographics and cumulative clinical and labora-
tory manifestations during the period of disease were noted in 
every patient. Our study protocol was approved by the Institu-
tional Ethics Committee. Sera, separated from the blood samples, 
were decomplemented by heating at 56 °C for 30 min and stored 
in aliquots at -20 "C with 0.\% sodium azide as preservative. 
Statistical analysis 
Data are given as mean ± SD. Statistical significance of the data 
was determined by student's t-test (statgraphics, origin 6.1). A p 
value of $0.05 was considered statistically significant. 
Results 
Characterization of Amadori-rich glycated HSA by physicochemical 
methods 
HSA(10 (iM) was incubated with 12.5,25 and 50 mM glucose at 
37 °C for one week, sufficient time for Amadori product formation 
[2930). The content of Amadori produrt in glycated-HSA samples 
was determined by NBT assay which is a reliable parameter for early 
glycaiion products. The yield of Amadori product measured as fruc-
tosamine was 27.4,51.3.94.4 nmol/mg, respectively (Fig. la). Higher 
yield of Amadori product was seen in HSA glycated with 50 mM glu-
cose. Under identical conditions, native HSA gave almost negligible 
fructosamine concentration of 2.3 nmol/mg. Moreover, after reduc-
tion with NaBH4 the level of fructosamine in glycated samples de-
creased to 12.2, 21.3 ar>d 46.1 nmol/mg respectively (Fig. lb). The 
formation of Amadori product (fruaosyl lysine) measured as furo-
sine was further confirmed by HPLC (data not shown). 
Boronate affinity chromatography for Amadori produa 
HSA incubated with different concentrations of glucose was 
passed through boronate column and the results are given in 
Fig. 2. Percentage of Amadori bound by the matrix increased with 
glucose concentration. Native HSA did not show any retention on 
the boronate column. 
Ultraviolet analysis of native and glycated-HSA 
Glycation-induced structural changes in the samples were evalu-
ated by UV absorption spectroscopy (Fig. 3). Native HSA gave character-
istic peak at 280 nm, whereas in glycated samples with increasing 
concentration of glucose, an increasing hy perchromicity was observed. 
Highest modification reached at 50 mM of glucose, which showed a 
marked hyperchromicity (58.2%) as compared to native analog. 
Elearophorctic pattern of native and glycated-HSA 
Fig. 4 shows the migration pattern of native and glycated sam-
ples in 10% SDS-PAGE. As compared to native HSA, glycated sam-
ples showed appreciable change in eleCTrophoretic mobility with 
concomitant increase in band intensity. Moreover, HSA incubated 
with 50 mM glucose showed maximum change in electrophoretic 
mobility accompanied with an increase in band intensity. Thus, 
on the basis of higher level of Amadori content as deteaed by 
NBT, boronate binding, increased hyperchromicity and significant 
change in electrophoretic migration pattern of HSA modified with 
50 mM glucose, we chose it for further characterization. 
fluorescence analysis of native and glycated-HSA 
Tryptophan specific fluorescence of native HSA and HSA glycat-
ed with 50 mM glucose was measured by spectrofluorometer. Both 
native as well as glycated-HSA were excited at 295 nm. Native HSA 
showed a strong emission peak at 340 nm because of its single 
tryptophan residue (Trp 214). Glycation induced structural change 
in glycated-HSA was evident from 43.2% loss in intensity (Fig. 5). 
Furthermore, the glycated-HSA did not show AGEs specific fluores-
cence at 370 nm ().ex) 3nd 450 nm (>.<ni) (data not shown). 
FT/R spectra of native and glycated-HSA 
FTIR Sf>ectra recorded for both native (Fig. 6a) and glycated-HSA 
(Fig. 6b) were analyzed on the basis of shape and frequency of the 
amide I and II bands and other characteristic group present in their 
struttures. Amide I band (arising from C=0 stretching) in native 
HSA showed a peak at about 1660 cm"' which was consistent with 
the absorption peak of ot-helbc This band at 1660 cm"' shifted to 
1651 cm"' in glycated-HSA. The amide II band (originating from 
N-H bending vibrations of peptide groups) at 1543 cm"' in native 
HSA shifted to 1532 cm"' in glycated-HSA. A new peak at 
1711.2 cm ' corresponding to keto (C=0) group of Amadori prod-
uct was observed in the spectra of glycated-HSA. Moreover, in na-
tive HSA the band at 3209.1 cm"' related to the stretching 
vibration of the OH group shifted to 3309.1 cm"' in glycated-HSA. 
Detection offurosine in native and glycated-HSA by LC-MS 
Furosine, a known gold standard of Amadori adduct was evaluated 
in the acid hydrolysate of glycated-HSA, Fig. 7a-c shows mass 
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Fig. 8. Level of induced antibodies against native and glycated-HSA. Direct binding 
EUSA of (a) HSA and (b) glycated-HSA with pre-immune (-D-) and immune (-•-) 
sera. Microtitre plates were coated with the respective antigens (10 pgyml). 
spectroscopic pinfile of Standard furosine, acid hydrolyzed native HSA 
and acid hydnolyzed glycated-HSA. As shown in Fig. 7c, the acid 
hydrolysate of glycated-HSA showed a m/z value of 255. matching 
with m/z value of standard furosine. No such species was observed 
in the hydrolysate of native HSA. Peak identity was assigned by reten-
tion time, chromatographic pattern and spike of authentic standard. 
Antigenidry of glycated-HSA 
Native HSA injected into rabbits induced moderate antibody re-
sponse with a titre of < 1:6400 as revealed by direct binding ELISA 
(Fig. 8a). On the other hand glycated-HSA was found to be a potent 
immunogen and induced high titre antibodies (>1:12,800) 
(Fig. 8b). Under identical conditions preimmune serum included as 
control, showed negligible binding with either of the immunogens. 
IgG was purified from preimmune and immune sera of native 
HSA as well as glycated HSA by affinity chromatography on Pro-
tein-A Sepharose column. The purified IgG eluted as a single sym-
metrical peak. SDS-PAGE of purified IgG under non-reducing 
conditions showed a single homogeneous band. Direct binding ELI-
SA of purified anti-glycated HSA IgG and anti-HSA IgG showed 
strong binding with their respective immunogens. However, 
negligible binding was observed with pre-immune IgG (data not 
• M All 1 -M 1M 
Inhibitor concentration (|ig/ini) 
fig. 9. Iithibition ELBA of anti-glycated HSA IgC. The inhibitors were native HSA (-
a-X glycated-HSA (-•-] and NaBH< reduced HSA (-A-). Microtitre plates were 
coated vnth glycated HSA (10 tig/ml). 
shown). The results indicate that the immunogen binding property 
of purified IgC was intact even after giving harsh conditions during 
purification procedures. 
Antigenic specificity of anti-glycated HSA antibodies was fur-
ther ascertained by inhibition ELISA (Fig. 9). A maximum of 
89.3% inhibition in antibody binding was observed when glycat-
ed-HSA (the immunogen) was used as inhibitor. An inhibitor con-
centration (immunogen) of only 3.5 Uglml was required to achieve 
50% inhibition in the antibody binding. Native HSA used as inhib-
itor showed a maximum of 48.2% inhibition, whereas NaBH4 re-
duced glycated HSA resulted in 69.4% inhibition in antibody 
binding. The anti-glycated HSA IgG exhibited binding with glycat-
ed forms of BSA. IgG, histone and PLL (poly-t-lysine). The antigen 
binding characteristics of anti-glycated HSA antibodies has been 
summarized in Table 1. 
Visual detection of antigen-antibody interaction was monitored 
by gel retardation assay. The formation of immune complex be-
tween glycated HSA and anti-glycated HSA IgG was ascertained 
from appearance of high molecular weight immune complex with 
retarded mobility (Fig. 10a). It clearly indicates that, on increasing 
the amount of anti-glycated HSA IgG there was an increase in the 
formation of high molecular weight immune complex which re-
sulted in retarded mobility and corresponding decrease in un-
bound antigen. Native HSA incubated with the same amount of 
anti-glycated HSA IgG did not show high molecular weight im-
mune complex or decrease in the intensity of the unbound antigen 
under identical experimental conditions (Fig. 10b). 
Detection of autoantibodies against glycated-HSA in type 1 diabetes 
sera by enzyme immunoassay 
Serum samples of type 1 diabetes were divided into two groups 
on the basis of presence or absence of secondary complications. 
The demographic and clinical characteristics of normal and dia-
betic subjects included in the study are presented in Table 2. Fifty 
sera from type 1 diabetes and twenty one sera from normal human 
subjects were tested for binding to native, glycated and NaBH^ re-
duced glycated-HSA. Seventy three percent (16 of 22) of type 1 sera 
with secondary complications showed enhanced binding with gly-
cated-HSA as compared to native and NaBH4 reduced glycated-HSA 
(Fig. 11). Furthermore, only sixty four percent (18 of 28) of type 1 
sera without secondary complications, showed enhanced binding 
with glycated-HSA forms of HSA as compared to the native form. 
Whereas, type 1 diabetic group (without secondary complications), 
out of 28 samples tested, only 18 samples had enhanced binding 
^ , i C <=.\S 
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Table! 
Cross-reaction of affinity purified anti-glycated HSA IgC with various inhibitors as determined by intiibition ELISA. 
Inhibitors Maximum % inhibition at 20 |jg/ml 
Glycated HSA 
Native HSA 
NaBlit reduced HSA 
ROS-glycated HSA 
Native BSA 
Glycated BSA 
ROS-giycated BSA 
Native human IgC 
Glycated human IgC 
ROS-glycated human IgC 
Native histone 
Glycated histone 
ROS-glycated histone 
Native poly r-lysine 
Glycated poly i-lysine 
ROS-glycated poly t-lysine 
Native lysine 
Glycated lysine 
ROS-glycated lysine 
Native aiginine 
Glycated arginine 
ROS-glycated arginine 
Native tryptophan 
Glycated tryptophan 
ROS-glycated tryptophan 
Native tyrosine 
Glycated tyrosine 
ROS-glycated tyrosine 
Native phenylalanine 
Glycated phenylalanine 
ROS-glycated phenylalanine 
89.3 
A82 
69.4 
285 
35.5 
57.1 
30J 
26.5 
45.7 
24.5 
25.7 
42.8 
23.6 
17.4 
49.4 
21.6 
38.6 
74.7 
33.2 
23.4 
30.2 
19.3 
20.1 
41.6 
39.2 
22.1 
38.6 
21.7 
22.3 
33.8 
24.5 
Concentration for 50* inhibition (fig/ml) Percent relative affinity 
3.5 
11.1 
18.2 
100 
31.5 
19.3 
10.8 32.4 
with glycated-HSA. Normal human sera did not show appreciable 
binding with coated antigens. 
Bindingspecificity of the autoantibodies in type 1 diabetes sera 
with secondary complications was evaluated by competition ELISA, 
using native-HSA, glycated-HSA and NaBH4 reduced glycated-HSA 
as inhibitors {Table 3). Data reveals specificity of autoantibodies 
towards glycated-HSA. 
Discussion 
Non-enzymatic glycation of macromolecules has been linked to 
pathogenesis of various complications of diabetes. Although Ama-
dori-glycated proteins are the major glycated modifications, most 
studies so far have focused on the characterization of AGEs and 
their possible role in assessing diabetic complications, whereas 
only a few studies have highlighted the role of early glycation 
products or Amadori products. The predominant form of glycated 
proteins in plasma exist as Amadori produrts rather than the more 
labile SchifTbase form |31}. Furthermore, concentration of Amado-
ri-glycated proteins is at least 2% of serum proteins, whereas the 
concentrations of ACE-equivalents are less than 0.0t% [32J. It has 
been found that Amadori-modified albumin is an independent 
and potent trigger of molecular mediators contributory to diabetic 
complications and various diabetic complications are ameliorated 
upon inhibition of albumin glycation (3334|. Against this back-
drop, the present study describes the structural and immunological 
characterization of Amadori-rich glycated HSA. 
The formation of Amadori-HSA was confirmed by NBT reduc-
tion which is a specific and reliable parameter for Amadori prod-
ucts (early glycation product) and not for AGEs |191. Under our 
experimental conditions we found high content of Amadori prod-
uct in glycated samples. However, the yield of Amadori decreased 
upon treatment of glycated samples with NaBH^ Reduction of the 
samples with NaBH^ leads to the elimination of keto group of 
Amadori products, thereby causing loss in the fructosamine yield. 
which indicates that the glycated samples are rich in Amadori 
products. Moreover, glycoxidation and crosslinking was inhibited 
by DTPA which is known to inhibit the development of AGE-spe-
cific fluorescence in proteins without significantly affeaing the 
glycation of proteins |35.36J. The extent of Amadori adduct in gly-
cated-HSA samples was further evaluated on boronate affinity ma-
trix. The species retained on the boronate matrix speaks of 
Amadori product. It may be plausible to think that at high glucose 
concentration adduct formation is facilitated in a short period of 
time. 
HSA samples modified with 12.5, 25 and 50 mM glucose 
exhibited hyperchromicity of 14.3%. 38.3% and 58.2%, respec-
tively. The observed hyperchromicity could be due to modifica-
tion of aromatic amino acids or changes in the micro 
environment of aromatic amino acids. It has been reported that 
glycation induced AGE-specific absorbance in proteins and their 
unfolding leading to cross linking and aggregation are responsi-
ble for a change in conformation of protein 137]. In our case, 
the onset of AGE formation in the glycated samples was ruled 
out by the absence of absorbance between 300 and 400 nm. 
SDS-PAGE of glycated samples showed noticeable concentration 
dependent decrease in electrophoretic mobility with concomitant 
increase in band intensity, which might be due to the adduction 
of glucose moieties with the amino groups of the protein at 
Amadori stage. Moreover, no dimer or polymer formation was 
observed, which cleariy indicate the absence of any cross-linked 
structure. Late glycation of HSA results in crosslinked dimers 
111). 
Eariy stages of glycation occurs primarily on the E-amino 
groups of lysine residues 113). Glycation of lysine residues might 
play an important role in altering the tryptophan micro-environ-
ment. As HSA contains only one tryptophan residue (Tryp-214), 
the loss in fluorescence intensity observed in glycated-HSA could 
be ascribed to the alteration of tryptophan-214 micro-environ-
ment as a result of glucose modification. 
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Fig. 10. Bjnd shift assay of anti-glycated-HSA IgC binding to (a) glycated HSA and 
(b) native HSA. Elearophoresis was performed on 10% SDS-PACE for 4 h at 80 V.(a) 
Glycated HSA (25 |ig.Une 1) was incubated with 10.20. 30and40)iganti-glycated 
HSA IgC. respectively (lanes 2-5) for 2 h at 37 °C and overtiigttt at 4 °C (b) Native 
HSA was incubated with 10, 20. 30 and 40 (ig anti-glycated HSA IgC respectively 
(lanes 2-5) under identical conditions. Lane (8a and b) contains anti-glycated HSA 
IgC alone. 
FT-IR spearal analysis clearly reflects the position and intensity 
of characteristic bands in native and glycated-HSA. It is well estab-
lished that the FT-IR spearum of proteins exhibit a number of 
amide bands, which represent difTerent vibrations of peptide moi-
eties |38]. Amide I and II constitute two major bands of the protein 
infrared spectrum. Amide I band is mainly associated with the C=0 
stretching vibration of the peptide linkage and corresponds mainly 
to ot-heiix structure. The amide II band, in contrast, derives mainly 
from N—H in-plane bending and from C—N stretching vibration 
(381. The shifting and decrease in intensity of amide I and II bands 
indicate structural changes in intramolecular bonding and may 
come from the impact of early glycation on the overall protein 
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Fig. II. Direct binding ELISA of serum autoantibodies of type 1 diabetes subjects 
with and without secondary complications with native-HSA (a), glycated-HSA (|) 
and MaBHi reduced glycated-HSA (:<-^. 
conformation. Additional evidence to support the effect of early 
glycation comes from the appearance of a new peak at 
1711.2 cm~' corresponding to the carbonyl group of ketones in 
glycated-HSA which confirmed the presence of Amadori product 
in modified HSA |39]. The vibrational mode due to OH stretching 
lies in the region 3100-3600 cm"' (40|. In glycated-HSA an in-
crease in absorption in the stretching vibration region of OH 
groups could be due to the attachment of glucose moieties to 
HSA. Moreover, in the FT-IR spectra of glycated-HSA low intensity 
absorbtion peak was observed at 1082.7 cm"'originating from 
C—C/C—O stretching vibration of sugar moieties, since carbohy-
drates (glucose) have strong absorption bands in this region (411 
it might be due to glucose bound to HSA. Furosine is the gold stan-
dard of early glycation reaction [23,42.431 and its positive detec-
tion in the glycated-HSA by LC-MS suggests definite presence of 
Amadori adduct. 
Immunogenicity of native and glycated-HSA was evaluated by 
inducing antibodies in female rabbits. Glycated-HSA was found 
to be a potent stimulus inducing high titre antibodies. Native 
HSA induced low titre antibodies. Our results suggest glycation-in-
duced structural alteration in HSA, presenting potential neo-epi-
topes that lead to substantially enhanced immunogenicity of 
glycated-HSA as compared to native HSA. Antigenic specificity of 
affinity purified anti-glycated HSA IgC reiterated that the antibod-
ies preferentially recognized the modified epitopes on glycated-
HSA. Notable feature of the anti-glycated HSA IgG was that the 
maximum inhibition in antibody binding was caused by glycat-
ed-HSA followed by NaBH -^reduced glycated HSA and least with 
the native HSA. The reduction of glycated-HSA with NaBH4 causes 
structural alteration of Amadori product. More stable hemiketal 
furanose or pyranose ring structure is formed by the cyclization 
of the straight chain of Amadori adduct |44]. Reduction of Amadori 
product by NaBH^ leads to the elimination of the keto group. This 
Tabk2 
Demographic profile and clinical features of normal and diabetic subjects. 
Variables Normal subjects Type 1 diabetes with secondary complications Type 1 diabetes without secondary complicatiotu 
Sample size (n) 
Age (years) 
Sex (malerfemale) 
HbAlc(«) 
BMI 
Blood glucose (mg/dl) 
21 
39 ±3 
9:12 
4.2 ± 0.04 
21.7 + 3.9 
107 ±6.8 
22 
54 + 8 
7:15 
8.1 ±1.5 
25.5 ± 5.2 
361 ± 32.4 
28 
27 ±6 
16:12 
7.2 ±1.3 
26.3 ± 4.6 
326±21.3 
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Tables 
Detection of autoantibodies against native-HSA and glycated-HSA in sera of type 1 
diabetes patients with secondary complications. 
Sera 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Mean t SD 
Maximum percent inhibit ion at 20 (ig/ml 
Native HSA 
24.3 
21.0 
33.3 
25.2 
26.1 
24.9 
26.4 
25.7 
32.1 
26.0 
31.5 
22.0 
26.7 
31.0 
22.4 
21.1 
26.2 1 3.8X 
Glycated 
62.5 
54.4 
68 _2 
66.0 
67.3 
57.0 
67.9 
61.1 
67.0 
60.8 
64.0 
58.6 
67.3 
68.0 
65.0 
54.2 
-HSA 
63.08 i 4 3 X 
NaBH4 reduced glycated-HSA 
41.7 
36.8 
49.5 
46.3 
48.0 
39.6 
48.3 
40.2 
47.1 
41.0 
44.5 
47.0 
45.0 
49.1 
43.3 
35.1 
433 143% 
results in shifting the existing equilibrium between the linear 
configuration and the furanose or pyranose ring structures more 
toward the linear configuration 145]. Therefore, reduced inhibition 
of antibody binding by NaBH^ treated glycated-HSA as compared 
to its non-reduced counterpart suggests epitope recognition on 
Amadori product. Our results are in full agreement with earlier re-
ports that the ring structure of Amadori-HSA is essential for the 
recognition of the induced antibodies 145]. The induced antibodies 
also exhibited polyspecificity with respect to antigen binding as 
determined by inhibition assay. The binding of induced antibodies 
was tested against native, glycated and ROS forms of BSA, IgG. his-
tone and PLL The induced antibodies showed variable degree of 
recognition of the glycated forms of the above mentioned proteins. 
Since PLL is a homopolymer of lysine residues and BSA, IgG, histone 
are lysine rich proteins, the observed cross-reactivity could be due 
to glycation of lysine residues. These results indicate towards the 
epitope sharing between Amadori rich glycated-HSA and glycated 
forms of PLL, BSA, IgG and histone. 
Gel retardation data further substantiated the preferential rec-
ognition of glycated-HSA over native HSA by anti-glycated HSA 
antibodies. The formation of high molecular weight immune com-
plex and appreciable decrease in the unbound antigen observed 
with glycated HSA. compared to native HSA, shows that the major 
antibodies are directed against the modified epitopes. 
Amadori products of HSA are found to be immunogenic and 
Type 1 diabetic patients with retinopathy and nephropathy have 
higher Amadori albumin levels than those without it |45,46]. The 
possible role of native and modified forms of HSA (reduced and 
non-reduced) was also investigated in type 1 diabetic patients. Ser-
um autoantibodies in type 1 diabetic patients with secondary com-
plications showed preference for Amadori-HSA, indicating a causal 
role of Amadori-glycated proteins in the pathogenesis of diabetic 
secondary complications. Therefore, the systemic rise in the level 
of autoantibodies against Amadori-HSA <x)uld emerge as additional 
authentic biomarker for assessing secondary complications in type 
1 diabetes. 
The present study has identified the modifications and struc-
tural changes in HSA (lysine rich protein) induced by glucose in a 
specified rime period. Based on our data we conclude that, the gly-
cated lysine residues in Amadori-HSA present unique antigenic 
determinants, rendering it highly immunogenic. Our results 
demonstrate that the neo-epitopies generated on HSA by Amadori 
modification might play a role in the inducrion of autoanti-
bodies in type 1 diabetic patients, especially those with secondary 
complications. Hence, inhibition of Amadori-glycated albumin may 
be a target for reduction of diabetic vascular complications. 
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A B S T R A C T 
Reactions of reducing sugars with free amino groups of proteins can form advanced glycation end prod-
ucts (AGEs). While the foi mation of nucleoside AGEs has been studied in detail, no extensive work has 
been carried out to assess DNA Amadori and DNA advanced glycation end products. In this study, we 
report biophysical/chemical characterization of glucose-induced changes in DNA, as well as DNA Amadori 
and DNA advanced glycation end products. Glucose treated DNA exhibited hypeichromicity, decrease 
in melting temperature, and enhanced emission intensity in a time dependent manner. Formation of 
DNA Amadori product and DNA advanced glycation end products, mainly CEdG (N^-carboxyethyl-2'-
deoxyguanosine). were the major outcome of the study. 
© 2012 Elsevier B.V. All rights reserved. 
1. Introduction 
The free amino groups of proteins can non-enzyniat ical ly react 
w i t h the carbonyl group of reducing sugars such as glucose to 
generate Schiff base. W i th in a relatively short period of t ime the 
Schiff base reaches equi l ib r ium w i t h more stable but sti l l reversible 
Amadori products. The Amador i products can then undergo a series 
of further rearrangements and dehydrat ion to form irreversible sta-
ble end products 11.2]. It is we l l established that proteins are readily 
glycated in vitro and in vivo \3]. The first glycat ion product to be 
detected in vivo was glycated-hemoglobin (HbAic), the Amadori 
product of HbA [4]. AGEs accumulate on serum proteins and in var-
ious tissues, particularly dur ing aging, diabetes and renal failure 
[5]. Elevated ACE levels contr ibute to the development o f diabetes 
and uremic complications, such as atherosclerosis, nephropathy 
and ret inopathy [6.7]. 
Analogous to proteins, glycation may also affect DNA. In vitro. 
nucleobases and DNA react w i t h sugars in a s imi lar way as pro-
teins [7 -9 ] . The exocyclic amino group of 2'-deoxyguanosine 
is particularly prone to glycation reactions leading to the 
formation of N^-carboxyethyl, N^-carboyxmetl iy l , N^-( l -carboxy-
3-hydroxypropyl) and N^"- ( l -carboxy-3,4 ,5- t r ihydroxy-penty l ) 
modifications as we l l as cyclic dicarbonyl adducts | 9 - 1 2 j . T h e t w o 
diastereomers of N^-carboxyethyl-2'-deoxyguanosine (CEdGA.s) 
are stable reaction products that are formed f rom a variety of 
glycating agents such as glucose, ascorbic acid, dihydroxyacetone 
(DHA). or methylglyoxal [ 11,13|. First evidence that CEdG is formed 
in vivo was put forward by Schneider et al. (14]. Later on, the 
" Corresponding author. Fax: •91 571 2720030. 
E-mail address: kalam786@rediffmail.com (K. Alam). 
presence of CEdG in human urine was confirmed by immunoaf f in -
i ty chromatography coupled w i t h HPlC-diode array detector (DAD) 
[151. Using the same method. CEdG was also detected in the 
genomic DNA of human smooth muscle cells and bovine aorta 
endothel ium cells in vino (15|. Furthermore, nuclear DNA glyca-
t ion has been observed in the kidney cells f rom patients w i th 
diabetic nephropathy and in the aorta of diabetic and non-diabetic 
hemodialysis patients. Moreover, CEdC has also been detected in 
human kidneys and aorta by immunohistochemist ry w i t h the mon-
oclonal CEdC antibody. Thus, CEdC is the only DNA-ACE wh ich 
has been detected in vivo so far (16|. Nucleic acids can be directly 
modif ied by reducing sugars such as glucose 6-phosphate. The 
result ing modi f ied DNA shows increased mutat ional events in 
bacteria and eukaryot ic cells 117-19). Furthermore, CEdG was iden-
t i f ied as a major glycation product of DNA under physiological 
conditions. This chemical ly defined modif icat ion induces damage 
in DNA such as strand breaks, wh ich are responsible at least in 
part for the observed reduct ion of the transformation rate. Fur-
thermore. DNA AGEs are potent ia l ly genotoxic compounds and 
could be direct ly l inked to alterations in the DNA structure and 
funct ional i ty. CEdG, selectively introduced into the DNA, desta-
bilized the N-glycosidic bond between carboxyethylguanine and 
the sugar-phosphate DNA backbone, leading to the specific loss 
of the modi f ied guanine (depurinat ion). Consequently, the occur-
rence of single-strand breaks was observed in CEdC-modified DNA 
leading to mutat ions [12,201. The transformation of bacterial cells 
by glycated plasmids resulted in an increased mutat ion frequency 
[20] caused by insertions, deletions, as we l l as mul t ip le species 
[17]. Likewise, single-base substitut ions and the transposit ion of an 
Alu-contain ing element were observed, when DNA, wh ich was pre-
treated w i t h glyoxal or sugars, was transfected into mammal ian 
cells [21.22]. In vivo, i t has been shown that 3-deoxyglucosone 
0141-8130/$ - see front matter ©2012 tl.sevier B.V. All rights reserved, 
http :;/dx.doi.org/10.1015/j.ijbiomac.2012.06.013 
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(a glucose degradation product) induces embryonic malformation 
and teratogenicity, an effect that may be related to DNA AGEs [231. 
The CEdC in a gene may lead to a reduced transcription and to a 
loss of gene function due to mis-sense or nonsense mutations (24). 
In this study, we have studied the glucose induced struc-
tural changes in native DNA by physicochemical methods as well 
as quantitative estimation of DNA Amadori products and DNA 
advanced glycation end products in glucose-modified DNA. 
2. Materials and ^ nethods 
2.1. Chemical 
Analytical gradep-glucose and dihydroxyacetone (DHA) were 
purchased from E. Merk. Germany. Calf thymus DNA, dialysis tub-
ing, ethidium bromide, sodium azide and agarose were purchased 
from Sigma Chemical Company, USA. Chloroform, methanol, iso-
propanol. sodium chloride, sodium carbonate, sodium bicarbonate, 
sodium monobasic and dibasic salts were purchased from Quali-
gens, India. Nitroblue tetrazolium (NBT) was purchased from 
Hi-Media. India. 
2.2. DNA glycation 
220 270 320 370 420 
Wavelength (nm) 
470 
Fig.1. UV absorption profile of native DNA(-)and one ( - Q - ) . two ( -D- ) . three 
(—A—) and four weeks old (—4—) glycated-DNA. 
of helix denaturation. The process was characterized by determin-
ing the percent DNA in denatured state as a function of temperature 
[28]. 
Commercially obtained calf thymus DNA was purified (25) 
and glycated in 0.2 M phosphate buffer (pH 7.0) containing 
0.02% sodium azide, as described earlier [26). Briefly, native DNA 
(25[xg/ml) was incubated with 130 mM ^ -glucose (final volume 
3 ml) and for one. two. three and four weeks at ^ A € along 
with native DNA as control. After incubation, excess glucose was 
removed by extensive dialysis against lOmM sodium phosphate 
buffer (pH 7.4) containing lOOmM sodium chloride. Levels of gly-
cation and structural changes in DNA were analyzed. 
2.3. UV-visible and fluorescence spectroscopy 
UV^visible spectra were recorded in the wavelength range of 
200^600 nm on spectrophotometer (model UV-1700; Shimadzu 
Corporation. Japan). Fluorescence emission spectra were recorded 
on spectrofluorometer (model RF-5301; Shimadzu Corporation. 
Japan). Native and glycated-DNA samples were excited at 290 and 
400 nm respectively and emission profiles were recorded. 
2.4. Circular dichroisnj (CD) measurement 
CD studies were carried out on spectropolarimeter (model J-
810;Jasco Inc., Great Dunmow, UK) in a cell of 1 cm path length at 
S^AC in 220-400 nm range. The base line was corrected with PBS 
(pH 7.4) and the DNA was used at a concentration of 37.8 JJLM. Molar 
ellipticities \t)] were calculated in terms of base pair concentration 
according to the followingj^quation: 
' ' lOcd 
where 0 (theta) is the measured ellipticity (mdeg), c is the molar 
concentration of DNA (in terms base pair), and d is the path length 
j(incm). 
2.5. Thermal denaturation studies 
Thermal denaturation [27) of native and glycated-DNA was 
evaluated under identical conditions by a temperature scan from 
30AC to 05 -€ at an increment of4TQAC/min on spectrophotometer 
attached with a temperature programmer and controller assem-
bly. The increase in absorbance at 260 nm was taken as a measure 
2.6. Agarose gel electrophoresis and nucfease SI assay 
The change in electrophoretic migration pattern of native and 
glycated-DNA was observed on 0.8% agarose gel which was elec-
trophoresed at 30 mA for 2ji in TAE buffer (40 mM Tris-acetate, 
2 mM EDTA, pH 8.0). Bands were visualized under UV light after 
staining with EtBr. Native and glycated-DNA were incubated with 
nuclease SI (20U/p,g DNA) for 30min at ^ A G and the reaction 
was terminated by adding 200 mM EDTA, pH 8.0 and then elec-
trophoresed under the same conditions as described above (27]. 
2.7. High-performance liquid chromatography (HPLC) and LC-MS 
HPLC analysis of native and glycated-DNA samples was per-
formed with an Agilent 1100 capillary HPLC system (Palo Alto. 
^A) equipped with a Synergi Cjg (Synergi, USA) analytical column. 
C18 column (2 mm x 150 mm; particle size 4 (xm); eluent A (5 mM 
aqueous ammonium acetate buffer, pH 7), eluent B (acetonitrile 
gradient solution). The acetonitrile concentration was raised from 
0 to 4.0% in first 5 min; from 4.0 to 6,5% over 30 min; held at 6.5% for 
5 min. and raised to 90% to wash residual material off the column 
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Fig. 2. Fluorescence emission profile of native DNA (—) and one (-O—)• two (-1.1—). 
tliree ( - A - ) and four weeks old ( —i —) glycated-DNA. Samples were excited at 
290 nm. 
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Fig. 4. Post-NBT profile of native DNA ( - ) and one ( - Q -
and four weeks old (-4—) glycated-DNA. 
, t w o ( - D - ) , three ( - A - ) 
at a constant flow rate of 500^1/min. DNA bases were detected 
by diode array detector (DAD) at 254 nm. LC^MS analysis of CEdC 
standard was performed using Micromass Quattro Ultima Triple 
Quadrupole Mass Spectrometer (Beverly, MA) interfaced to an Agi-
lent Capillary HPLC system. 
2.8. Determination of DNA Amadori products 
Amadori products in glycated-DNA samples were determined 
by NBT reduction test (29,30]. The DNA samples (100 |i l) were 
mixed with 1 ml of 100 mM sodium carbonate^bicarbonate buffer, 
(pH 10.8) containing 0.25mM nitroblue tetrazolium (NBT) and 
incubated at 3^A€ for 45 min. The color (absorbance) was read at 
525 nm against distilled water and content of DNA Amadori prod-
ucts (nM/ml) was determined by multiplying absorbance by the 
coefficient 12.64. typical of monoformazan. 
2.9. HPLC-etectrospray ionization mass spectrometry 
(HPLC-ESI-M5) 
HPLC-ESI-MS study requires an orthogonal time-of-light (TOF) 
mass spectrometer (Beverly, MA, USA) equipped with standard 
electrospray ionization (ESI) device, PE Sciex's TurbolonSpray (TIS), 
and atmospheric pressure chemical ionization (APCI) sources. The 
50 70 
Temperature, °C 
Fig. 6. Melting profile of native D N A ( - ) a n d o n e ( -
and four weeks old (—* —) glycated-DNA. 
"--). two ( -n - j . three (-A-
LC system includes the Agilent 1100 capillary HPLC unit (Palo Alto, 
jfA) equipped with a 100-position autosampler, a DAD, a thermo-
static column compartment, and a ^ iiicro-vacuttni degasser. The 
mass spectral data were collected at positive ion polarity. Nitro-
gen was used as the nebulizer, heater, and collision gas. The Sciex 
heater was set to 350 C, and the spray tip potential was adjusted 
at 4000 V. Under these conditions, the MS system was then oper-
ated in full scan (m/z 40-1000). Spectra acquisition was performed 
Table 1 
Effect of incubation time on generation of NBT reactive early glycation product of 
DNA. 
Day Absorbance at 525 nm 
0.008 
0.020 
0.025 
0.080 
0.100 
0.175 
0.200 
0.251 
0.177 
0.162 
iM,-. 
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Rg. 7. (a) Agarose gel electrophoretic pattern of native and glycated-DNA. Native DNA (lane 1). one week old glycated-DNA (lane 2). two weeks old glycated-DNA (lane 3). 
three weeks old glycated-DNA (lane 4) and four weeks old glycated-DNA (lane 5). (b-u) Agarose gel electrophoretic pattern of nuclease SI treated native and glycated-DNA. 
j^b) Native DNA (lane 1). nuclease SI treated native DNA (lane 2), one week old glycated-DNA (lane 3) and nuclease SI treated one week old glycated-DNA (lane 'tJ.J^c) Native 
DNA (lane 1). nuclease SI treated native DNA (lane 2). two weeks old glycated-DNA (lane 3) and nuclease SI treated two weeks old glycated-DNA (lane ^ j . ^ d ; Native DNA 
(lane I ) , nuclease SI treated native DNA (lane 2), three weeks old glycated-DNA (lane 3) and nuclease SI treated three weeks old glycated-DNA (lane 4). 'c) Native DNA (lane 
1). nuclease SI treated native DNA (lane 2), four weeks old glycated-DNA (lane 3) and nuclease SI treated four weeks old glycated-DNA (lane 4). 
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Fig. 8. ESI-MS analysis of native DNA (a) and one week old glycated-DNA (b) hydroiysate fol lowing HPLC separation. 
every 2 s. and a total of 10 spectra were collected. All ions measured 
by MS were in the [M+H|* form. 
respectively. Furthermore, stable glycated product appeared dur-
ing one day incubation (Table 1). 
3. Results 
3.1. UV analysis of glucose-modified DNA 
The DNA samples exhibited 38.6^78% hyperchromicity (/.max 
260 nm) depending on the time of incubation (Fig. 1). Additional 
peaks at 320 and 380 nm were observed on increase in incubation 
period. 
3.2. Fluorescence studies on glucose-modified DNA 
DNA j^non-fluorescent) incubated with glucose for 1^4 weeks 
was excited at 290 nm and 400nm and emission profiles were 
recorded to ascertain the formation of Amadoric and advanced gly-
cation end products. When excited at 290 nm, modified samples 
for 1^4 weeks showed gradual increase in emission fluorescence 
intensity (A a^x 450nm) (Fig. 2). The observed fluorescence inten-
sity in one, two, three, and four weeks old glycated-DNA samples 
was 72.7,132.3,162.4 and 171.6 arbitrary units, respectively. When 
the same samples were excited at 400 nm. fluorescence intensity 
of one week old glycated-DNA sample was found to be decreased 
from 72.7 to 46.4 (A.U.) (Fig. 3) while two, three and four weeks old 
glycated-DNA samples showed increase in fluorescence intensity 
from 132.3 to 148.4; 162.4 to 186.9 and from 171.6 to 216.3 (A.U.), 
respectively. 
3.3. Nitroblue tetrazolium (NBT) reduction assay for DNA 
Amadori products 
NBT reduction assay is specific for Amadori products and not 
for ACEs [32]. Generation of DNA Amadori products was confirmed 
from reduction of yellow NBT to purple monoformazan (Fig. 4). 
In quantitative terms, the Amadori content was determined to be 
3.18±0.07, 1.65±0.12, 1.17 ±0.08 and 0.83 ±0.13 nM/ml in DNA 
samples modified by glucose for one, two, three and four weeks. 
3.4. Circular dichroism (CD) profile of glucose-modified DNA 
The CD profile of native DNA exhibited a negative peak of 
^9.8mdegat 245 nm and a positive peak of+10.7mdegat275nm 
(Fig. 5). DNA modified by glucose for 1^ 4 weeks did show negative 
peaks at 245 nm but ellipticity values were found to be^6.5, -5.2, 
-4.0 and -3.4 mdeg respectively compared to^9.8 mdeg ellipticity 
of native DNA. Under identical conditions and at275nm positive 
peak the ellipticities of 1^4 weeks old glucose-modified DNA sam-
ples were found to be +8.8, +7.9, +6.7 and +6.0^ideg, respectively. 
3.5. Thermal denaturation of glucose-modified DNA 
The melting temperature (Tm) of native DNA was found to be 
8€A€, However, Tm of DNA modified by glucose for 1^4 weeks was 
found to be 80,78,75 and 7iS/^G-, respectively (Fig. 6). The decrease 
in 7",n to the extent of 6. 8, 11, and HS/^Q may be attributed to 
structural alterations in the DNA molecule as a result of glucose 
induced modification. Generation of strand breaks and base mod-
ification appears to be major structural change that has occurred 
during glycation which maybe responsible for early onset of melt-
ing in modified DNA samples. The physicochemical characteristics 
of native and modified DNA samples are summarized in Table 2. 
3.6. Agarose gel electrophoresis 
Compared to native DNA, the electrophoretic migration pat-
tern of the modified samples (0.8% agarose gel) indicates structural 
alteration/fragmentation. DNA modified by glucose for four weeks 
showed maximum mobility (Fig. 7^). Reaction of glycation induced 
intermediates and/or superoxide radicals with sugar-phosphate 
back bone of DNA might be responsible behind generation of strand 
breaks/small size DNA fragments showing faster mobility [34-36]. 
In order to confirm the generation of single strand breaks, sam-
ples were digested with nuclease SI (20^/mg DNA) for SOmin 
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Fig. 9. HPLCchronidtogr.sni of standard dC and CEdG{a)and two weeks old glycated-DNA(b). three weeks old glycated-DNA(c). and four weeks old glycated-DNA(d). 
Table 2 
Ultraviolet and thermal denaturation characteristics of native and glycated-DNA under described experimental conditions. 
Parameter 
Absorbance ratio {A2bolAiso) 
Melting temperature (f,,. i. - ^ 
Native DNA 
1.82 
86 
68 
One week old 
glycated-DNA 
1.72 
80 
62 
Two weeks old 
glycated-DNA 
1.65 
78 
53 
Three weeks old 
glycated-DNA 
1.49 
75 
46 
Four weeks old 
glycated-DNA 
1.45 
72.5 
44 
and electrophoresed on 0.8% agarose gel. DNA modified by glucose 
for one, two, three and four weeks showed decrease in fluores-
cence intensity when treated with nuclease SI. However, nuclease 
SI treated native DNA co-migrated with control native DNA and 
had almost similar fluorescence intensity (Fig. 7^-e). These obser-
vations clearly demonstrate glucose induced strand breaks in the 
DNA rendering it susceptible to digestion by nuclease SI. 
3.7. CliaracKrizacion of DNA Awadori products by ESI-MS 
To confirm the generation of Amadori products, native and one 
week old glycated-DNA sample was hydrolyzed and subjected to 
ESI-MS.^ 'ig. 8a and b shows the mass-spectral profiles of native and 
one week old glycated-DNA hydrolysate. The ion at m/z 315.18 is 
consistent with a (Schiff base+H]* molecule resulting from the con-
densation and dehydration reaction of guanine (Mr 151.13) with 
glucose (Mr 180.16). The result suggests presence of stable Amadori 
intermediatespost-Schlff base rearrangement. 
^.8. Synthesis and characterization of 
/V-^^C;-carbo;(yer/iy/>2-deoxynii/iosine (CEdG) by HPLC and 
analysis of glucose-modified DNA 
CEdC was synthesized in laboratory according to the procedure 
described previously (12]. CEdC was isolated from the final prepa-
ration by preparative HPLC using ammonium acetate buffer and 
methanol as eluents. The elution of CEdG was seen at a reten-
tion time of 14.26 min when UV detector was used. However, 
for deoxyguanosine (dC) elution, the retention time was Or+min 
(Fig. 9a). 
Fig. 9J5-d shows representative HPLC chromatograms of acid 
hydrolysate of two, three and four week's old glycated-DNA. In 
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Fig. 10. LCr-MS analysis of standard CEdC (a) and two weeks old glycated-DNA (b), three weeks old glycated-DNA (c). and four weeks old glycated-DNA (d). 
case of native DNA and one week old glycated-DNA we did not 
observe any peal< with a retention time of 14.26 min, thereby show-
ing the absence of CEdCj^ figure not shown). However, two, three 
and four weeks old glycated-DNA showed peak with retention time 
of 14.061 min, 14.213 min, 14.224 min which shows the presence of 
N2^(l-carboxyethyl)-2-deoxyguanosine (CEdC) as it matches with 
the retention time of standard CEdC. Furthermore, the CEdG peak 
was found to be gradually increasing with incubation time. The 
CEdC is a marker of DNA glycation formed with glucose and other 
reducing compounds. 
The CEdC synthesized from dC was analyzed on mass spectrom-
eter which showed a mass (m/2) of 338 significantly different from 
the 266 mass of dC (Fig. 10a). When native DNA and;pne-vveek-old 
glycated-DNA were analyzed under identical conditions they did 
not show mass value matching with CEdC j|figure not shown). Fur-
thermore, analysis of two, three and four weeks old glycated-DNA 
suggests CEdC formation and m/z value of 338 [24] was seen in all 
three cases (Fig. 10^-d). 
4. Discussion 
Preliminary studies with nucleic acids have demonstrated that 
amino groups of DNA bases can non-enzymatically react with 
reducing sugars. Furthermore, incubation of DNA with reducing 
sugars can generate chromophores and fluorophores with struc-
tural properties similar to advanced glycated protein products 
[19,31]. Although efforts to characterize structural and functional 
changes in proteins by glycation continue, fine studies on nonenzy-
matic glycation of eukaryotic DNA have received minimal attention. 
In this study, we have demonstrated that glucose can cause 
extensive damage to DNA structure leading to strand breaks 
and formation of DNA Amadori products and DNA advanced 
glycation end products. Hyperchromicity observed at 260 nm in 
glycated-DNA samples with reference to native DNA may be 
due to adduction-cum-free radical mediated damage to sugar-
phosphate backbone followed by partial unfolding of double helix 
and more exposure of chromophoric bases [33,34]. Furthermore, 
J M Ashrafet al / /nremationa/Journa/ of Biological Macromolecules xxx (2012) xxx-xxx 
appearance of new peaks and/or increased absorbance between 
^00 and 400 nm indicates formation of DNA AGEs (mainly CEdG). 
Increased absorbance in 300^400 nm range [31) and its usefulness 
in glycation of DNA/nucleotide/proteins with reducing sugars has 
been well documented [37,38]. The systemic decrease in Tm val-
ues of modified-DNA samples could be attributed to strand breaks, 
unstaking and base modification that may lead to altered hydrogen 
bonding between base pairs (35,36). Strand breaks were specifically 
confirmed from positive nuclease SI action on glucose-modified 
samples compared to native DNA. which remained resistant to 
nuclease SI. 
Amadori products in^ne-week-old glycated-DNA sample were 
evident from reduction of yellow color of NBT to purple mono-
formazan. Here it may be noted that the NBT reduction assay is 
negative for ACEs j32]. Earlier studies have suggested that the 
reduction of NBT may be due to generation of superoxide radi-
cals and degradation intermediates of Amadori products [39-42]. 
The ESl-MS result further substantiated the presence of Amadori 
products in^ne-week-old glycated-DNA. Evidence in favor of fluo-
rescent DNA AGEs (mainly CEdG) in two, three and four weeks old 
glycated-DNA samples came from results of fluorescence, HPLC and 
LC^MS [30,43]. This study demonstrates that glucose can induce 
structural changes and strand breaks in DNA. Moreover, glycation 
of DNA evolves from the formation of Amadori products finally 
culminating into DNA AGEs. 
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